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Abstract 
 
 
Treatment options for severe uveitis are predominantly limited to systemic 
immunosuppressants, which are often accompanied by significant side effects. 
Ocular gene transfer, though, may serve as a sustained local immunomodulating 
therapy. New adeno-associated virus (AAV) serotypes were used to investigate 
gene therapy for uveitis in mouse models. Experimental autoimmune uveoretinitis 
(EAU) was used to model human disease; whilst endotoxin induced uveitis (EIU) 
was employed to dissect factors affecting immune suppression by AAV. 
 
Refinement of AAV production processes improved the quality of vectors including 
AAV8, AAV9 and ShH10. Technical issues were assessed, confirming apical 
transgene secretion from RPE and examining the effects of endotoxin 
contamination. 
 
New methods for the evaluation and quantitative scoring of disease severity in both 
animal models were developed, based on flow cytometry and optical coherence 
tomography (OCT) for EIU and EAU in C57BL/6J mice, respectively. 
 
The complexity of the role of IL-10 in EAU became evident, and pronounced species 
differences between murine and human IL-10 were identified in EIU. Despite 
generating intraocular levels comparable to those of recombinant protein known to 
be effective, AAV-derived human IL-10 did not suppress EIU.  
 
Gene delivery of soluble monomeric TNF receptors did not suppress EAU or EIU, 
and in vitro exhibited less TNF neutralising effects than an equivalent dimeric Fc-
fusion protein. Local expression of this dimeric protein from different vectors 
however was also unable to attenuate EAU.  
 
An NFκB-motif based promoter to regulate the expression of AAV-delivered 
transgenes in uveitis was developed in parallel. It demonstrated activation only in 
the presence of, and in proportion to the degree of inflammation in EAU. 
 
Despite these advances, neither IL-10 nor TNF-inhibitors proved optimal targets for 
local suppression of intraocular inflammation by AAV. Further work is needed to 
assess the response of the eye to viral gene transfer in the context of uveitis. 
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Abbreviations 
 
AAV Adeno-associated virus 
APC Antigen presenting cell 
BSA Bovine serum albumin 
CMV Cytomegalovirus 
CNV Choroidal neovascularisation 
DMSO Dimethyl sulphoxide 
EAE Experimental allergic encephalomyelitis 
EAU Experimental autoimmune uveoretinitis 
EIU Endotoxin-induced uveitis 
FBS Fetal bovine serum 
FCS Fetal calf serum 
gc Genome copies 
IFNγ Interferon gamma 
IRBP Interphotoreceptor binding protein 
ITR Inverted terminal repeat 
OCT Optical coherence tomography 
p.i. Post‐induction (of EAU) 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
TNF Tumour necrosis factor 
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1 Introduction 
 
Parts of this chapter have been published as a review: 
 
Chu CJ, Barker SE, Dick AD & Ali RR.  
Gene Therapy for Noninfectious Uveitis 
Ocular Immunology and Inflammation (2012) 20(6), 394–405. 
 
CJ Chu performed the literature search and wrote the draft manuscript. Other 
authors provided senior review and suggested revisions where appropriate. 
 
 
1.1 The burden of disease and unmet therapeutic needs for 
uveitis 
 
Uveitis is defined as inflammation of the uveal tract. This consists of the iris 
anteriorly, the ciliary body and then the choroid posteriorly. In clinical 
practice, a broad anatomical division has proven more relevant to patient 
management and international consensus was standardised in 2005.1 The 
division similarly includes anterior (iris and ciliary body), intermediate and 
posterior uveitis (retina and choroid) or panuveitis if the whole eye is 
involved. Whilst anterior disease can be treated with drops, posterior disease 
often requires systemic medication. The majority of uveitis is caused by 
either direct infection (bacteria, virus, parasite), autoimmunity or a combined 
abnormal immune reaction to infectious agents. Common infectious causes 
include tuberculosis, syphilis, herpetic viruses and parasitic diseases such as 
toxoplasmosis. Commonly associated systemic autoimmune disorders 
include SLE, sarcoidosis, HLA-B27+ spondyloarthropathies, psoriasis, 
Behçet’s and inflammatory bowel disease.2   
 
Uveitis is a significant ocular disease, accounting for 10% of blindness in the 
working age population with a disproportionately large economic burden for 
its prevalence. Direct costs alone have been estimated at $242 million per 
year in the US.3,4 Estimated to affect 115 per 100,000 of the Western 
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population, it typically follows a chronic relapsing course and can occur at 
any age.5 There is wide international variation however, with prevalence 
rates of up to 310 per 100,000 in developing countries such as India, where 
infectious causes occur more frequently.6 In the most recent published study 
the division was into 72% anterior, 6% intermediate and 22% 
posterior/panuveitis. Associated causes were established in only 37% of 
cases with the remainder classed as idiopathic.7 
 
Current therapies for uveitis are not optimal and around 35% of patients 
remain visually disabled with a demonstrably poor quality of life.8 Even in the 
mildest forms of uveitis such as the distinct group of anterior uveitis, 
treatment with topical corticosteroid demands often intolerably frequent drop 
regimes and many hospital visits around each attack. Steroid side-effects 
such as glaucoma and cataract can be more visually disabling than the 
disease being treated – particularly if chronic or recurrent therapy is required. 
Recently the introduction of depot formulations of corticosteroid for posterior 
disease (Ozurdex) have been shown to be a useful tool, but again require 
repeat administration and can result in the same complications.9 For severe 
forms of uveitis with chronic posterior segment involvement, the mainstay of 
current therapy is based upon systemic immunosuppression, which now also 
includes the use of biological therapies such as antibody based anti-TNF 
agents.10,11  
 
In many cases, patients have either isolated intraocular inflammation, or 
ocular involvement is the single manifestation of otherwise satisfactorily 
controlled multi-organ disease. The accompanying serious side effects of 
systemic immunosuppression are accepted in order to control local ocular 
disease and preserve vision. Current widely used second line agents after 
oral corticosteroids include T-cell inhibitors (tacrolimus and ciclosporin), anti-
metabolites (methotrexate, mycophenolate mofetil, azathioprine) and 
alkylating agents (cyclophosphamide, chlorambucil).12 Even with these 
potent immunosuppressants remission is not attained in 20-30% of patients 
at one year with long-term outcomes remaining poor in certain subgroups of 
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uveitis patients.13,14  
 
Whilst novel treatments such as tumour necrosis factor-α (TNF) inhibitors 
have entered widespread use and are effective, they have the disadvantages 
of high cost, need for regular administration and significant systemic side 
effects.15 All of the local (intraocular) treatments emerging from 
pharmaceutical pipelines are corticosteroid based, recombinant cytokines or 
monoclonal antibodies. Again, inherent limitations exist including uncertainty 
how best to select specific biologic therapy for individual patient groups, as 
well as risks associated with repeated intraocular injection for local therapy. 
Other therapeutic paradigms are clearly needed and gene therapy may 
provide a solution. 
 
1.2 Animal models of Uveitis 
1.2.1 Experimental	  autoimmune	  uveoretinitis	  
Experimental autoimmune uveoretinitis (EAU) is an animal model that 
phenotypically and biochemically mirrors human posterior uveitis. It has been 
central to our understanding of disease pathogenesis and the development 
and introduction of new therapies into clinical practice.10,15  Spontaneous and 
inducible EAU can be obtained using a variety of wildtype animals and 
transgenic mouse strains to achieve different disease kinetics, severity and 
T-cell polarity of immune response. Common to all is the initiation of an 
antigen-specific immune response to retinal proteins. In the Lewis rat S-
antigen is used, whilst different fragments of retinol-binding protein-3 (Rbp3 
or IRBP) are used in mice. EAU can also be induced in rabbit, guinea pig and 
non-human primates.16 The mouse has been the most widely used, due to 
the capacity for transgenic manipulation, relative availability of reagents and 
range of subtypes of EAU possible. Details of the different mouse models 
currently available are summarised in table 1.  
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Strain Form Year introduced 
C57BL/6 mouse  Induced mild EAU with RBP-3 (1-20 
residues). 
199217 
B10.RIII mouse  Induced severe EAU with RBP-3 (161-
180 residues). 
199518 
Humanised HLA-DR 
transgenic mouse 
Inducible EAU using human S-Antigen. 200319 
Aire-knockout mouse Spontaneous EAU from failure of thymic 
selection. 
200220 
TrP-HEL transgenic 
mouse 
Spontaneous EAU designed to model 
Vogt-Koyanagi-Harada syndrome. 
200621 
HEL-transgenic 
mouse 
Spontaneous EAU by crossing IRBP-HEL 
mice with HEL-specific-TCR CD4+ cells.  
200722 
IRBP R161H 
Transgenic B10.RIII 
mouse 
Spontaneous EAU in mice with auto-
reactive CD4+ T-cells to RBP-3. 
201323 
 
Table 1. Common mouse models of inducible and spontaneous experimental 
autoimmune uveoretinit is.  
 
EAU primarily causes posterior uveitis with marked chorioretinitis and 
minimal anterior segment involvement. In this project the C57BL/6 strain has 
been predominantly used with the B10.RIII strain employed for selected 
experiments. B10.RIII mice mount a proportionately stronger reaction to the 
pathogenic RBP-3164-180 peptide than C57BL/6 strain mice do to their own 
most pathogenic RBP-31-20 peptide.18 The result is both a more rapid and 
severe disease, with time from induction to peak around 12 days. Retinal 
detachments, extensive photoreceptor loss and posterior synaechae are 
common. In contrast, the C57BL/6 strain does not reach peak disease until 
over 20 days and develops only moderate photoreceptor destruction. 
 
Both inducible models are unrepresentative of human disease in that they 
are monophasic in nature with a single acute peak, followed by apparent 
resolution of inflammation. Most human posterior uveitis is chronic with 
periodic exacerbations. Recent work has however illustrated the more 
dynamic nature of post-peak EAU in the C57BL/6 mouse, with accumulation 
of an exhausted phenotype CD8+ T-cell population.24 Tissue and vascular 
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remodelling also occur and can be clearly identified in this phase by a variety 
of techniques.25 As such, this model may be more appropriately chronic and 
less monophasic than first apparent.  
 
Both inducible models require subcutaneous peptide delivery emulsified in 
complete Freund’s adjuvant. This is predominantly a mineral oil and 
Mycobacterium tuberculosis mixture, which provides a strong and 
indispensable innate stimulus. This has however been shown to drive CD4+ 
T-cell polarisation towards a TH17 dominant phenotype, compared to TH1 in 
disease induced by adoptive transfer.26 Additionally both - with a lower 
amount required in B10.RIII mice - need cotemporaneous systemic 
administration of Bordetella pertussis toxin for full expression of disease. 
Evidence shows that this not only weakens blood-retinal barrier integrity, but 
can also polarise T-cells towards a pathogenic Th1 phenotype.27 These 
limitations of the induction process must be considered in any successful 
modulation of disease. 
 
Whilst spontaneous models are ideally suited for testing therapeutic 
intervention in active disease, all publications using gene therapy to date 
have treated prophylactically. Spontaneous models of murine EAU arguably 
better reflect the true pathogenesis of uveitis, but are not widely available. 
Aire-deficient mice lack thymic expression of RBP-3 and develop 
spontaneous uveitis as autoreactive T-cells are not clonally deleted.20 
Transgenic mice with Hen egg lysozyme (HEL) expressed under the RBP-3 
promoter are crossed with mice expressing HEL specific T-cell receptors on 
CD4+ cells. They develop severe spontaneous EAU by postnatal day 22 on 
average.22 The same approach can be used with the Tyrosinase-related 
protein-2 promoter to give the mice an appearance similar to that seen in 
Vogt-Koyanagi-Harada syndrome.21 With an 87% penetrance, mice 
developed characteristic vitiligo and uveitis. The most recent model is one 
generated in the B10.RIII strain that possesses a transgenic T-cell receptor 
specific for RBP-3. All mice develop detectable EAU by 12 weeks of age.23 
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A cautionary note arises from use of the HLA-A29 transgenic mouse line, 
generated as a model for the associated uveitic disease of Birdshot 
retinochoroidopathy.28 A phenotype was seen only after one year and later 
suspected to be the rd8 mutation found to contaminate all C57BL/6N lines.29 
For testing our gene therapy approach we used the C57BL/6J strain, 
confirmed free of the rd8Crb1/Crb1 mutation that has confounded so many 
ocular studies to date.30  
 
1.2.2 Endotoxin	  induced	  uveitis	  
Endotoxin-induced uveitis (EIU) as a surrogate model of human anterior 
uveitis was first described as part of a systemic response to the gram-
negative bacterial cell wall component lipopolysaccharide (LPS).31 It can be 
induced by peritoneal or footpad injections in rodents, as well as by direct 
intravitreal injection. Whilst predominantly an acute innate response to the 
presence of LPS, the rationale derives from the strong association of anterior 
uveitis and the HLA-B27 haplotype. Patients with this haplotype have long 
been characterised as more susceptible to gram-negative bacteria and 
chlamydial infections. Theories of molecular mimicry have been proposed, 
but the evidence is still inconclusive.32 
 
In the mouse EIU is characterized by blood-aqueous barrier breakdown, 
activation of innate immunity and an ocular infiltrate predominantly comprised 
of polymorphonuclear leukocytes. Historically this has only been defined 
using immunohistochemistry with OX-42 staining for neutrophils. A smaller 
number of monocytes enter the eye in the later stages of EIU, which have 
only been identified using the ED1 marker. Changes in other cells types 
including T-cells have not been widely observed, though it is suspected that a 
decrease in the number of resident mast cells reflects activation and 
degranulation.32  
 
After systemic induction, barrier breakdown can be detected after two hours, 
with leukocytes infiltrating the ciliary body and iris by 12 hours. Maximum cell 
                                                                                                                   18 
counts peak around 24 hours, with some optic disc infiltration, however the 
absolute number is fairly low. Due to mild severity local intravitreal injection of 
LPS has been used and results in over a hundred-fold greater number of 
infiltrating cells over a more rapid timecourse.33 It is still unclear why the 
disparity exists between the two routes and in practice they are treated as 
separate entities. Both are believed to self-resolve without tissue damage 
though over unclear timespans. Severity has classically only been assessed 
by either paraffin histology and semi-quantitative cell counts of haematoxylin-
stained cells, or with total protein assays on aqueous humour.34  
 
1.3 Pathogenesis and effector mechanisms in posterior 
uveitis 
 
Uveitis is typically considered as an autoimmune disease to retinal proteins 
including S-antigen and RBP-3, orchestrated by CD4+ T cells that secrete 
signature cytokines - either interferon gamma (IFNγ) from TH1 or interleukin-
17 from TH17 cells. Concurrent activation of the innate immune response 
occurs and is also central to the overlap between the autoimmune, 
autoinflammatory and infectious aetiology of this heterogeneous disease.16  
 
Mechanisms of thymic escape of autoreactive T-cells and a breakdown in 
peripheral tolerance are thought to partly underlie the initiation of the disease 
in humans. Supportive evidence of the importance of thymic deletion comes 
from studies of animal models of uveitis. Only strains lacking thymic 
expression of IRBP are susceptible to the induction, whilst AIRE-knockout 
mice develop spontaneous disease.16,35 FoxP3+CD25+ Treg cells form part of 
the peripheral tolerance mechanism and are able to suppress pathogenic 
auto-reactive T-cell activation. They are likely to be important as genetic 
inactivation of FOXP3 by mutation leads to extensive systemic autoimmunity 
and uveitis in humans.36 Whilst the exact triggers leading to the initiation of 
uveitis remain unclear, the effector pathways and cell types have been 
interrogated using animal models of EAU (Summarised in Figure 1). 
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Figure 1. Immunological mechanisms of init iation and effector pathways active in the 
inducible EAU model.  Subcutaneous in ject ion of RBP-3 in complete Freund’s adjuvant A)  
act ivates resident APCs such as dendri t ic  cel ls ,  which take up the ant igen and B)  t raf f ic  to 
regional lymph nodes. There RBP-3 fragments are eventual ly presented C)  to naive auto-
react ive T-cel ls ,  which become act ivated and  D)  home to the blood-ocular barr ier.  E)  Ear ly 
interact ion occurs with resident per ivascular myeloid cel ls .  The result ing product ion of pro-
inf lammatory cytokines such as IL-1 and TNF leads to mult ip le ef fects.  F)  This includes the 
upregulat ion of ICAM-1 and P-select in,  and degradat ion of the integr i ty of  the blood-ocular 
barr iers that leads to further inf i l t rat ion of the eye wi th act ivated lymphocytes and monocytes. 
G)  In the t issue, predominant ly TH1 polar ised T-cel ls  produce IFNγ ,  which act ivates myeloid 
cel ls .  H)  These then produce TNF to further increase inf i l t rat ion into the eye. TNF also acts 
v ia TNFR1, to cause further act ivat ion and the induct ion of n i t r ic  oxide synthetase. I )  I t  is  the 
result ing peroxin i t r i te radicals that lead to photoreceptor loss and t issue damage. Potent ia l  
ant i - inf lammatory targets such as soluble receptors might inhibi t  the ef fects of  TNF at mult ip le 
stages (purple bar) .  Evidence suggests that IL-10 can suppress T-cel l  and macrophage 
act ivat ion, as wel l  as prevent ing in i t ia l  ant igen presentat ion (purple arrows).  
 
In inducible strains such as C57BL/6 mice their permissive H-2K MHC 
haplotype is required to respond to subcutaneous RBP-3 mixed with 
complete Freund’s adjuvant.17 Antigen-presenting cells traffic to lymph nodes 
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and establish a CD4+ T-cell antigen specific immune response against RBP-
3. These CD4+ cells have been shown to be sufficient alone to establish 
EAU using adoptive transfer experiments.37 Acitvated CD4+ cells enter the 
eye and establish disease through the recruitment of myeloid cells. CD4+ 
cells have been shown to be of mixed TH1 and TH17 polarity when recovered 
from the eye dependent upon the method of induction. They are capable of 
secreting high levels of IFNγ or IL-17 respectively, which lead to inflammation 
of the intraocular environment.38 IFNγ specifically has been implicated as a 
key cytokine, licencing myeloid cells to produce TNF. In an autocrine 
manner, TNF upregulates nitric oxide synthetase to produce destructive 
peroxinitrite radicals that ultimately cause tissue damage and photoreceptor 
loss.39 
 
The clinical phenotype of this underlying process can be followed in vivo in 
C57BL/6 mice.40 Whilst timing varies slightly, typically fundal changes begin 
around day 14 with optic disc swelling and infiltrate around peripheral 
collecting ducts. At peak disease around day 25 disc swelling has extended 
into vasculitis and intraretinal lesions are seen. Post-peak, progressive 
apparent scaring occurs, with disc swelling resolving.  
 
Flow cytometry has identified the cell types involved during EAU across the 
same timepoints.41 A summary of the key markers used for assessment of 
EAU and EIU are listed in Table 2. In the B10.RIII strain, three stages of 
disease can be appreciated in the retina. Before disease occurs, there are 
negligible numbers of CD4+ T-cells and the small CD11b+ cell count is 
contributed by the resident parenchymal and perivascular microglial 
population. In the prodromal phase at 5 days small increases are seen, but it 
is at peak disease that an explosion in CD4+ and CD11b+ cell counts occurs. 
Characterisation of the CD11b+ population with Ly6G confirmed a large 
neutrophil component.42 The remainder of the CD11b+ population may 
comprise myeloid derived suppressor cells (MDSCs), as activated CD4+ 
cells are suppressed following co-culture with this population. The post-peak 
phase of secondary regulation was typified by globally reduced cell counts, 
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with an increase in the percentage of FoxP3+CD4+ Tregs and the 
accumulation of an exhausted phenotype CD8+ population occurs.24 
 
Marker Description Cell types 
CD45 Surface glycoprotein known also known 
as leukocyte common antigen. 
White blood cells (all 
haematopoietic cells except 
platelets and mature 
erythrocytes) 
CD11b Cell surface integrin (αM) involved in 
adhesion and trafficking. 
Predominantly on cells of the 
myeloid lineage.  
Ly6G 
(1A8 clone) 
Component of the myeloid differentiation 
antigen Gr-1. 
Predominantly present on 
peripheral neutrophils. 
Ly6C 
(HK1.4 clone) 
Component of the myeloid differentiation 
antigen Gr-1. 
Predominantly present on 
inflammatory monocytes. 
Gr1 
(RB6-8C5 clone) 
A glycosylphosphatidylinositol-linked 
protein and composite epitope of Ly6G 
and Ly6C. 
Expressed on granulocytes 
and macrophages. 
CD4 Immunoglobulin superfamily member 
TCR co-receptor. 
Predominantly thymocytes 
and helper T-cells 
CD8 Immunoglobulin superfamily member 
TCR co-receptor. 
Predominantly thymocytes 
and cytotoxic T-cells 
CD94 C-type lectin involved in control of NK 
cell activation. 
Present on all NK and NKT 
cells 
Table 2. Immunological cell  surface markers used in f low cytometry of mouse EAU.4 2 - 4 4   
 
In terms of the cytokine environment within the eye during EAU, multiple pro-
inflammatory proteins other than IFNγ and IL-17 have been detected. IL-1, 
IL-2 and IL-6 as well as TNF play critical roles and are elevated during 
disease initiation and peak inflammation.45 During later phases of disease 
levels of these cytokines fall and those associated with resolution such as IL-
10 increase.26 This partly reflects changes in cell populations, not only T-cells 
but myeloid cells. Depletion of monocytes using the antibody MC-21 after 
peak disease in C57BL/6 mice leads reduces Treg numbers in the eye and 
worsens histological damage.46,47 
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1.4 Ocular gene therapy and its application to treat uveitis 
 
Gene therapy is the strategy of exogenously producing a target protein 
encoded by DNA (known as the transgene) in selected cells. The mechanism 
of DNA transfer is broadly divided into those implemented by viral and non-
viral vectors. Various non-viral gene transfer techniques have been used in 
the eye, but thus far they are without exception, inefficient and limited in 
duration compared with effective viral vectors. The most promising viral 
vectors to date for use in the eye are those based on adeno-associated virus 
(AAV) and lentiviruses. Both are currently being used in clinical trials of 
ocular gene therapy and their use has been recently reviewed.46 Details of 
the key vectors used for gene transfer are summarised in Table 3. 
 
Results from three independent clinical trials of ocular gene supplementation 
therapy for a form of early-onset retinal dystrophy suggest that AAV-based 
gene therapy can result in improved vision in patients.48-50 These promising 
trials have thrust the eye into the limelight as one of the most promising 
target tissues for gene therapy, and as a result, the research effort into ocular 
gene therapy has expanded, both in academic and commercial settings. The 
rapid progress of gene therapy for ocular disorders, compared to therapy for 
many other conditions, highlights the suitability of the eye as a target for 
gene therapy.  
 
The eye is compartmentalised, small and isolated from the rest of the body 
by the blood–retinal barrier. Cells can be targeted effectively either by 
intravitreal injection or subretinal delivery of relatively modest doses of 
vector. Another advantage of ocular gene therapy, and retinal gene therapy 
in particular, is that the target cell populations are typically very stable. The 
lack of cell division allows the use of non-integrating vector systems for 
sustained transgene expression and also reduces the risk of malignant 
transformation of cells following the use of integrating vector systems. The 
age and disease status of the retina itself can also affect transduction 
patterns. For example, lentiviral vectors can transduce photoreceptors only in 
early post-natal stages but fail to do so in the presence of the rd1 
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degeneration.51 
 
Vector Posterior segment cells 
transduced 
 
Anterior 
segment 
cells 
transduced 
Duration 
of gene 
expressi
on 
 
Comments 
Intravitreal 
injection 
Subretinal 
injection 
AAV2 Ganglion 
cells  
Photorecepto
rs and RPE52  
Trabecular 
meshwork53 
Long-term  
Pseudotyped 
AAV2/8 
None Photorecepto
rs and RPE54 
Minimal 
unless self-
complementa
ry genome54 
Long-term Faster onset, 
less vector-
directed 
immune 
responses 
and stronger 
expression 
than rAAV2 
Pseudotyped 
AAV2/9 
Ganglion 
cells55   
Photorecepto
rs, RPE and 
Muller cells56 
Photorecepto
rs and RPE 
only 
Long-term Muller cell 
transduction 
at high titre 
only 
AAV ShH10 Muller and 
ganglion 
cells57 
Unpublished 
to date 
Unpublished 
to date 
 
Long-term Engineered 
by in vivo 
evolution to 
target Muller 
cells 
Lentivirus 
(HIV1) 
None RPE Corneal 
endothelium, 
iris and 
trabecular 
meshwork58 
Long-term  
Adenovirus Ganglion 
cells  
RPE Trabecular 
meshwork59   
Short 
duration 
due to 
immune 
mediated 
clearance 
Use of this 
vector has 
been limited 
by strong 
inflammatory 
responses  
Ciliary 
muscle 
electro-
None Ciliary 
muscle60 
Short-
term 
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transfer  
Naked 
plasmid DNA 
Unknown Unclear Short-
term 
Expression 
only 
confirmed by 
detection of 
transgene 
products in 
the aqueous 
fluid and 
retina61 
Nanoparticles RPE62 Unknown At least 3 
months 
Various  
approaches 
and 
formulations 
 
Table 3. Comparison of the different methods of gene transfer used in ocular gene 
therapy. Adapted from Chu CJ et a l .  (2012).  Gene Therapy for Noninfect ious Uveit is .  Ocular 
Immunology and Inf lammation, 20(6),  394–405.  
 
Non-viral electrotransfer of plasmids into the ciliary muscle is rapid and 
repeatable, but transgene expression is transient and at relatively low 
levels.60,63 This technique has been used to reduce disease severity following 
delivery of plasmids encoding chimeric TNFα-receptors in the rat EAU model. 
However, the beneficial effect appeared to be rapidly lost and translation into 
human therapy for chronic disease is unlikely due to the frequent need for 
repeat injection. 
 
A number of viral vectors have been used to deliver immunomodulatory 
genes in various animal models of uveitis. Although the first reported study 
on the development of gene therapy for uveitis utilised a second generation 
adenoviral vector to treat EAU in rodents, the utility of adenoviral vectors for 
this purpose is limited by the strong immune responses they elicit.59 Lentiviral 
vectors are able to mediate long-term and efficient gene delivery to cells in 
the anterior chamber and the retinal pigment epithelium, with limited immune 
responses compared to adenoviral vectors and are thus potentially usefully 
for the treatment of uveitis. HIV-1 based vectors have been used to 
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transduce anterior segment structures in order to treat EIU.34  
1.5 Adeno-associated virus 
 
Vectors based on AAV, a single stranded DNA parvovirus of the genus 
Dependovirus, are now the most commonly used type of vector for ocular 
gene transfer. This small (25nm diameter) non-pathogenic virus was first 
identified as a contaminant in isolates of adenovirus and is currently the most 
promising vehicle for gene delivery to the retina and photoreceptors in 
particular. Identification of a large number of serotypes has further enhanced 
the utility of AAV as a vector platform. Many of these variants have unique 
transduction characteristics defined by their capsid, that can be used to 
target different ocular cell types.64  
 
Production of recombinant AAV for research and therapeutic purposes is 
based upon the AAV2 genome, though often packaged within the capsid of 
another serotype in a process known as capsid pseudotyping. For example, 
wildtype AAV2 could be referred to as AAV2/2, whilst capsid psuedotyped 
AAV8 serotype would be AAV2/8.54 In common usage and within this thesis, 
vectors labelled as AAV2, AAV8, AAV9, and ShH10 should be assumed to 
contain the recombinant AAV2 genome.  
 
Figure 2. Schematic of recombinant AAV .  Note the icosahedral  capsid arrangement that 
contains the genomic construct h ighl ighted. The transgene fo l lows the promoter and is 
typical ly  fo l lowed by a SV40 poly-adenylat ion s i te.  
 
The key component of the AAV genome, responsible for most of its biological 
function once inside a target cell, is the two diametrically positioned inverted-
terminal repeats (ITRs). These 125bp palindromic repeats of single stranded 
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DNA form secondary structures at both the 5’ and 3’ ends and enclose the 
viral genes Rep and Cap required for the native lifecycle.65 In recombinant 
AAV, these genes have been removed and the desired promoter and target 
transgene can be inserted, usually followed by an SV40 poly-adenylation site 
(Figure 2). AAV lacks an envelope, but has an icosahedral capsid formed of 
sixty proteins of three varieties – VP1, 2 and 3 in a 1:1:10 ratio respectively. 
These enclose the genomic construct and the ITRs have been shown to be 
crucial to efficient packaging. Many capsids will spontaneously assemble and 
lack a viral genome. They are known as ‘empty’ or ‘unpackaged’ capsids and 
during recombinant AAV2 production can account for over 90% of the 
population.66 They lack the ability to effect gene expression but can still 
trigger antiviral immune responses. 
 
AAV enters cells using receptor-mediated endocytosis, the target of which 
varies with serotype. For example, wildtype AAV2 predominantly binds to 
surface Heparan-sulphate proteoglycan whilst AAV9 binds N-linked 
galactose.67 Low pH then allows endosomal escape, the single-stranded 
genome enters the nucleus and second-strand synthesis occurs. The 
genome then remains as long-lasting episomal concatemers, which enable 
expression in non-dividing cells. AAV otherwise will only replicate itself in the 
presence of active adenoviral infection.65 
 
New serotypes are still being characterised and refinements in vector 
efficiency have been engineered by mutating capsid surface tyrosine 
residues.55 Further optimisation by engineering a self-complementary viral 
genome has been shown to increase the level and speed of transgene 
expression by eliminating the requirement for intracellular conversion into 
double-stranded DNA.68 One significant limitation is AAV packaging capacity, 
which is limited to 4.9kb of DNA - significantly less than adenoviral or 
lentiviral vectors. Groups have extended this to 9kb using a trans-splicing 
approach, splitting the transgene across two AAV vectors with appropriate 
splice donor and acceptor sites. This results in lower efficiency of expression 
however.69  
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AAV has historically been defined as non-integrating, however wildtype AAV2 
does undergo relatively site-specific integration in a region known as AAVS1 
on human chromosome 19 in up to 70% of integrations. Whilst the 
recombinant forms of AAV used lack the required Rep78, Rep68 and IEE 
elements for integration, emerging evidence is that largely random genomic 
integration does occur.70 The frequency is very low however, estimated at 
less than 0.1% of infections in systemic studies. Significant carcinogenesis 
has not been associated with these events in long-term mouse, dog or non-
human primate studies.71,72 In over two hundred patients treated with rAAV in 
clinical trials to date, no tumours have been reported.65 
 
In the eye, the transgene and its target cell type, determine the choice of 
AAV serotype and administration site. For instance, AAV2 transduces 
ganglion cells following intravitreal injection whereas sub-retinal 
administration results in transduction of photoreceptors and RPE cells. 
Intracameral administration with a self-complementary genome variant 
permits transduction of the trabecular meshwork, iris, corneal epithelium and 
ciliary body.53 Whilst expression of anti-inflammatory proteins from the RPE 
may treat retinitis, it is not certain if diffusion might occur to affect the anterior 
chamber, or if anterior structure transduction would affect retinal disease. 
 
Several serotypes have been used in the course of this project (Table 2). 
AAV2 is the most extensively characterised, the first to be discovered and 
the first serotype used in an ocular clinical trial.73 As highlighted, its 
transduction characteristics are dependent upon site of delivery within the 
eye. The main limitation is the slow speed of onset, requiring over three 
weeks to approach near peak levels of expression. To improve upon these 
characteristics searches for other naturally occurring serotypes was 
undertaken. Both AAV8 and AAV9 serotypes were isolated from non-human 
primate tissue.74 When generated as AAV2/8 and injected into the subretinal 
space of mice, strong RPE and photoreceptor expression was seen after 
even one week. Furthermore, final peak levels at four weeks appeared to be 
higher in photoreceptors with AAV8 than with AAV2.54 A similar profile was 
                                                                                                                   28 
seen with AAV2/9, though additional Muller cell transduction was seen 
following subretinal injection.56 AAV9, unlike AAV8 can also transduce 
ganglion cells after intravitreal injection.55 ShH10 is a newly created artificial 
AAV serotype based upon AAV6. It was generated by a technique of directed 
in vivo evolution, in an attempt to transduce Muller cells efficiently following 
intravitreal injection. Combined with a tyrosine to phenylalanine mutation in 
the capsid, has been claimed as able to generate widespread transduction of 
Muller cells in a single injection.57  
 
1.6 The immune response to AAV 
 
AAV generally elicits minimal immune responses in an un-inflamed eye 
compared to vectors such as adenovirus and most do not efficiently 
transduce antigen presenting cells, making them potentially ideal for gene 
transfer in a uveitic eye.75 Whilst it might be justifiable to treat posterior 
uveitis by subretinal injection of vector, isolated anterior uveitis would 
probably require delivery either by intracameral or intravitreal injection. These 
routes of administration would also be usable for the treatment of posterior 
uveitis, but they may not be as optimal as subretinal administration since the 
anatomical site of injection appears to influence vector-directed immune 
responses.  
 
Studies in mice suggest that subretinal administration of high doses of AAV 
vectors can be achieved without developing a neutralising antibody response 
to capsid antigens.76 This has also been observed in clinical trials, although 
transient immunosuppression was used to minimise the risk of immune 
responses in patients.48-50 In contrast, the more clinically desirable route of 
intravitreal administration can result in systemic capsid-directed immune 
responses in animal models, which generate serum neutralising antibody 
levels nearly equivalent to intramuscular injection. Although initial 
administration does result in transgene expression, this response negates 
therapy in the contralateral eye or repeat ipsilateral treatment.77 Using 
different capsid serotypes and transient immunosuppression may partly 
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circumvent this problem in patients, but immunologically intravitreal 
administration remains a greater challenge.  
 
Other factors affect the immune response to gene transfer including the 
vector, dose, the transgene itself and the local inflammatory state. Common 
concerns are that pre-existing inflammation from chronic uveitis could 
counter effective transgene expression whilst vector directed responses 
might exacerbate the degree of intraocular inflammation. Indeed gene 
therapy for systemic disease, where large intravenous doses of AAV are 
given has been particularly hampered by vector-induced immune reaction.78 
Initially, this is due to complement activation and capsid-directed neutralising 
antibodies from prior exposure to wildtype AAV. Whilst 60% of the general 
population are seropositive for AAV2, other serotypes such as AAV8 are less 
prevalent and pre-existing antibodies are detected in only 20% of 
individuals.79  
 
The foreign protein of AAV capsids is not the only target of immune 
responses. Transgenes producing neo-antigens, such as the monogenic 
replacement of wildtype protein into a completely deficient host, trigger 
adaptive immune mechanisms as thymic deletion of autoreactive T-cells 
would not have occurred. This has been well documented in systemic 
applications such as for Duchenne muscular dystrophy.80 Following 
subretinal administration of RPE65 protein into deficient patients, no RPE65-
specific responses have been seen, presumed secondary to the immune 
deviant properties of the subretinal space.48-50 
 
Differences with human immunology need to be considered. Systemic AAV 
used in human clinical trials generates robust cytotoxic CD8+ T-cell 
responses that clear transduced cells.81 Mouse models do not reflect this and 
mice rarely develop T-cell responses to AAV, unless persistently re-
challenged. Even if a CD8+ T-cell response can be detected, significant 
clearance of transduced cells is not seen.82 Effective humoral neutralising 
antibody responses however are seen.  
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The innate immune response to AAV is more poorly characterised. There are 
clearly acute contributions by the complement system and Muller glia have 
been observed to express the activation marker GFAP in response to AAV.83 
Resident retinal microglia clearly have a role to play and indications are that 
activation occurs after subretinal injection of AAV above PBS control (Ulrich 
Luhmann, personal communication). The effects of innate ligands, such as 
unmethylated CpG islands in AAV genomes have been also investigated and 
shown to be one anti-viral component through the activation of endosomal 
TLR9, such that both transgene and capsid contribute to any immune 
response.84 Endotoxin contamination during AAV production is likely and not 
routinely tested for. It is unclear if this may be important when using AAV for 
immunomodulation. 
 
1.7 Bacterial endotoxin and its implications for gene therapy 
 
Endotoxin was first described by Richard Pfeiffer in 1894, as a heat-stable 
toxin discovered in V.cholerae. Later work confirmed the pyrogenic 
properties of this compound and its origin as a component of the outer leaflet 
of the outer cell membrane of Gram-negative bacteria. It was not until 1947 
that endotoxin was discovered to be bacterial lipopolysaccharide (LPS).85 
The primary structure is comprised of variable length O-antigen 
polysaccharide chains linked to a lipid A core. The spontaneous mouse 
mutant line lps allowed the exact signalling pathway to be discerned, as it 
was found that a single point mutation led to complete unresponsiveness to 
endotoxin. In 1998 the mutation was localised to the TLR4 receptor.86 It is 
now known that the main mechanism of endotoxin-induced fever is through 
the triggered release of TNF from TLR4 activated macrophages. 
 
The toxin is extremely resistant to removal and is not cleared by standard 
autoclaving procedures. These are likely to only increase the degree of 
contamination through lysis of environmental gram-negative bacteria. Dry 
heat at 180°C for three hours is typically required for inactivation. Unless 
specific steps are taken all standard laboratory experiments should be 
assumed to have endotoxin contamination. The main FDA approved testing 
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method is based on extracts from the horseshoe crab – the Limulus 
amoebocyte lysate (LAL) assay. LPS reacts with the lysate to trigger a 
clotting cascade-like process that results in a gel clot formation. Serial 
dilutions and calibration against a standard curve can allow the level of 
quantification, typically expressed as endotoxin units (EU/ml).87  
 
Whilst known to be a potent inflammatory stimulus, no studies examining the 
effect of endotoxin upon AAV-mediated gene transfer have been published 
and no consensus exists on acceptable research grade levels. Tolerable 
levels are currently determined by individual judgement based upon target 
organ and condition. GMP produced clinical grade AAV is typically assured 
to below 10EU/ml, but this is not an internationally agreed standard.88 In the 
eye, the response to LPS has been studied in the acute form of EIU. The 
focus has been upon the acute recruitment of neutrophils and transient 
degradation of blood-ocular barriers, but long-lasting sequelae have not been 
examined.32 In terms of retinal cells, both Muller glia and photoreceptors 
have been observed to express TLR4. In culture activation by LPS has been 
shown to reduce photoreceptor survival after oxidative stress, in line with 
similar observations of CNS neuron-induced damage.89 Worsened 
intraocular inflammation is also possible, as resident microglia have been 
shown to respond to LPS in a dose-dependent fashion, progressively 
activating and generating pro-inflammatory cytokines in concert with Muller 
cells.90 In the context of an adaptive inflammatory response such as in 
uveitis, it is also important to consider that LPS through TLR4 signalling has 
the potential to alter CD4+ T-cell polarisation, preferentially inducing IL-17 
production. If unrecognised, this could potentially confound any therapeutic 
manipulation of the immune environment.91  
 
1.8 The approach of gene therapy for uveitis 
 
While still early in development, gene therapy approaches have the potential 
to provide constitutive, self-regulating, and enduring suppression of 
intraocular inflammation following a single treatment. The potential 
advantages and limitations are summarized in Table 4.  
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Advantages Disadvantages 
Long-term production of therapeutic protein 
following a single treatment. 
Initial need for intraocular injection. 
Local therapy with no systemic 
immunosuppression. 
Difficult to reverse without tissue destruction. 
Combined injection of multiple vectors 
encoding different therapeutic transgenes is 
possible. 
Transgene and vector-directed immune 
responses can occur. 
Inflammation-regulated promoter control is 
possible, to restore a form of homeostasis. 
 
 
Table 4.  A comparison of gene therapy against other treatment approaches for uveit is. 
 
Current approaches in experimental animal models involve intraocular 
delivery of vectors encoding anti-inflammatory molecules in order to 
modulate disease and restore homeostasis. This might be achieved by 
delivering molecules that either have a direct anti-inflammatory effect or 
neutralise circulating pro-inflammatory cytokines. To date, potential 
therapeutic strategies have utilised recombinant cytokines, a soluble pro-
inflammatory cytokine receptor or a natural antagonist. Strategic approaches 
using virus-based gene therapy are summarised in Figure 3. Selection of 
transgene has been based primarily on targets believed to be critical in 
animal models such as murine experimental autoimmune uveoretinitis (EAU), 
endotoxin-induced uveitis (EIU) and experimental autoimmune anterior 
uveitis (EAAU). Although the exact cause of human uveitis is unknown, 
animal models inducing an immune response towards retinal antigens have 
proven an invaluable starting point.  
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Figure 3. Strategy of viral vector-mediated gene therapy for uveit is.  a)  Subret inal  
in ject ion of  AAV vectors results in photoreceptor and/or RPE transduct ion. b)  Intravi t real  
administrat ion of AAV2 transduces only gangl ion cel ls.  c)  Attenuat ion of EAU has been 
demonstrated fo l lowing AAV vector-mediated expression of soluble ant i - inf lammatory proteins 
such as IL-10, IFN-α ,  and IL-1ra. d)  AC in ject ion of lent iv irus results in t ransduct ion of i r is ,  
corneal endothel ium and trabecular meshwork. Suppression of EIU has been demonstrated 
fo l lowing lent iv ira l-mediated expression of IL-1ra and IL-10. Adapted from Chu CJ et a l .  
(2012).  Gene Therapy for Noninfect ious Uveit is .  Ocular Immunology and Inf lammation, 20(6),  
394–405.  
 
Although gene therapy may eventually be used to treat relapsing anterior 
uveitis, the major impact clinically and therefore likely to be used initially in 
trials, is for the treatment of posterior uveitis. Posterior segment involvement 
accounts for the greatest burden of visual disability, even with optimal 
biologic treatment. Initial control of inflammation will inevitably continue to 
use conventional immunomodulatory therapies, but once in a chronic indolent 
phase, gene transfer may provide superior long-term control. Patients who 
have persistent inflammation on maximal therapy, visual decline and isolated 
ocular involvement would be ideal candidates for proof-of-principle human 
studies.  
 
There are, however, still a number of challenges in order to take gene 
therapy for uveitis through to clinical application. These include determining 
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which approach (combination of vector, gene(s), promoter and route of 
administration) might be most effective in animal models, whose 
appropriateness, particularly given the heterogeneous nature of uveitis, is 
unclear. The effect of gene transfer into an already inflamed environment, 
particularly if the blood-retinal barrier is not intact, must also be determined.92 
Finally, long-term animal studies are also required in order to determine 
whether the constitutive expression of specific immunomodulatory molecules 
may eventually lead to toxicity. Alternatively, to address this final issue and 
as a final technical refinement, the use of inducible promoters responsive to 
inflammation were examined.  
 
1.9 Inflammation-regulated promoters 
 
All promoters used so far in gene therapy for uveitis have been essentially 
constitutive. Whilst one study used a tetracycline-inducible system, it 
required constant administration of exogenous Doxycycline to activate.93 This 
‘Tet-on’ promoter is described as leaky, in that basal transcription occurs in 
the absence of tetracycline. Furthermore it is based upon prokaryotic 
sequences and so unlikely to be approved for human use.  
 
The ideal promoter would be self-regulatory, activating transcription of the 
anti-inflammatory transgene only in the presence of and in proportion to local 
inflammation. In other organ systems, promoters based upon pro-
inflammatory cytokine promoters have been used, and these are 
summarised in Table 5. No publications have yet employed a self-regulating 
promoter in the eye. 
 
Promoter details Vector and 
transgene 
Target tissue Year published 
Hybrid IL-1/IL-6 
promoter 
Adenovirus-IL-4 
 
Articular 
chondrocytes 
 
200794 
Lentivirus-IL-10 
 
201195 
Human neurotropic AAV1 Glial-cell Hippocampal 201396 
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polyoma virus 
NFκB segments 
line derived 
neutrotropic factor 
(GDNF) 
neurons 
IL-6 promoter Adenovirus LacZ 
and hIL-10 
Lung parenchyma 201097 
HIV derived NFκB 
repeats 
AAV5 Human 
sTNR1-Fc fusion 
protein 
Articular 
chondrocytes 
200798 
Intermediate-early 
CMV promoter 
(spontaneously 
disease inducible) 
rAAV2 LacZ Articular 
chondrocytes 
199999 
 
Complement 
component C3 & 
HIV promoter 
fusion 
Adenovirus-hIL-10 Articular 
chondrocytes 
2002100 
E-selectin promoter Lentivirus-IL-10 Articular 
chondrocytes 
2012101 
 
Table 5. Inflammation-regulated promoters published for use in gene therapy. 
 
It was felt the most appropriate strategy to employ in gene therapy for uveitis 
would use promoters responsive to IFNγ and TNF. Both these pro-
inflammatory cytokines are known to be pivotal to EAU pathogenesis, are 
almost undetectable in the absence of disease, and fall rapidly during 
resolution of inflammation.  
 
IFNγ signals via the Janus-activated-kinase (JAK/STAT) system. When it 
binds to its surface receptor IFNγ-receptor 1, this associates with JAK1 and 
then recruits IFNγ-receptor 2. This co-receptor is constitutively associated 
with JAK2 and receptor convergence leads to auto-phosphorylation and 
activation of both JAKs. These then phosphorylate STAT1 on the 701-
tyrosine residue which triggers homodimerisation and translocation into the 
nucleus. Only STAT1-STAT1 dimers bind to conserved regions called 
gamma-activated sequences (GAS) to trigger IFNγ-specific transcription. The 
DNA consensus sequence has been defined as TTC/ANNNG/TAA.102 
Activation is regulated by negative feedback from SOCS1, itself transcribed 
in response to STAT1 signalling which can bind and directly inhibit JAK 
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enzymatic activity at the IFNγ-receptor complex by acting as a pseudo-
substrate.103  
 
TNF predominantly acts through the canonical-NFκB signalling system. 
Soluble trimeric TNF binding to TNFR1(p55) triggers conformational changes 
leading to the recruitment of the TRADD-adaptor protein.104 This in turn 
recruits TRAF2 and RIP, which activate the IKK complex. This complex 
phosphorylates IκBα targeting it for ubiquitin-mediated proteosomal 
degradation and liberating NFκB dimerization partners such as RelA and 
p50. These enter the nucleus and bind to NFκB response element motifs 
(e.g. GGGAATTTCC) to drive transcription of a wide array of genes. MAPK 
signalling is also triggered by TNF. Negative regulators are active such as 
the de-ubiquitinase A20, which is induced by NFκB and inhibits IKK complex 
activation via effects upon RIP.105  
 
Any attempt to produce an inflammation responsive promoter for use in 
uveitis, should investigate promoters responsive to both or either NFκB and 
STAT1 signalling. These signalling pathways are known to be rapid in onset, 
but whether the levels of expression achieved will be sufficient in a 
therapeutic setting is still unknown. As well as use in gene therapy, an 
inflammation-responsive promoter delivered by AAV could also be used as 
an in vivo reporter of tissue inflammation, to further examine mechanisms in 
EAU.  
 
1.10 Systematic review of published pre-clinical studies of 
gene therapy for uveitis: translating knowledge of 
immunological mechanism into therapy  
 
For the purposes of this introduction, studies addressing intraocular 
inflammation with either direct gene therapy or cell based treatments using 
ex vivo genetic manipulation have been included (Table 6). Although the use 
of siRNA is a form of downstream genetic modification, these studies have 
not been included as they involve repeated administration of siRNA 
molecules rather than gene delivery. To date several biological pathways 
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have been targeted using gene transfer. Although self-reactive TH1 and TH17 
CD4+ cells are thought to initiate EAU, it is the subsequent infiltration of 
myeloid cells, coordinated through macrophage signalling that cause 
structural and functional damage to the eye. Deviation of this final effector 
pathway has been the predominant target of many recent studies.106  
 
Gene 
transferred 
Mechanism of 
transfer 
Site of 
transfer 
Disease model Year  
Human 
sTNFR1-
mIgG1 
 
Plasmid 
electrotransfer 
 
 
 
Ciliary muscle 
 
EIU in Lewis rat 200563 
EAU (S-Ag induced) 
in Lewis rat 
2009107 
Human 
sTNFR1 p55 
variants 
EIU in Lewis rat 200960 
Viral IL-10 
 
Adenovirus Subconjunctiv
al, retro-orbital 
sinus and 
systemic 
injection 
EAU (S-Ag induced) 
in Lewis rat and B10-
A mouse 
200259 
Ex vivo 
adenoviral 
transfected 
retinal Muller 
glial cells or raw 
adenovirus 
 
 
 
Intravitreal 
injection 
EAU (S-Ag induced) 
in Lewis rat 
2003108 
rAAV2 with and 
without tet-on 
promoter. 
EAU (S-Ag induced) 
in Lewis rat 
200593 
Murine IL-10 Adenovirus Intraperitoneal 
injection 
EAAU in Lewis rat 2005109 
rAAV-2 Subretinal 
injection 
EAU (IRBP induced) 
in C57BL/6 mice 
2005110 
Murine IL-
10, 
IL-1ra and in 
combination 
Lentivirus Intracameral EIU in C57BL/6 mice 200834 
Human IL-
1ra 
rAAV2 Intravitreal 
injection 
IL-1 mediated EAU 
in New Zealand 
white rabbits 
2009111 
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Table 6. Published preclinical studies of gene therapy for uveit is.  Adapted and updated 
from Chu CJ et a l .  (2012).  Gene Therapy for Noninfect ious Uveit is .  Ocular Immunology and 
Inf lammation, 20(6),  394–405.   
 
1.10.1 	  	  Interleukin-­‐10	  
Mouse Interleukin-10 was first termed cytokine synthesis inhibitor factor and 
identified as a critical factor produced by mouse TH2 CD4+ T-cells that could 
suppress the activation of TH1 cells. IL-10-/- knockout mouse lines highlighted 
its critical regulatory role, as they developed spontaneous inflammatory colitis 
and an enhanced severity of induced autoimmune disease.116 Linkage to 
genetic polymorphisms in IL-10 has now been identified in multiple human 
autoimmune diseases including uveitis.117 
 
IL-10 is well characterised in human and mouse, with both encoded on 
chromosome 1 and consisting of five exons. The two proteins possess 73% 
amino acid homology and though mouse IL-10 is N-glycosylated, this is not 
thought to alter function. Human IL-10 is recognised to be active on mouse 
cells, but mouse IL-10 has no effect upon human cells.118  
 
A protein isolated from Epstein-Barr virus known as BCRF-1, was found to be 
highly similar to mouse and human IL-10 and re-named viral IL-10. This has 
α-MSH (as 
precursor 
ACTH1-17) 
Naked plasmid Subconjunctiv
al injection 
EAU (IRBP induced) 
in C57BL/6 and 
B10.RIII mice  
200961 
Human IFN-
α 2a 
rAAV2 Subretinal 
injection 
EAU (IRBP induced) 
in B10.RIII mice 
2011112 
Human IFN-
α2a & 
murine IL-4 
2012113 
Murine IL-
27p28 
rAAV2 Subretinal 
injection 
EAU (IRBP induced) 
in B10.RIII mice  
2012114   
gp100 (to 
immunise 
against 
EMIU) 
Adenovirus Systemic 
injection 
Experimental 
melanin-protein 
induced uveitis 
(EMIU) in Lewis rat  
1998115 
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an 84% amino acid homology to the human protein, with differences primarily 
occurring at the N-terminus at a key isoleucine/alanine exchange at position 
87. It is thought to have evolved to lose many of its pro-inflammatory 
characteristics, as it lacks the ability to activate B-cells and Mast cells.119,120  
 
IL-10 forms a homodimeric protein complex and binds to IL-10 receptor-1. 
The IL-10 receptor-2 co-receptor is then recruited engaging Jak/Stat family 
tyrosine kinases Jak1 and Tyk2. These lead to phosphorylation and 
activation of Stat1, 3 and 5, which lead to the changes in transcription 
responsible for most of the effects of IL-10. Whilst the exact mechanisms are 
unclear, rapid and high levels of SOCS3 are generated, that is suspected not 
only to be a form of negative feedback for IL-10, but also may enact its anti-
inflammatory effects.119 
 
IL-10 can be produced by almost any cell of the immune system, but is 
predominantly derived from activated macrophages and T-cells.121 It is 
critically involved in the effector function of regulatory T-cells.122 IL-10 down-
regulates MHCII and co-stimulatory molecule expression as well as inhibiting 
the production of many pro-inflammatory cytokines including TNFα, 
interferon-γ (IFNγ), interleukin-1 (IL-1) and interleukin-12.119 Reduced levels 
of these cytokines in particular, impair the generation of superoxide anions 
and nitric oxide, limiting the destructive potential of myeloid cells in the retina 
during EAU.123  
 
The importance of IL-10 is supported by studies that have shown that levels 
of IL-10 in ocular fluids is lower from patients with idiopathic uveitis than from 
controls124 and that EAU-susceptible rat strains show lower basal levels of IL-
10 expression than their resistant counterparts.125 IL-10 levels increase 
during the spontaneous resolution phase of EAU, indicating a crucial role in 
reasserting control over the inflammatory process.41 Furthermore, 
intraperitoneal injection of recombinant IL-10 for five days after the induction 
of murine EAU has been shown to reduce IFNγ production and disease 
scores, though this is likely through inhibition of disease initiation.126  
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One of the earliest approaches for gene therapy for uveitis involved sub-
conjunctival injection of an adenoviral vector expressing viral IL-10. This 
approximately halved histological EAU scores in both rats and mice when 
given one day before induction.59 Another group used intraperitoneal 
administration of an adenoviral vector expressing murine IL-10, to 
prophylactically treat a rat model of anterior uveitis (EAAU). Although they 
reported a ten-fold reduction in anterior chamber leukocyte infiltration, the 
indirect effect of systemic immunosuppression was not quantified and IL-10 
production appeared to be lost by two weeks.109 Whilst intraocular 
administration of adenoviral vectors is not beneficial since the vectors elicit 
such a strong immune response, Lentiviral and AAV vectors in particular, 
generate relatively minimal immune responses. Sub-retinal injection of AAV2 
encoding murine IL-10 two weeks before induction of disease has been 
shown to reduce the histological EAU disease score in C57BL/6 mice by 
40%, without evidence of systemic immunosuppression. A reduction in co-
stimulatory molecule expression on CD11b+ cells isolated from the retina and 
reduced levels of peroxynitrite damage were also observed.110 Similar results 
have been obtained in a rat EAU model using tetracycline-inducible viral IL-
10 delivered by an AAV2 vector. A comparable 40% reduction in histological 
scores was obtained in the group where oral Doxycycline was 
administered.93 Anterior chamber administration of an HIV-1 vector 
expressing murine IL-10, fourteen days prior to the induction of EIU has been 
shown to reduce the degree of anterior chamber infiltration by 74%, but this 
effect was not maintained upon re-challenge.34  
1.10.2 	  	  Tumour	  Necrosis	  Factor-­‐α	  
Most of the inflammatory damage responsible for visual loss in uveitis is 
mediated through macrophage activity when destructive superoxide radicals 
and nitric oxide are generated primarily in response to the high levels of 
IFNγ. The induction of nitric oxide synthase in macrophages is crucially 
dependent upon the autocrine action of tumour necrosis factor alpha (TNF) in 
response to IFNγ.127  
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TNF itself is synthesised as a 26kDa pro-TNF protein, which assembles into 
trimers on the cell membrane. This transmembrane complex is active and 
capable of binding and stimulating TNF receptors. Following processing and 
cleavage by the matrix metalloproteinase TACE (known also as ADAM-17), 
the active soluble form is released.128 Soluble and transmembrane forms of 
TNF are produced by leukocytes, fibroblasts or smooth muscle cells and 
signal differentially through two receptor pathways. Activation of TNF-
Receptor 1 (TNFR1/p55) on macrophages is necessary for the pro-
inflammatory phenotype seen in EAU, is involved in cell infiltration and the 
receptor has a greater affinity for soluble TNF. TNF-receptor 2 (TNFR2/p75) 
preferentially binds transmembrane TNF and has been implicated in 
modulating angiogenesis and tissue repair (Figure 4).104,129  Soluble forms of 
TNFR1 and 2 also exist and may form part of a homeostatic mechanism, by 
competitively regulating the amount of free soluble TNFα. There is some 
evidence however that at low concentrations they may in fact stabilise TNF 
trimers and potentiate their effect.130   
 
TNF levels are normally undetectable. It is elevated in the blood and aqueous 
of patients with active uveitis, where it stimulates the production of cytokines 
including IL-6 and IL-12, and promotes tissue infiltration through endothelial 
ICAM-1 and ELAM-1 adhesion molecule up-regulation and blood-retinal 
barrier degradation.131 In TNFR1 knockout mice, nitric oxide production is 
prevented and there is both resistance to the induction of EAU and reduced 
myeloid infiltration.132 Consequently, neutralising systemic TNFα activity in 
EAU prevents end organ damage, despite the presence of a significant 
cellular infiltrate.133  
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Figure 4. TNF forms and their binding receptors. Two TNF receptors exist ,  TNFR1 (p55) 
and TNFR2 (p75).  p75 preferent ia l ly  b inds to transmembrane TNF (tmTNF) whi lst  p55 
preferent ia l ly  b inds to soluble TNF (sTNF). Both however can bind ei ther form. sTNF is 
generated by c leavage of t ransmembrane TNF by the matr ix metal loprotease ADAM17. Each 
receptor resul ts in d i f ferent downstream effects as summarised above. Autocr ine s ignal l ing is 
an important mechanism in macrophages. The phenomenon of ‘ reverse s ignal l ing’ can also 
occur,  where receptor bound tmTNF can lead to intracel lu lar s ignal t ransduct ion and changes 
in the tmTNF expressing cel l .  Adapted from Khera et a l ,  2010.1 0 4 
 
Anti-TNF therapy, using drugs developed for systemic autoimmune diseases 
such as rheumatoid arthritis and ankylosing spondylitis, has been employed 
increasingly over the last decade for the treatment of refractory uveitis. It is 
now even recommended by consensus as first line treatments for ocular 
Behçet’s disease.134 The most commonly prescribed agents are chimeric 
(Infliximab) or fully humanized (Adalimumab) monoclonal antibodies to TNF 
itself. With systemic administration, promising results have been attained in 
cases resistant to standard immunosuppressive drugs, with reported 
response rates, between 78-100% across different age groups and subtypes 
of uveitis depending on definition of response.10,15,135 Despite these benefits 
there are significant side effects due to systemic administration of these anti-
TNFα agents, including reactivation of latent tuberculosis, predisposition to 
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opportunistic infection and a theoretical increase in malignancy. The 
development of multiple sclerosis has also been reported.136 Local inhibition 
of TNFα activity by gene therapy may provide the same degree of disease 
suppression, without these adverse effects. A single gene treatment would 
additionally deliver long-term benefit, avoiding the need for weekly 
subcutaneous injections or monthly intravenous infusions.  
 
It is still unclear if local TNF inhibition alone is sufficient to attenuate EAU. 
Whilst intravitreal delivery of a TNFR1 fusion protein suppresses EAU 
induced structural damage in mice by two-thirds, the effect of local TNF 
inhibition upon acute intraocular inflammation in humans remains 
unknown.129 Intravitreal administration of anti-TNF antibodies has no effect 
on macular oedema in otherwise quiescent eyes. In one clinical study, 
intravitreal Infliximab for non-uveitic macular oedema actually induced severe 
inflammation in 42% of eyes, although this may have been due to the 
chimeric nature of the molecule leading to non-specific myeloid activation via 
Fc binding. Inflammation was not seen at a lower dose, or when Adalimumab 
was used.137,138  
 
Several studies have investigated the potential of local inhibition of TNF 
activity by gene therapy. Plasmid DNA electrotransfer to ciliary muscle has 
been used to deliver chimeric soluble TNFα receptor. This resulted in 
reduced inflammation in concurrently induced EIU in Lewis rats, but when 
assessed using luciferase, transgene expression was all but lost by three 
weeks.63 Using various monomeric variants of the soluble p55 TNFα 
receptor, prolonged transgene production was obtained at 3 months, which 
reduced the clinical score of EIU.107 A similar approach was used to delay 
onset and attenuate the severity of EAU in the rat, but the effect appeared to 
reduce by day 17 and did not completely prevent structural damage.60 This 
technique has certainly shown potential as a treatment for acute anterior 
uveitis, but may not last long enough to treat posterior uveitis, which often 
runs a protracted course of many years.  
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1.10.3 	  	  Interferons	  
Interferon-alpha (IFNα) and Interferon-beta (IFNβ) are human cytokines 
typically induced as an innate immune response to viral infection. Both are 
classed at Type I interferons and distinct from the Type II member IFNγ. 
They have the capacity to be both suppressive and stimulatory, depending 
on the context of the surrounding cytokine environment and the interferon 
subtype. Their exact mechanism of action is still unclear, but they may exert 
their anti-inflammatory effects by suppressing Th17 responses and 
stimulating the production of IL-10.139  
 
Many groups have examined the potential of IFNα administration as a 
treatment for posterior uveitis, particularly in Behçet’s disease. One rationale 
for this approach is that when stimulated in vitro, plasmacytoid dendritic cells 
from uveitis patients have been observed to produce less IFNα than 
controls.140 Several studies have shown that subcutaneous injection of 
recombinant IFNα-2a may have a beneficial effect on refractory uveitis and 
chronic cystoid macular oedema (CMO).141,142 In one group of 37 patients 
with Behçet related panuveitis resistant to conventional immunosuppression, 
95% achieved quiescence and the rate of relapse was reduced four-fold at 
24 months. However, weight loss occurred in 24% of subjects and all were 
affected by transient flu-like symptoms. Alopecia, dermatitis and leucopaenia 
also occurred in a significant number of patients.143 Localised delivery of 
IFNα by a gene therapy vector could potentially avoid these side effects and 
the need for subcutaneous injections three times a week. 
 
Tian et al.112 have shown that subretinal AAV2-mediated transfer of human 
IFNα can decrease IL-17 production and lymphocyte proliferation and 
attenuate clinical and histological scores in murine B10.RIII EAU. Peak 
expression of IFNα did not occur, however, until 42 days after injection and 
as the effects of IFNα expression were only assessed up to 3 months, further 
evaluation is required. Combined therapy delivering murine Interleukin-4 (IL-
4) alongside IFNα by AAV2 was also trialled, but failed to show any 
additional benefit over IL-4 or IFNα alone.113 A clinical study to investigate 
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intravitreal injection of recombinant IFN-α2b for neovascular macular 
degeneration reported a transient reduction in ERG responses and this may 
need to be addressed before pursuing IFN-α therapy further.144  
 
Intraocular inflammation has been reported to occur in 15% of patients with 
multiple sclerosis (MS) and often manifests as intermediate uveitis.145 IFNβ 
therapy is licensed as a disease modifying treatment for MS and increasing 
evidence suggests it may also have an effect upon MS-associated uveitis. 
One retrospective study of 24 eyes after systemic IFNβ therapy, reported 
improvement in disease activity in 71% of eyes and resolution of pre-existing 
CMO in 82%.146 Although the use of IFNβ appears promising, interferon 
treatment for isolated ocular inflammation has to be balanced against the 
significant reported side effects. Persistent flu-like symptoms may account for 
the average compliance rate of only 50% at two years when IFNβ-1a is used 
for treatment of MS.147 However, the prospect of using gene therapy to 
express IFNβ within the local intraocular environment may provide 
therapeutic benefit without unwanted systemic side effects. One study has 
used AAV8-mediated transfer of IFNβ to treat a mouse model of 
retinoblastoma,148 but this approach has yet to be tested in a model of 
uveitis.  
 
1.10.4 	  	  Interleukin-­‐1	  receptor	  antagonist	  (IL-­‐1ra)	  
IL-1 is a key mediator in both EIU and EAU. It promotes breakdown of the 
blood-retinal barrier, leukocyte infiltration through the expression of ICAM-1 
and the production of pro-inflammatory cytokines including IL-8 and IL-6 by 
RPE.149,150 IL-1ra is a naturally occurring structural variant that competitively 
inhibits the activation of IL-1 receptors.151 Attenuation of EAU in mice was 
demonstrated following subcutaneous injections of recombinant IL-1ra 
(Anakinra) and subsequent case reports have suggested benefit following 
systemic administration in CINCA syndrome and Behçet disease.1,152-154 One 
study has investigated the potential of local IL-1ra gene transfer in mouse 
EIU. Following anterior chamber administration of a lentiviral vector 
expressing IL-1ra, there was a reduction of protein leakage into the anterior 
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chamber after EIU induction, suggesting that there was partial preservation of 
the blood-aqueous barrier. Concurrent neutrophil infiltration was also reduced 
significantly. After re-challenge 12 weeks later, there was no statistically 
significant reduction in protein leakage, which may be explained by 
successive loss of vascular integrity after the second episode of EIU.34 
Combination therapy with IL-10 and IL-1ra gene transfer did not result in 
greater efficacy over either gene in isolation.  
 
1.10.5 	  	  α-­‐melanocyte	  stimulating	  hormone	  (α-­‐MSH)	  
α-MSH, an endogenous derivative of pro-opiomelanocortin (POMC), is an 
immunosuppressive molecule with a diverse mode of action. It is 
constitutively present in the anterior chamber where it inhibits IFNγ release 
from primed T-cells. It is also implicated in the generation of locally derived T 
regulatory cells thought to be responsible for the resolution of ocular 
inflammation in mice.155 Effects upon other types of cells may contribute to 
resolution of inflammation, with reduced levels of NF-κB and phosphorylated 
p38 MAPK observed in macrophages after exposure to α-MSH.156 Direct 
plasmid transfer of ACTH1-17, converted in ciliary and retinal pigment 
epithelial cells to α-MSH, has been used to suppress murine EAU in both 
B10.RIII and C57BL/6 models.61 Following gene transfer the histological EAU 
disease scores were around a third lower than in empty plasmid controls. 
The specificity of the therapy was confirmed, as there was loss of the 
protective effect when EAU was induced in melanocortin 5 receptor deficient 
mice. 
 
1.10.6 	  	  Interleukin-­‐27	  
The importance of the TH17 polarity of CD4+ T-cells has become increasingly 
recognised in multiple autoimmune diseases, including uveitis.157 IL-27 is part 
of the IL-12/IL-6 family of cytokines and is a heterodimer of EBI3 and IL-
27p28 subunits. IL-27 and even the IL-27p28 subunit alone are able to 
suppress both TH17 and TH1 responses. Transgenic IL-27p28 expression 
was observed to attenuate EAU induced three-weeks after subretinal 
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injection of AAV2 in B10.RIII mice. A mild reduction in intraocular IL-17 and 
an increase in IL-10 were seen at peak disease, compared to AAV2-GFP 
controls.114 
1.10.7 	  	  Antigen	  based	  therapies	  
Gp100 is a melanocyte differentiation antigen recognised by HLA-A2 
restricted CD8+ cells. Adenoviral-mediated transfer of gp100 has been used 
as pro-immunogenic treatment for malignant melanoma. Chan and 
colleagues used a similar approach to attenuate the induction of 
experimental melanin-protein induced uveitis (EMIU) seven days after 
prophylactic systemic administration of adenovirus encoding gp100.115  
 
B cells have the capacity to act as tolerogenic antigen presenting cells. 
Retroviral vectors expressing IRBP161-180 in frame with the mouse IgG1 heavy 
chain have been used to transduce B cells ex vivo. Ten days after 
intraperitoneal infusion back into syngeneic B10.RIII mice, EAU was induced, 
but showed significantly reduced levels of disease compared with controls. 
Of greater clinical relevance, the disease course was unaltered when a single 
infusion was given seven days after the induction of EAU. However, following 
repeated alternate day dosing from day 7, a significant reduction in disease 
score was obtained, implying a potentially different mechanism of action.158  
 
Almost all published experimental studies have used a prophylactic 
approach, that is, treating before the induction of EAU. While such an 
approach is a logical first step for proof of concept, intervention during 
established disease in a chronic model is more clinically relevant. Refinement 
of animal models of EAU may help to achieve this. Standard inoculation of 
rats with S-antigen results in aggressive, short-lived, monophasic disease, 
terminating when complete retinal destruction removes the source of antigen. 
Inducing B10.RIII mice with IRBP peptides causes an acute and damaging 
peak of disease followed by a form of resolution, but continued retinal 
infiltration.159 Reducing the dose of peptide can alter disease dynamics, but 
alternatively a different model can be used. C57BL/6 mice develop milder, 
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slower and persistent disease, with evidence of retinal angiogenesis and 
continued changes four months after initiation.160 Aside from spontaneous 
models, this would therefore be the most appropriate model to use in the 
interrogation of gene therapy for uveitis. 
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1.11 Aims and Objectives 
 
The main project aim was to build upon previous published work that used 
AAV2 to suppress EAU. Provisional objectives at the outset were: 
 
1. To improve assessment of the EAU model where possible, adopting 
the routine use of flow cytometry and TEFI, and examining new 
modalities such as OCT or scanning-laser ophthalmoscopy.  
2. To test if expressing IL-10 initially using the modern serotype AAV2/8 
would lead to superior suppression of EAU in the C57BL/6 model. 
This would include assessment of severity of disease using histology 
and flow cytometry. Levels of IL-10 achieved would be determined by 
ELISA. 
3. To examine the effectiveness of other anti-inflammatory transgenes 
delivered by gene transfer particularly including soluble TNF receptors 
1 and 2. Other options could include TGF-β, IL-4 or CD200. If these 
were all successful, combinations could be tried to see if there was a 
synergistic effect. 
4. Other modern serotypes apart from AAV2/8 could be trialled and 
techniques for AAV production and purification examined to ascertain 
if a refined process can improve therapy further. 
5. To assess the feasibility of an intrinsic inflammation-regulated 
promoter to control the expression of anti-inflammatory transgenes. 
Selection of the promoter would be based upon pro-inflammatory 
mediators known to be critical in the EAU model, such as IFNγ and 
TNF. 	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2 Materials & Methods 
 
2.1 Animal procedures 
2.1.1 Animal	  strains	  and	  husbandry	  
Unless stated otherwise, all mice used were female C57BL/6J (Harlan, UK), 
brought into the animal facility at 4-6 weeks of age and maintained on the 
open shelf, with food and water ad libitum. B10.RIII mice were obtained from 
the Animal Services Unit at Bristol University, Bristol, UK a minimum of one 
week prior to procedure. 
 
All procedures were performed under the UK Home office project licence 
PPL 70/1279 and conformed to the Association of Research in Vision and 
Ophthalmology (ARVO) statement for the use of animals in ophthalmic and 
vision research. 
2.1.2 Mouse	  anaesthesia	  
Adult mice were anaesthetised with a bolus intraperitoneal injection of 200μl 
of a mixture of medetomidine hydrochloride (1 mg/ml), 100 mg/ml ketamine 
(Orion pharmaceuticals, Helskinki, Finland), and water in the ratio 5:3:42. 
Post-procedure, anaesthesia was reversed by peritoneal injection of an equal 
volume of AntiSedan (Pfizer pharmaceuticals, USA). Mice were recovered 
overnight on heat mats and supplied with hydrated chow. 
2.1.3 Ocular	  injections	  
Under reversible anaesthesia, pupils were dilated with a single drop of 
tropicamide 1% (Chauvin Pharmaceuticals, Romford, UK) prior to the 
application of Viscotears (Novartis Pharmaceuticals, UK) and a small glass 
coverslip to the ocular surface. A standard ophthalmic operating microscope 
(Carl Zeiss, Jena, Germany) and a 34-gauge needle (Hamilton, Switzerland) 
attached to a 5μl glass syringe was used for all injections. At the end of all 
procedures, 1% Chloramphenicol ointment was applied to the eye 
(Martindale Pharma, UK). 
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1.1.1.1 Sub-­‐retinal	  and	  intravitreal	  injection	  
Using an operating microscope (Carl Zeiss, Jena, Germany) a 34-gauge 
needle (Hamilton, Switzerland) was passed posterior to the equator into the 
subretinal space via the sclera and 2μl of viral suspension or other agent 
injected. For intravitreal injection, the needle was passed perpendicular to 
the sclera, approximately 0.6mm from the corneal limbus, then angled 
posteriorly to avoid the lens and enter the vitreous cavity. Up to 2μl of agent 
was subsequently injected.  
 
1.1.1.2 Intra-­‐cameral	  injection	  
A 34-gauge needle was advanced horizontally 0.5mm anterior the to the 
corneal limbus, to enter the anterior chamber. Posterior pressure was applied 
to vent a small amount of aqueous from the eye, prior to the injection of 4μl 
of agent. The needle was held in place for 10seconds and then withdrawn.  
 
2.1.4 Induction	  of	  Experimental	  Autoimmune	  Uveoretinitis	  (EAU)	  
For the induction of EAU in C57BL/6J mice, human IRBP1-20 peptide 
(GPTHLFQPSLVLDMAKVLLD) was synthesised (Cambridge Peptides, UK) 
and reconstituted in 10% DMSO/PBS (Sigma Aldrich, Dorset, UK) to a 
concentration of 20mg/ml. The stock was subjected to five freeze-thaw 
cycles and stored at -80°C. 
 
On the day of injection the stock solution was diluted with PBS to a 
concentration of 10mg/ml and mixed with an equal volume of Complete 
Freund’s Adjuvant (Sigma Aldrich, Dorset, UK) supplemented with 1.5mg/ml 
of Mycobacterium tuberculosis H37Ra (Difco laboratories, BD, Oxford, UK). 
The solution was vigorously mixed to obtain a white emulsion and 50µl was 
subcutaneously injected into each flank to give a total dose of 500µg per 
mouse. 1.5µg of Bordetella Pertussis toxin (Tocris Bioscience, Bristol, UK) 
per mouse was injected into the peritoneum, from a 0.1mg/ml stock diluted in 
PBS.   
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B10.RIII mice were injected in an identical fashion, but substituting 300μg of 
Human IRBP161–180 (SGIPYIISYLHPGNTILHVD) from Cambridge Peptides 
and injecting only 0.4μg Bordetella pertussis toxin (Sigma Aldrich, Dorset, 
UK) intraperitoneally. 
 
2.1.5 Induction	  of	  Endotoxin	  induced	  uveitis	  (EIU)	  
1ng of LPS from E.coli 055:B5 (Sigma Aldrich, Dorset, UK) was injected in a 
volume of 2µl from a stock dissolved in PBS at 0.5ng/μl into the vitreous 
cavity as described. A dedicated Hamilton needle and syringe was used and 
the working solution made freshly prior to injection. 
 
2.1.6 Dissection	  and	  extraction	  of	  non-­‐ocular	  mouse	  tissues	  
Serum was obtained as a terminal procedure only. Mice were injected with 
250μl of 200mg/ml Euthatal (Merial Animal Health, UK). When the pain reflex 
was confirmed absent, a 23-gauge needle was passed trans-thoracically into 
the heart and an average 500μl blood withdrawn. This was placed into an 
Eppendorf tube and allowed to clot at 4°C. Following centrifugation at 
13,000rpm, the serum was aspirated into a fresh tube and stored at -20°C 
until use. 
 
Lymph nodes were dissected from the cervical and inguinal regions using 
blunt, curved forceps and placed into D10 medium on ice. Spleens were 
dissected and collected in the same way. Homogenisation was performed 
with the plunger of a 2ml disposable syringe, washed through a 70µm filter 
with PBS. Dependent upon subsequent application, red cell lysis was 
performed with red-cell lysing buffer (Sigma Aldrich, Dorset, UK) according to 
the manufacturer’s instructions. 
2.1.7 Topical	  Endoscopic	  Fundus	  Imaging	  (TEFI)	  
Adapting a published method, a 5cm endoscope 3 mm in outer diameter 
(1218AA; Karl Storz, Tuttlingen, Germany), was connected by fibre-optic 
cable to a Nikon D80 digital camera with a 10-million pixel charge-coupled 
device image sensor. Pupils were dilated for 8 minutes with topical 
tropicamide 1%, phenylephrine 2.5%, oxybuprocaine 0.4% (Chauvin 
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Pharmaceuticals, Romford, UK) and finally Viscotears (Novartis 
Pharmaceuticals, UK) as a coupling agent for corneal contact. Using an 
adapted clinical grading system, fundal images were scored masked 
according to changes in the optic disc, vessels and surrounding retina.40,159  
 
2.1.8 	  OCT	  imaging	  and	  fundus	  fluorescein	  angiography	  
Spectralis™ HRA and OCT (Heidelberg Engineering, Heidelberg, Germany) 
with an aspheric, 80mm focal length, near-infra-red lens adaptator (Linos, 
Qioptiq, Luxembourg) was used to capture images. The OCT+IR channel 
was used to correlate the retinal position with the obtained OCT optical 
section. Animals were injected in the peritoneal space with 200µl of 2% 
fluorescein in PBS. Fundus fluorescein angiography was obtained using the 
autofluorescent channel of the Spectralis™ HRA. Images were then exported 
and processed in Adobe Photoshop CS5.1 (Adobe Systems Incorporated, 
San Jose, USA). Images using the HRA2 scanning laser ophthalmoscope, 
were obtained and analysed in an identical manner. 
 
2.1.9 Slit-­‐lamp	  fluorescence	  fundal	  imaging	  of	  GFP	  
Following anaesthesia and dilation with 1% Tropicamide, mice were imaged 
using the standard fluorescein excitation filter on an SL-16 slit-lamp (Keeler, 
Windsor, UK). The optic disc was focussed centrally, with Viscotears as a 
coupling agent and a glass coverslip. Images were captured using the 
attached Leica DC500 camera, with a 30.5s exposure time for GFP and 
200.5ms for brightfield images. 
 
2.1.10 	  Mouse	  electroretinography	  
Animals underwent overnight dark adaptation prior to ERG. Anaesthesia was 
used as described above and eyes dilated with 1% Tropicamide and 2.5% 
Phenylephrine. ERGs were recorded using commercially produced 
equipment (Espion E2, Diagnosys LLC, MA, USA). The bandpass filter cut-
off frequencies used were 0.312 Hz for the low and 1000 Hz for the high- 
frequency cut-off. Scotopic recordings were obtained from dark-adapted 
animals at the following increasing light intensities: 0.003, 0.007, 0.03 and 
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0.5 cd.s/m2. The recordings used 15 responses per intensity with a 10 
second dark adaptation interval between each set. The final response was 
then averaged for each intensity and analysed at 0.03 cd.s/m2. Photopic 
recordings were performed following a 10-minute light adaptation interval on 
a background light intensity of 20 cd/m2, which was then used as background 
illumination for the duration of photopic flash and flicker recordings. Photopic 
flash recordings consisted of the average of 25 responses for each intensity 
with a 60s light adaptation interval between each step. Light intensities used 
were 0.1, 1, 3, 5, 10 and 20 cd.s/m2.  
 
2.1.11 	  Dexamethasone	  treatment	  
A stock solution of 2mg/ml Dexamethasone (Sigma Aldrich, Dorset, UK) was 
made in endotoxin free PBS. This was diluted 1:10 and 100μl injected i.p. 24 
hours before, after and contemporaneously as the sub-retinal injection. 
 
2.2 Initial AAV production 
2.2.1 Plasmid	  production	  
The pD10 vector backbone containing CMV-mIL-10-IRES-eGFP and CMV-
hrGFP between two ITR regions were provided by Dr Susie Barker. AAV9 
capsid and pHGTI helper plasmids were already generated. Plasmids were 
grown in DH5α bacteria, cultured for 16 hours in Miller’s LB broth (Merck, 
UK) with ampicillin selectivity and DNA isolated using a PureLink HiPure 
Plasmid Megaprep Kit (Invitrogen life technologies, Paisley, UK). 
 
2.2.2 Recombinant	  AAV2/9	  production	  
Twenty 15cm diameter Nunclon plates (Nunc, Thermo Fisher Scientific, 
Rochester, USA) were prepared per viral batch and seeded with HEK-293T 
cells at 4.5x106 in Dublecco’s modified eagle medium (DMEM) with 10% 
Fetal Calf Serum and 1x Anti-Anti (Invitrogen, life technologies, Paisley, UK).  
These were simultaneously transfected with 10µg of PD10 genomic plasmid, 
10µg of AAV9 capsid plasmid and 30µg of pHGTI helper plasmid per plate 
using Polyethylenimine (PEI). The plates were incubated at 37°C. Fresh 
media was replaced after 18 hours and the cells were harvested 72 hours 
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after transfection by scraping, suspension in TD Buffer and frozen at -80°C. 
Prior to purification three-freeze that cycles are performed. 
 
2.2.3 FPLC	  purification	  of	  AAV2/9	  using	  Sephacryl	  and	  Poros	  columns	  
On the day of purification, the viral lysate was defrosted and 50 units of 
Benzonase nuclease (Sigma Aldrich, Dorset, UK) per ml of lysate incubated 
for 30 minutes at 37°C. Multiple spins at 5000g for 20 minutes and 0.22µm 
filtration were performed to achieve debris-free supernatant. Using an AKTA 
prime plus FPLC machine the supernatant was passed over sequential 
Sephacryl and Poros columns (GE healthcare, Little Chalfont, UK). 
Sephacryl S-300 FPLC medium separates on the basis of size, retarding 
larger proteins less. AAV is thus eluted earlier than contaminant debris. 
Subsequently the elute is further purified by quaternary amine anionic 
exchange using Poros HQ50 medium, eluted in high salt buffer, collected 
and concentrated with a Vivaspin 40 column (Sartorius, Germany) to a 
volume of 200μl. Aliquots of virus are frozen at -80°C. 
 
2.2.4 Recombinant	  AAV2	  production	  
Twenty 15cm diameter plates (Nunc, Thermo Fisher Scientific, Rochester, 
USA) of BHK cells seeded at 4.5x106 were prepared per viral batch. Feeding 
medium for these cells consists of 500ml Glasgow MEM BHK-21 media 
(Gibco, Grand Island, NY, USA) is supplemented with 50ml Fetal Calf Serum 
(First Link, UK), 25ml of 1x Tryptose Phosphate broth (Gibco, USA). The 
BHK cells were transfected with 30µg per plate of the pD10-CMV-IL-10-
IRES-eGFP construct plasmid and an equal amount of pHAV7.3 (rep/cap 
helper) plasmid. This was combined with 45µg of Lipofectin reagent 
(Invitrogen life technologies, Paisley, UK) and 200µg Peptide 6 (Insight 
Biotechnology, Wembley, UK) per plate. After 72 hours incubation at 37°C, 
cells were harvested, re-suspended and freeze-thawed three times. On the 
day of purification, 50 units of Benzonase (Sigma Aldrich, Dorset, UK) per ml 
of lysate were incubated for 30 minutes at 37°C. The mixture is then spun at 
5000g for five minutes and the supernatant brought to a 0.5% final 
concentration of deoxycholic acid (Sigma Aldrich, Dorset, UK). Following a 
further 30-minute incubation, the mixture is passed through a 0.8µm filter. 
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Purification was carried out using a Heparin packed column (Sigma Aldrich, 
Dorset, UK), which specifically binds the AAV2 capsid. The column is 
washed with 0.1M NaCl and the virus then eluted with 0.4M NaCl and 
concentrated in a Vivaspin 40 column (Sartorius, Germany) to a volume of 
200μl. Aliquots of virus are frozen at -80°C. 
 
2.2.5 SYPRO	  Ruby	  Gel	  analysis	  of	  AAV	  preps	  
Two dilutions of each AAV prep were incubated with Laemmli buffer 
(4%SDS, 20%glycerol, 0.004% Bromophenol blue, 0.125M Tris HCl, 0.2M 
DTT) and incubated at 95°C for 5 minutes. Samples were run on a 10% 
acrylamide gel to completion. The gel was fixed with 7% acetic acid in 50% 
v/v methanol, then stained overnight with SYPRO Ruby total protein stain 
(Invitrogen life sciences, Paisley, UK). Following two washes with 7% acetic 
acid in 10% methanol v/v the gel was imaged on a standard UV gel imager 
(Syngene, UK). 
 
2.2.6 Dot	  blot	  based	  AAV	  prep	  titre	  determination	  	  
Different dilutions of AAV prep were incubated with Proteinase K (Sigma 
Aldrich, UK) for 30 mins at 56°C. The DNA was precipitated then dissolved in 
the working buffer of 0.4M NaOH 10mM EDTA. A known standard curve of 
linearised plasmid was created in the same buffer. All samples were 
denatured at 95°C for 2 minutes, then transferred on to a Hybond-N+ 
membrane (GE Healthcare) in a 96-well plate vacuum transfer apparatus 
(BioRad, Hemel Hempsted, UK). The membrane is then dried and hybridised 
in a rotisserie oven at 65°C overnight with a biotinylated DNA probe to the 
region of interest, eg. CMV promoter. Multiple washes first with 5%SDS/ 
125mM NaCl/ 25mM sodium phosophate, then with a 1:10 dilution are 
performed. Streptavidin-Alkaline phosphatase labelling with Phototope-Star 
detection kit (NEB, Hitchin, UK) A solution containing 0.79g Tris-HCl/ 0.29g 
NaCl/ 0.048g MgCl in 500ml distilled water is used for washing, before 
chemiluminescent development and photography on a Nikon LAS4000 CCD 
imager. Image J was used for densitometry and the titres calculated against 
the standard curve of plasmid.   
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2.3 Refined AAV production process 
2.3.1 Recombinant	  AAV8	  and	  ShH10	  production	  process	  
The pDP8.ape plasmid was obtained from PlasmidFactory GmbH & Co. 
KG (Bielefeld, Germany) at 1mg/ml concentration, produced in endotoxin-
free conditions. Genomic plasmids, the ShH10 capsid plasmid and pHGTI 
helper were grown in DH5α bacteria, cultured for 16 hours in Miller’s LB broth 
(Merck, UK) with ampicillin selectivity. DNA was isolated using an EndoFree 
Plasmid Mega Kit (Qiagen, Valencia, USA). 
 
2.3.2 Recombinant	  AAV8	  and	  ShH10	  production	  
Twenty 15cm diameter Nunclon plates (Nunc, Thermo Fisher Scientific, 
Rochester, USA) were prepared per viral batch and seeded with HEK-293T 
cells at 4.5x106 in Dublecco’s modified eagle medium (DMEM) with 10% 
Performance Plus Fetal Bovine Serum and 1x Anti-Anti (Invitrogen, life 
technologies, Paisley, UK). These were simultaneously transfected with 10µg 
of pD10 genomic plasmid, 10µg of ShH10 capsid plasmid and 30µg of pHGTI 
helper plasmid per plate using Polyethylenimine (PEI). For AAV8 10µg of 
pD10 plasmid was combined with 30µg of pDP8.ape. Plates were incubated 
at 37°C. Medium was aspirated after 18 hours and replaced with DMEM and 
Anti-Anti alone. The cells were harvested 72 hours after transfection by 
scraping, suspension in TD Buffer and frozen at -80°C. Prior to purification 
three-freeze that cycles are performed and lysates were assured at below 
2.5EU/ml endotoxin. 
 
2.3.3 Purification	  of	  AAV8	  and	  ShH10	  vectors	  
On the day of purification, the viral lysate was defrosted and 50 units of 
Benzonase nuclease (Sigma Aldrich, Dorset, UK) per ml of lysate incubated 
for 30 minutes at 37°C. A single spin at 18000g for 30 minutes and 0.22µm 
filtration were performed to achieve debris-free supernatant. Lysate is diluted 
to 45ml with endotoxin-free PBS and passed into a disposable 1ml AVB 
affinity column (GE Healthcare, UK) at 2ml/min on a 0.5M Sodium hydroxide 
sanitised AKTA prime plus FPLC machine. AAV is eluted with a solution of 
50mM Glycine (pH2) into 1.5ml tubes containing 30µl 1M Tris pH8.8 from 
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Trizma base (Sigma Aldrich, Dorset, UK). The pooled aliquots corresponding 
to the peak of viral elution are diluted 1 in 2 with PBS and concentrated with 
a Vivaspin 40 column (Sartorius, Germany) to a volume of 200μl. Aliquots of 
virus are frozen at -80°C. 
 
2.3.4 Limulus	  Amoebocyte	  Lysate	  assay	  
Single use gel-clot limulus amebocyte lysate assay tubes of 0.03EU/ml 
sensitivity (Pyrotell, Associates of Cape Cod, USA) were used to test 
samples for endotoxin. Briefly, samples were diluted with endotoxin-free PBS 
to achieve the desired threshold for testing e.g. 1:83 to test at 2.5EU/ml. 
200ul were added to each tube and incubated undisturbed for one hour at 
37°C. A positive result is confirmed by static clot formation, despite inversion 
of the tube. Positive control tubes were used to detect the presence of any 
test inhibitors in all samples (Charles River, France). 
 
2.3.5 Viral	  titre	  calculation	  using	  qPCR	  
Custom ITR primers (see Table 7) were used with a bespoke FAM probe 
based assay (Sigma Aldrich, UK) to determine genomic titre with a 
quantitative PCR thermal cycler 7900HT (Applied Biosciences, USA). 
Following initial denaturation at 95°C for 10minutes all AAV capsids are 
lysed, exposing DNA to direct primer annealing. 40 cycles of 15sec at 95°C 
and 1min at 60°C annealing extension are used. From linearised pD10 
plasmid of known concentration a standard curve was generated. Master mix 
was from Roche Diagnostics, UK. For each sample, technical triplicates were 
performed over a four two-fold dilutions.  
 
2.3.6 Capsid	  separation	  process	  
Following standard production and AVB purification, fractions are pooled and 
diluted in MilliQ water in a 1:10 ratio. A 1ml Sepharose QXL column (GE 
Healthcare, UK) is equilibrated with 10mM NaCl solution. The vector is 
loaded and washed with 5 column volumes. Using a 250mM NaCl solution as 
the second buffer, a step to 30% mix was performed, before a gradient from 
30%-100% over 50ml. 1ml fractions were retained separately for analysis. 
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2.3.7 Electron	  microscopy	  of	  AAV	  
AAV fractions were washed with distilled water and concentrated using a 
Vivaspin 40 column (Sartorius, Germany). 8µl is placed upon a glow 
discharged EM grid. Following two PBS washes, 2% Uranyl acetate is 
applied for 1 minute. A single wash with distilled water is then performed. 
Grids were imaged by Dr Hannah Armer from the Institute of Ophthalmology 
imaging core facility on a JEOL 1010 100kV Transmission electron 
microscope with a Gatan Orius digital camera. 
 
2.3.8 AAV	  neutralising	  antibody	  and	  ELISPOT	  assays	  
30,000 HEK-293T cells were plated in each well of a 96-well plate and 
expanded over 24hr. Serial dilutions of serum to be tested were made with a 
minimum of neat and 1:100 dilutions. 5x108gc AAV8-CMV-hrGFP per well 
diluted in 20µl DMEM was combined with 20µl of diluted serum and 
incubated at 37°C for 10minutes. 110µl of D10 medium was added and the 
combined volume of 150µl added to each well of 293T cells. After 72hrs cells 
were dissociated with 0.05% Trypsin and 10,000 events acquired on a BD 
FACScalibur flow cytometer. Technical triplicates were performed and the 
percentage of GFP+ cells enumerated.  
 
Mouse ELISPOTs were performed with Dr Pete Gardner. Briefly, a 96-well 
Immobilon-P plate (Merck Millipore, Watford, UK) was prepared and coated 
with rat anti-mouse anti-IFNγ antibody plate (clone R4-6A2, eBioscience, 
San Diego, USA) at 10µg/ml in 100µl PBS. After incubation at 4°C overnight, 
the plate was washed four times with PBS, blocked for an hour at 37°C with 
neat FBS (Invitrogen life technologies, Paisley, UK) and then washed again 
with PBS. Cryopreserved splenocytes were recovered and diluted to a 
concentration of 2.5x106 cells/ml in D10 medium. 100µl of cells were added 
to each well, including positive and negative control wells. Finally, to test 
directly against viral capsid protein, AAV-CMV-eGFP was added to each well 
to achieve a final concentration of 108gc/ml. The plate was incubated at 37°C 
for 48 hours, before removal of cells and washing with PBS. 100µl secondary 
biotinylated anti-mouse IFNγ (clone XMG1.2, eBioscience, San Diego, USA) 
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was applied at 1µg/ml and incubated for 2 hours at room temperature. 
Following PBS washing, 1:1000 dilution of ExtrAvidin (Sigma Aldrich, Dorset, 
UK) in PBS is incubated for 30mins at room temperature, before repeat 
washing and development using AP-substrate buffer (AP-conjugate substrate 
kit, BioRad, Hemel Hempsted, UK) at working dilution. This takes 
approximately 30 minutes and is quenched by washing with tap water. The 
membrane is dried overnight and subsequently punched out from the plate, 
and spot counts calculated using ImmunoScan (C.T.L. Bonn, Germany). 
 
2.4 Lentivirus preparations 
 
Lentivirus SFFV.mIL-10 and SFFV.eGFP were a kind gift of Dr Susie Barker 
and Dr Anastasios Georgiadis. Briefly, vectors were produced using transient 
triple transfection of 293T cells. At 28–72 h post-transfection, supernatant 
was harvested and filtered through a 0.45μm filter. The virus particles were 
concentrated using a Resource Q anionic exchange column (Amersham, UK) 
and eluted using a sodium chloride gradient. The eluted fractions were 
placed in an ultra centrifuge at 90000g for 2h. The pelleted virus was re-
suspended in OptiMEM medium and stored at -80°C. 
 
2.5 Molecular biological techniques 
2.5.1 Basic	  cloning	  techniques	  
All restriction enzymes were from New England Biosciences or Promega. T4 
ligase was used for ligation (Promega). DH5α competent cells were from 
Bioline, UK. Gel electrophoresis was performed with 1-2% Agarose 
(Invitrogen Life Sciences) and run with TE buffer (Invitrogen Life Sciences) in 
the Mini-Sub cell system (Biorad laboratories, Hemel Hempsted, UK). DNA 
and RNA quantification employed spectrophotometry on a Nanodrop ND-
1000 (Thermo Scientific, UK). PureLink HiPure Plasmid Mini-prep Kit 
(Invitrogen life technologies, Paisley, UK). 
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2.5.2 Synthesis	  of	  mouse	  p75-­‐Ig,	  viral	  and	  human	  IL-­‐10	  
All synthesis was performed by GenScript, Piscataway, USA. The open 
reading frame of BCRF1 from Human Herpes Virus 4, type 1 (NCBI 
Reference Sequence: NC_007605.1) was synthesized after human codon 
optimization (USA) and ligated into pD10 under the control of the immediate-
early CMV promoter. The human IL-10 sequence (NM_000572.2) was 
synthesized with flanking restriction enzyme sites and also ligated into the 
pD10-CMV plasmid. The mouse p75-Ig (TNF receptor 2 Fc-fusion protein) 
was synthesized according to the sequence obtained from Doll et al. 161 This 
was also ligated into pD10-CMV. 
 
2.5.3 Interferon	  gamma	  inducible	  promoter	  and	  NFκB	  constructs	  
The sequence for human Interferon Regulatory Factor 1 (IRF1) was obtained 
from the ENSEMBL database (ENSG_00000125347) and a previously 
identified enhancer region was amplified using PCR.162 The primer 
sequences are shown in Table 7. Promoter fragments were cloned into the 
commercially available pGL4-Luc2 construct (Promega, USA). The minimal 
SV40 promoter was synthesised and cloned downstream of the short IRF1 
enhancer fragment (Genscript, Piscataway, USA). A five-repeat NFκB 
enhancer sequence (GGGAATTTCC)5 in front of a minimal SV40 promoter in 
the pGL4 plasmid was commercially available (Promega, UK). This was in 
turn cloned in place of the CMV promoter in pD10. 
 
Name Sequence Use 
Short IRF1-F GTCGACGCGCCCGGCCGGAGAG PCR 
Short IRF1-R AGATCTCGAGCAGCGGCGCCACCGA PCR 
ITR_F GGAACCCCTAGTGATGGAGTT qPCR 
AAV titre 
ITR_R CGGCCTCAGTGAGCGA qPCR 
AAV titre 
FAM-ITR probe [6FAM]-CACTCCCTCTCTGCGCG qPCR 
AAV titre 
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Table 7. All  ol igonucleotides were synthesised by Sigma Aldrich, Dorset,  UK. 
 
2.5.4 Luciferase	  assessment	  of	  promoter	  activity	  	  
Candidate pGL4 constructs were transfected into HEK-293T cells using 
0.75µl Lipofectin (Sigma Aldrich, Dorset, UK) suspended in Optimem 
medium (Gibco, Invitrogen life technologies, Paisley, UK) and 1µg of plasmid 
per 50,000 cells for four hours. A pTK-Renilla control plasmid was co-
transfected at a ratio of 1:50. After 40 hours, the medium was supplemented 
with different concentrations of recombinant human IFNγ or TNF (Invitrogen 
life technologies, Paisley, UK). Four hours later cells were harvested in 
30µl/well 1x Passive Lysis Buffer (PLB) and then tested using the Dual-
Luciferase Reporter assay system (Promega, Madison, USA). 1µl of PLB 
was combined with 15µl LARII reagent, then 15µl Stop & Glo® buffer as 
directed. Luminescence was detected using a single sample TD-20/20 
luminometer (Turner Designs, Steptech, Stevenage, UK) with a two second 
delay and 15-second integration time. All tests were performed in triplicate 
with controls for background levels. 
 
2.5.5 RNA	  extraction	  and	  cDNA	  synthesis	  for	  RT-­‐PCR	  
RNA was extracted using RNeasy Mini Kit (Qiagen, USA) according to 
manufacturer’s instructions following tissue homogenization in mortar and 
pestle eppendorf tubes (VWR International, Dublin, Ireland). RNA was 
IFNγR1-F 
 
CATAACCGGAGTGGGGAGA RT-PCR 
IFNγR1-R TCCGTCTACTGAAATACAATATCTGG RT-PCR 
KC_F AGACTCCAGCCACACTCCAA qPCR 
KC_R TGACAGCGCAGCTCATTG qPCR 
CCL2_F CATCCACGTGTTGGCTCA qPCR 
CCL2_R GATCATCTTGCTGGTGAATGAGT qPCR 
TNF_F CTGTAGCCCACGTCGTAGC qPCR 
TNF_R TTGAGATCCATGCCGTTG qPCR 
Mouse β–actin F AAGGCCAACCGTGAAAAGA qPCR 
Mouse β–actin R GTGGTACGACCAGAGGCAT qPCR 
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reverse-transcribed using the QuantiTect Reverse Transcription Kit (Qiagen, 
USA). Ambion RNA-ZAP was used for decontamination of surfaces 
(Invitrogen life technologies, Paisley, UK). 
 
2.5.6 Quantitative	  PCR	  (qPCR)	  
For simple RT-PCR such as IFNγR1 detection, hot start master mix 
(Promega, USA) was used with 1µl cDNA and primers at 10µM (detailed in 
Table 7). A standard program of 40 cycles at 60°C annealing extension was 
used. 
 
Relative real-time quantitative RT-PCR was performed using the Universal 
Probe Library system and master mix (Roche diagnostics, UK). An Applied 
Biosciences 7900HT thermal cycler and SDS software was employed. 
Following initial denaturation at 95°C for 10min, 40 to 50 cycles of 15sec at 
95°C and 1min at 60°C annealing extension were used. Samples were run in 
triplicate and analysed using the 2-ddCT method. 
 
2.6 Histology and immunohistochemistry 
2.6.1 Frozen	  sectioning	  
Enucleated eyes were snap frozen with liquid nitrogen in Optimal Cutting 
Temperature (OCT) medium (Fisher scientific, Loughborough, UK). 12µm 
cryosections were placed on Superfrost plus ultra slides (VWR International, 
Dublin, Ireland), using a manual cryostat (OTF5000, Bright Instruments, 
Huntingdon, UK) If not used immediately, the slides were kept at -20°C for up 
to 3 months. 
 
2.6.2 Histological	  scoring	  of	  EAU	  using	  anti-­‐CD45	  
Slides were thawed, before fixation for 10 minutes at 4°C in 99.5% Acetone 
(Sigma Aldrich, Dorset, UK). Endogenous peroxidase activity was blocked 
with 0.3% Hydrogen Peroxide diluted in Methanol (Sigma Aldrich, Dorset, 
UK) for 15 minutes. Non-specific binding was blocked with 7.5% rabbit serum 
in 2% BSA/PBS for an hour and incubated overnight at 4°C with a CD45 rat 
anti-mouse primary antibody (Clone IBL-3/16, AbD Serotec, Kidlington, UK). 
Biotinylated rabbit anti-rat secondary antibody (Dako UK Ltd, Ely, UK) was 
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applied, diluted 1:200 in 0.1% BSA/PBS, before using Vectastain elite ABC 
kit (Vector laboratories, Peterborough, UK) according to manufacturer’s 
instructions to conjugate horseradish peroxidase to the secondary antibody. 
Between all of the above steps, two washes with PBS were performed on 
each slide. Chromogenic staining was performed using a 3, 3’-
diaminobenzidine (DAB) substrate kit (Vector laboratories, Peterborough, 
UK) for three minutes duration and counterstained with Haematoxylin (Vector 
laboratories, Burlingham, USA). Scoring was performed across the whole 
slide, selecting the most severe example of disease possible and marked 
according to a previously described system.163 A summary table of the 
scoring system is reproduced here for clarity. 
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2.6.3 Retinal	  flat-­‐mount	  dissection	  
Following enucleation, eyes were fixed in 4% PFA for 2 minutes then placed 
in 100µl PBS and dissected under an operating microscope (Zeiss, Jena, 
Germany). Briefly, a 28G needle is passed through the corneal limbus and 
then curved Vanna scissors used to remove the cornea and iris. The lens is 
carefully dislodged and removed, before four evenly spaced full-thickness 
cuts from limbus to near the optic disc are performed. The retina is mobilised 
from the RPE/choroid complex at each petal now formed and a cut made at 
the fusion around the region of the vitreous base. A final cut through the optic 
nerve head immediately under the retina is performed. Tissues are then fixed 
with 100% methanol and stored at -20°C. 
 
2.6.4 Frozen	  section	  and	  flat-­‐mount	  immunohistochemistry	  	  
Slides were defrosted and post-fixed with 4% PFA for 15minutes. Two PBS 
washes are followed by blocking with 1%BSA in PBS (Sigma Aldrich, Dorset, 
UK) and 5% normal goat serum (AbD serotec, Kidlington, UK) for one hour at 
room temperature. Primary antibodies were applied at concentrations 
described in Table 8 overnight at 4°C. After two PBS washes secondary 
antibodies were applied in 1%BSA in PBS in a 1 in 500 dilution at room 
temperature for two hours. Following two further PBS washes, slides were 
mounted in Fluorescent mounting medium (Dako, Ely, UK) containing 1:1000 
dilution of DAPI. 
 
Flat-mounts were placed into 1%BSA in PBS supplemented with 5% Triton 
as a detergent. 5% Normal goat serum is added and incubated at room 
temperature for two hours. Following three PBS washes, flat mounts were 
incubated overnight at 4°C in 1%BSA/PBS/5%Triton with primary antibodies 
at dilutions listed in Table 8. A further three PBS washes are performed and 
then incubated for another 24hr at 4°C in 1%BSA/PBS/5%Triton with 
secondary antibodies. Two PBS washes are performed before a 1:1000 
dilution of DAPI in PBS is applied for 1 hour. Three PBS washes precede 
mounting between two coverslips in Fluorescent mounting medium (Dako, 
Ely, UK). 
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Reactivity Host 
species 
Concentration Manufacturer Catalogue 
number 
CD45 Rat 1 in 200 AbD Serotec MCA1388 
CD4 Rat 1 in 200 BD 
Bioscience 
553043 
CD8 Rat 1 in 200 BD 
Bioscience 
553027 
IFNγR1 Armenian 
hamster 
1 in 300 BD 
Bioscience 
559911 
Nitrotyrosine Rabbit 1 in 400 Sigma N0409 
Isolectin-B4 Biotin 1 in 200 Sigma L2140 
CD11b Rat 1 in 200 BD 
Bioscience 
553308 
Iba-1 Rabbit 1 in 200 Wako 01-19741 
Collagen IV Rabbit 1 in 200 AbD Serotec 2150-1470 
Human 
Ezrin 
Rabbit 1 in 200 Cell Signalling 31545 
Human 
Phalloidin 
TRITC-
conjugate 
1 in 500 Sigma P1951 
 
Table 8. Primary antibodies used in immunohistochemistry.  Unless stated al l  ant ibodies 
are ra ised against mouse t issues. Al l  secondary ant ibodies used Goat ant i -
rat /rabbit /streptavid in -  Alexa Fluor 488/546/633 from Invi t rogen l ive sciences. 
 
2.6.5 Paraffin	  sections	  
Eyes were fixed in Serras fixative (60% Ethanol, 30% Buffered 37% 
Formalin, 10% Acetic acid, Sigma Aldrich, Dorset, UK) for 3 hours. This was 
then changed into 70% isopropanol and refreshed over 24hrs. Standard 
processing sequence was then performed and then embedded into paraffin 
wax. A microtome (Leica RM2235) was used to cut 6µm sections placed on 
to Polysine coated slides (VWR International, Dublin, Ireland). Slides were 
dewaxed and stained with haematoxylin and eosin. EAU scoring of these 
sections used a published method.164. Briefly, vitreous cells only = 1, 
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vasculitis = 2, retinal folds >10% retina = 3, moderate photoreceptor loss = 4, 
extensive retinal destruction = 5. 
 
2.6.6 Microscopy	  
Brightfield and simple fluorescence microscopy was performed using an Axio 
Observer.Z1 (Carl Zeiss Microimaging, Jena, Germany). High magnification 
immunofluorescent histology and retinal flat-mounts were imaged with a 
Leica DM5500Q confocal laser-scanning microscope (Leica Microsystems, 
Wetzlar, Germany). Z-stacks were obtained at 1µm intervals. 3D 
reconstruction was performed using Imaris software (Bitplane, Zurich, 
Switzerland). 
 
2.7 Detection of cytokines 
2.7.1 Enzyme	  linked	  immunosorbant	  assay	  (ELISA)	  
R&D Duoset ELISAs (R&D systems, Minneapolis, USA) were used to 
quantify all soluble cytokines and transgenes except Human IL-10 Deluxe 
(Biolegend, San Diego, USA) and human VEGF Quantikine ELISAs (R&D 
systems).  All were used according to manufacturer’s instructions. Cell 
culture supernatants were diluted 1:10 and 1:100. Homogenised ocular 
samples were spun at 13,000 rpm for 10 minutes and the supernatant 
typically diluted between 1:10 to 1:1000 prior to testing. Samples were 
analysed with technical triplicates unless limited material precluded this. Only 
results within the linear range of the standard curve were used. 
 
2.7.2 BCA	  total	  protein	  assay	  
Following the manufacturer guidelines, 5ul of sample was measured against 
a standard curve constructed from BSA of known concentration (Bio-Rad 
laboratories, Hemel Hempsted, UK). After a 20 minute incubation the result 
was read at 650nm on a plate spectrophotometer (Molecular devices Emax, 
Sunnyvale, USA). 
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2.7.3 Proteome	  Profiler	  
Pooled supernatants from 5 eyes, obtained through the standard EIU 
quantification protocol were combined and used for each membrane. The 
assay was otherwise carried out according to the manufacturer’s guidelines 
(R&D systems, Minneapolis, USA). Chemiluminescent imaging was 
performed with a Nikon LAS4000 CCD imager and saved as an 8-bit TIFF 
file. Densitometry was calculated with Image-J and each membrane was 
normalised to another using all six positive control spots and a background 
reading. 
 
2.8 Tissue culture 
2.8.1 Maintainance	  cultures	  
All HEK-293T and WEHI-164 cell cultures used D10 medium, composed of 
10% Fetal bovine serum and 1x Anti-anti in DMEM (Gibco, Invitrogen life 
sciences, UK).  Cell were maintained in 50ml tissue culture treated flasks 
(Cellstar, Greiner bioscience, Frickenhausen, Germany), until plated as 
required into 48- or 96-well flat bottom plates (Costar, Corning, NY, USA) 
 
2.8.2 Recombinant	  cytokines	  
Recombinant cytokines were stored and used according to manufacturers’ 
instructions and purchased in lyophilised aliquots of 10µg. Mouse TNF 
(Invitrogen life technologies, Paisley, UK), human TNF (Invitrogen life 
technologies, Paisley, UK), human IFNγ (Invitrogen life technologies, Paisley, 
UK and Biolegend, San Diego, USA), mouse IL-10 (Biolegend, San Diego, 
USA and Cell Signalling technologies, Danvers, USA) and human IL-10 
(Invitrogen life technologies, Paisley, UK) were used. 
 
2.8.3 Transfection	  of	  plasmids	  and	  transduction	  by	  AAV	  
The following day the cells were transfected using Lipofectin (Sigma Aldrich, 
Dorset, UK) and Peptide 6, suspended in Optimem medium (Gibco, 
Invitrogen life sciences, UK) and 0.3μg per well of pD10-NFKB-eGFP 
plasmid for four hours. After this the medium was replaced with D10. 
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2.8.4 NFKB-­‐eGFP	  based	  in	  vitro	  testing	  of	  TNF	  neutralising	  activity	  
30,000 HEK-293T cells were plated overnight into a flat-bottomed 96-well 
tissue culture treated plate and incubated in standard 37 degree 5% CO2 
conditions. The following day the cells were transfected using Lipofectin 
(Sigma Aldrich, Dorset, UK) and Peptide 6, suspended in Optimem medium 
and 0.3μg per well of pD10-NFKB-eGFP plasmid for four hours. After this the 
medium was replaced with D10.  
 
5ng/ml human TNF in D10 was mixed with the test sample (cell culture 
supernatants or recombinant antibody) and incubated at room temperature 
for 15 minutes. Cells were then culture in this mix for 16 hours before the 
media was aspirated, 100μl	  0.05% Trypsin-EDTA added to each well and 
 
2.8.5 WEHI-­‐164	  cytotoxicity	  assay	  
Cells were cultured in D10 medium and with 30,000 per well plated in a 48-
well plate for 3 days. 10ng/ml mTNF (Invitrogen Life Sciences) was added to 
Optimem and combined 1:1 v/v with 0.22um filtered 293T supernatants 
containing different proteins at room temperature for 30 minutes. D10 was 
aspirated from the WEHI-164 cells and replaced with the TNF-Inhibitor mix. 
After 18 hours in standard culture conditions (5% CO2. 37°C) the cells were 
trypsinised, spun down at 300g for 5 minutes before resuspension in 7AAD. 
(Sigma Aldrich, Dorset, UK) Cells were analysed for 10000 events on a 
FACScalibur analyser (BD Biosciences, Oxford, UK). 
 
2.8.6 Muller-­‐glia	  cultures	  
These were a kind gift of Dr Claire Hippert. Briefly retinae from the CRALBP-
GFP reporter mouse line were dissected and dissociated in 20U/ml Papain. 
Cells were sorted for GFP+ signal using FACS (MoFlow XDP, Beckman 
Coulter, UK) and plated on laminin coated 8-well tissue culture plates. 
Standard D10 medium was used. After 1 week of culture at 37°C cells 
elongate processes and are ready for analysis. They have been previously 
characterised as possessing a Muller cell phenotype. 
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2.8.7 Human	  ES	  and	  iPS	  cell	  derived	  RPE	  transwell	  cultures	  
Stem-cell cultures were a kind gift of Dr Anai Gonzalez-Cordero. Briefly, 
human embryonic stem (ES) and induced pluripotent stem (iPS) cells were 
differentiated into RPE using suspension conditions, which aid the formation 
of embryoid bodies (EBs). From day 2-4 SMAD inhibition of Wnt and BMP 
signalling was used to promote an anterior telencephalic phenotype. On day 
6, EBs were plated on laminin-coated 6-well flat-bottom plates and cultured 
at 37°C/5% CO2 in neural induction media until day 15. At this point retinal 
differentiation medium (RDM), but supplemented with activin A was used to 
induce RPE maturation and pigmentation.  
 
Patches of pigmented RPE were observed from day 30 in culture. These 
were dissected out using a 21G needle and expanded in a laminin coated 
24-well plate transwells of 0.22µm diameter pore size. These were cultured 
in the presence of FBS until confluence, when they were maintained in FBS 
free-RDM. ShH10 vector was added at an MOI of 15000 diluted in 300µl 
medium the apical compartment. 24 hours later 500µl of medium was added 
to each compartment. Viral expression was checked for GFP fluorescence 
and confirmed at 5 days. Media was sampled and exchanged at different 
timepoints from 5 days onwards. 
 
2.9 Preparation and analysis of eyes by flow cytometry 
 
2.9.1 Tissue	  dissection	  
Following enucleation, each eye was dissected in 100µl of PBS. Using a 
limbal incision the vitreous and retina were extracted. The anterior chamber 
was also opened and the contents washed into the dissecting fluid. The 
retina and PBS were completely aspirated and placed into a 1.5ml eppendorf 
tube. If AC and posterior chamber separation was required, the AC was 
opened by clear corneal incision first, PBS removed, then replaced before 
the retina and vitreous were dissected. RPE samples were dissociated 
initially by scraping with curved forceps in 100µl of PBS until only bare sclera 
is seen. The fluid is then transferred to a 1.5ml eppendorf tube.  
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2.9.2 Preparation	  of	  ocular	  tissues	  for	  analysis	  by	  flow	  cytometry	  
Mechanical cell dissociation was performed by rapping the eppendorf tubes 
containing the retinal or RPE sample across a standard tube rack ten times. 
The whole sample was placed into a 96-well 60µm cell strainer plate (Merck 
Millipore, Watford, UK) and washed with 100µl of PBS. The plate was 
centrifuged at 300g for 5 minutes, ‘retinal supernatants’ collected, with the 
remaining cell pellet transferred into a 96-well V-bottom plate. Where 
appropriate, cells were incubated in 100µl of working dilution fixable viability 
dye eFluor780 (eBioscience, San Diego, USA) for 30 minutes at room 
temperature. Cells were washed in the plate with 0.1% BSA in PBS before 
resuspension in 0.5µl of neat Fc-block rat anti-mouse CD16/CD32 (BD 
Biosciences, Oxford, UK) diluted in 50µl 0.1% BSA in PBS. After 5 minutes, 
another 50µl was added containing 0.5µl of each neat primary conjugated 
antibody (See Table 9). Following staining on ice for 20 minutes, the cells 
were washed twice then placed into 200µl 0.1% BSA in PBS in FACS tubes. 
Intracellular cytokine staining of retinal T-cells was performed by re-
stimulating for 2 hours with 50 ng/ml PMA and 500 ng/ml Ionomycin then 1 
mg/ml Brefeldin (all from Sigma Aldrich, Dorset, UK) in complete IMDM. 
Transcription Factor Buffer Set (BD Biosciences, Oxford, UK) was used 
according to the manufacturer’s protocol for intracellular staining. 
2.9.3 Flow	  cytometers	  
Three flow cytometers (FACScalibur, LSRII, Fortessa X-20) all from BD 
Biosciences were used during the project, dependent upon experiment. Each 
was regularly maintained and used according to manufacturers’ instructions. 
Medium or High flow rates were used. Compensation was performed using 
OneComp eBeads (eBioscience, San Diego, USA, 01-1111-42) and an ArC 
Amine reactive Compensation bead kit (Invitrogen Life Sciences, A10346) for 
the live-dead stain. Fluorescence-minus-one (FMO) controls were used to 
determine gate position. Analysis was performed using FlowJo (Treestar, 
Ashland, OR, USA).  
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2.9.4 Absolute	  cell	  count	  using	  flow	  cytometry	  
50,580 Sphero AccuCount Blank polystyrene beads of 7.28µm diameter 
(Spherotech Inc, Chigaco, USA) were diluted into 300µl of 0.1% BSA in PBS 
and eight, two-fold serial dilutions were made. These were acquired on the 
flow cytometer at on the same occasion as samples. Settings were kept the 
same, with the highest flow rate for a fixed duration - typically 45 seconds. By 
gating around the bead region and taking an absolute count (FlowJo, Tree 
star), a standard curve was constructed in relation to the number of expected 
beads, using a linear regression constrained through zero. (Graphpad Prism, 
La Jolla, USA). This method was used to estimate the absolute number of 
cells in each flow cytometry experiment. 
 
2.9.5 Primary	  conjugated	  antibodies	  used	  for	  flow	  cytometry	  
 
Reactivity Clone Conjugate Company Catalogue 
number 
CD45 30-F11 FITC eBioscience 11-0451-85 
CD45 30-F11 BV 421 Biolegend 103133 
CD11b M1/70 PE-Cy7 eBioscience 25-0112-82 
CD4 L3T4 PE BD Bioscience 557308 
Ly6G 1A8 APC Biolegend 127614 
Ly6C HK1.4 PE eBioscience 12-5932-80 
CD8b H35-17.2 eFluor 450 eBioscience 48-0083-82 
Ly6C HK1.4 PerCP Biolegend 128027 
IL-4 11B11 BV605 Biolegend 504125 
Gr1 RB6-8C5 APC eBioscience 17-5931-82 
FoxP3 MF23 Alexa 488 BD Bioscience 560403 
Ly6C HK1.4 BV605 Biolegend 128035 
CD11b M1/70 PerCP Biolegend 101230 
CD4 GK1.5 PE-Cy7 eBioscience 25-0041-82 
CD45 30-F11 BUV395 BD Bioscience 564279 
CD94 18d3 PE eBioscience 12-0941-81 
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IL-17A 17B7 eFluor 450 eBioscience 48-7177-82 
IFNγ XMG1.2 APC eBioscience 17-7311-82 
I-A[b] AF6-120.1 PE BD Bioscience 553552 
Fixable 
viability dye 
N/A eFluor 780 eBioscience 65-0865-14 
 
Table 9. Primary conjugated antibodies used for f low cytometry.  Unless stated otherwise 
al l  ant ibodies were ra ised against mouse t issues. 
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3 Results 1: Optical Coherence Tomography 
can be used to characterise and define the 
severity of murine Experimental Autoimmune 
Uveoretinitis 
 
Work presented in this chapter has been published as: 
 
Chu CJ, Herrmann P, Carvalho LS, Liyanage SE, Bainbridge JWB, Ali RR, 
Dick AD & Luhmann UFO 
Assessment and In Vivo Scoring of Murine Experimental Autoimmune 
Uveoretinitis Using Optical Coherence Tomography. 
PLoS ONE (2013) 8(5): e63002. 
  
 
CJ Chu performed the majority of the work and manuscript preparation.         
P. Herrmann provided technical assistance with OCT image capture. LS 
Carvalho and SE Liyanage provided independent EAU disease scores using 
the different systems. All other authors provided supervision, advice on 
experimental design and data interpretation. 
 
 
 
Before starting interventional studies to suppress EAU, it was apparent that 
the tools used for assessing disease severity and progression could be 
improved. The utility of conventional readouts for EAU such as histology, 
fundal photography and flow cytometry are each limited by either their 
inability to provide repeated in vivo assessment, their semi-quantitative 
nature or the lack of corresponding structural information. To surmount many 
of these limitations, a novel scoring system for EAU using optical coherence 
tomography was explored.  
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3.1 Optical Coherence Tomography has the potential to 
surmount the limitations of current methods of EAU 
scoring 
 
Central to the application of any animal model of human pathology, is the 
ability to follow the course of disease and assess the result of therapeutic 
intervention. In experimental autoimmune uveoretinitis (EAU) in C57BL/6 
mice, the gold standard for determining disease severity is with histology and 
several scoring systems have been validated.165,166 Obtaining post-mortem 
histology however necessitates large numbers of animals and precludes 
repeated examination or multiple terminal analyses upon the same eye.  
 
These limitations prompted the introduction of topical endoscopic fundus 
imaging (TEFI), which whilst a useful technique also has limitations. Based 
on a fundal image it only provides a surrogate measure of histological 
pathology. It additionally uses an extremely bright light source, which can 
induce confounding light damage across repeated examinations.167 
Furthermore, scoring of TEFI images (and histology using current scoring 
methods) features subjective measures that result in large inter-observer 
variation, in part due to the difficulty in distinguishing between scarring, 
infiltrate and resolving disc changes.  
 
 
Figure 5. An anatomical comparison between an OCT optical section and histology. 
Retina from a wi ldtype C57BL/6J  mouse is shown next to a matched OCT scan. 
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Optical coherence tomography (OCT) is analogously described as optical 
ultrasound scanning. By measuring changes in the coherence of light 
reflected from ocular tissues, a near histological level of detail can be 
obtained. The technology is now routinely employed in clinical practice for 
imaging the fundus.168,169 It is only recently however, that technological 
adaptations have permitted examination of the mouse eye.170 An example of 
the correlation between an OCT-derived ‘optical section’ and paraffin 
histology of the retina is shown in Figure 5. An early study had used a simple 
handheld OCT to examine EAU in the rat, but the signal quality obtained was 
poor, partly due to the severity of inflammation.171 No publications existed 
where OCT had been used to evaluate EAU pathology in the more widely 
used mouse model. Thus, a pilot study was launched to assess the utility of 
OCT imaging as an alternative for histology and TEFI. 
 
3.2 Pilot studies demonstrate the potential of OCT to detect 
pathology in the C57BL/6 mouse model of EAU 
 
We used our in-house Spectralis HRA and OCT from Heidelberg Engineering 
with an aspheric, 80mm focal length, near infrared lens to capture 30-degree 
angle images. It was possible to obtain adequate quality OCT images of the 
mouse fundus during EAU and they could be correlated with images 
obtained by TEFI (Figure 6). Changes in the disc, vitreous and retinal layers 
appeared to reflect changes seen on fundal images through the course of the 
disease. 
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Figure 6. Pilot OCT images of mouse EAU and matched TEFI photographs.  OCT scans 
centred on the opt ic d isc ( le f t)  f rom di f ferent mice with matched TEFI images ( r ight) .  An un-
induced CFA control  animal and scans from early (day 15 post- induct ion) and peak (day 26) 
EAU are shown. Note with EAU progression on OCT, black f lecks appear in the v i t reous and 
the s ignal corresponding to the opt ic d isc enlarges. ILM: Inner l imit ing membrane, ONL: Outer 
nuclear layer,  RPE: Ret inal  p igment epi thel ium. The opt ic d isc (red arrowhead) and a ret inal  
vein (b lue arrowhead) are indicated on the top TEFI image.  
 
Following these promising findings, a full timecourse of EAU in C57BL/6J 
female mice was started. OCT, fundus fluorescein angiography and TEFI 
were performed synchronously and a cohort also underwent 
electroretinography (ERG) to supplement the structural assessment with 
functional information. Several eyes were selected for retinal flat-mount 
immunohistochemistry and 3D reconstruction. Assessment was performed at 
15, 26, 36 and 60 days post-induction of EAU, with CFA (induced with 
complete Freund’s adjuvant and pertussis toxin only) control animals as a 
comparison. TEFI, histological and OCT scoring, the latter developed during 
the project, were all performed masked by three assessors. 
 
3.3 The development of key features of EAU can be 
systematically detected by OCT 
 
We initially aimed to confirm that all features of EAU could be detected using 
OCT. Firstly a spectrum of changes in the vitreous could be seen and 
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appeared to correspond with other structural changes. Whilst discrete lesions 
could be seen, it is likely that these represented clusters of infiltrate, rather 
than single cells (Figure 7). 
 
 
Figure 7. Vitreous condensation at the interface between the posterior hyaloid face and 
inner retinal surface is consistent with clinical vitr it is.  OCT scans centred on A)  the opt ic 
d isc and B)  per iphery are shown for a range of EAU sever i t ies compared to a CFA control  
eye. 
 
It is known that one of the earliest sites of infiltration is at the optic disc.172 
Even at day 15 post-induction, alterations in signal at the optic nerve head 
could be distinguished. Figure 8 shows representative examples that 
illustrate several differences between the imaging techniques. With TEFI 
alone, it is hard to distinguish early disease, as the angle and depth of focus 
affect the disc appearance and size (Figure 8A). Fluorescein angiography 
(FFA) is possible, but time consuming, and early leakage of fluorescein at the 
disc margin can be subtle. OCT allows an assessment of disc enlargement, 
presumed secondary to infiltration, most easily measured between marks 
placed at the limits of the OPL signal identified as a change in tissue 
reflectance (Figure 8C). Vitreous changes, presumed to be clusters of 
infiltrating cells are frequently seen at the optic disc.  
 
None 
(CFA) 
 
 
Mild 
 
 
Moderate 
 
 
 
Severe 
A B 
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Figure 8. EAU induces distinct optic nerve head changes on OCT.  Representat ive images 
from the same eyes, one at day 15 post- induct ion of  EAU (A–D)  and a matched CFA control  
(E–H) .  Blurred opt ic d isc margins on TEFI (A)  and disc hyperf luorescence by FFA (B)  are 
observed dur ing EAU. The green arrows show the or ientat ion and posi t ion of the OCT scans. 
Red dots indicate where the discrete s ignal f rom the outer p lexi form layer becomes obscured 
by disc enlargement,  as a landmark for comparison between eyes. Note the wider separat ion 
and vi t reous opacit ies in EAU (C) .  Matched histo logy demonstrates CD45+ inf i l t rat ion (DAB in 
brown with haematoxyl in counterstain) dur ing EAU only (D) .  Disc enlargement is  not seen as 
i t  is  l ikely a result  of  oedema which would be lots dur ing histo logical  processing. With TEFI 
a lone (E) ,  i t  is  possib le that changes in d isc appearance would erroneously be ident i f ied as 
disease with inf i l t rat ion in the CFA control .  Scale bar = 25µm. 
 
The detection of intraretinal structural change is one of the main clinical 
applications of OCT. Photoreceptor loss and the development of ‘retinal 
folds’ are described as a consequence of EAU. We wished to detect and 
characterise this latter feature, typically seen with an onset late in the 
disease course. An example (Figure 9) reveals that these lesions can be 
imaged and correlated with histology on retinal flat-mounts. 3D 
reconstruction confirms that the retinal folds project arise from photoreceptor 
displacement away from the subretinal space, which is full with microglia, 
myeloid and lymphoid cells. Within the displaced ONL, these cells protrude 
inwards. A video of the 3D reconstruction highlighting the retinal folds can be 
viewed online at:      
(http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.006
3002) 
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Figure 9. OCT imaging and matched histology identify deep retinal structural changes 
and an associated cellular infi l trate.  Images from an eye at day 80 post- induct ion of  EAU 
(A–C)  was analysed with matched ex vivo  h isto logy (D–F) .  By TEFI (A)  mult ip le pale ret inal  
lesions (white arrowheads) are present.  The infrared ( IR) image (B)  marks the posi t ion and 
or ientat ion of the s imultaneously obtained OCT scan. C)  Focal changes at the level  of  the 
subret inal  space/deep ret ina approximately correspond to observed lesions (red arrowheads).  
D)  Note the CD45+ cel lu lar inf i l t rate (DAB in brown with Haematoxyl in  counterstain) around 
the superf ic ia l  vessel and under the displaced outer nuclear layer.  E)  A l imited project ion 
image and 3D-reconstruct ion (F)  of  the sta ined ret inal  f lat-mount ident i f ies these lesions as 
fo lds in the outer nuclear layer contain ing T cel l  -  CD4+ & CD8+ (red),  myeloid -  isolect in B4 
binding (white) and Iba1+ (green) cel l  populat ions protruding from the subret inal  space (DAPI 
in b lue).  
 
Vasculitis or perivascular immune infiltrate is a predominant feature in murine 
EAU.37 To assess vascular changes in vivo and ex vivo, we compared TEFI, 
FFA and OCT images of CFA control (Figure 10A–C) and EAU (Figure 
10D–G, I) animals with corresponding immunohistochemistry for vascular 
and inflammatory cell markers on retinal flat-mounts (Figure 10H & J). 
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Figure 10. OCT identif ies vascular changes in EAU with appearances altered by depth 
and degree of infi l tration.  The CFA control  eye has normal TEFI (A)  and FFA (B)  
appearances. The green arrow indicates the or ientat ion and posi t ion of the OCT scan (C)  that 
t ransects a superf ic ia l  ret inal  arter io le (yel low arrowhead) and vein (b lue arrowhead).  
Matched images from an eye at day 36 post- induct ion of  EAU demonstrate the range of 
changes (D–J) .  Corresponding disc swel l ing and vascular changes are seen on TEFI (D)  and 
infrared SLO (E) ,  wi th mi ld leakage on FFA (F) .  One OCT scan transects two large vessels 
travel l ing near the ret inal  surface (G) .  The vessel (col lagen IV in red) with a l tered OCT signal 
in the per ivascular t issue (upward point ing blue arrowheads) is  densely inf i l t rated with 
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myeloid -  lect in B4 binding (white) and T cel l  -  CD4+ & CD8+ (green) cel ls as shown by 
immunohistochemistry on ret inal  f lat  mount (H) .  This is  in contrast to the ret inal  arter io le 
(downward point ing yel low arrowheads),  which lacks any local ised inf i l t rate.  Dif fuse hyper-
ref lect ive s ignal on OCT ( I )  corresponds to a deep ret inal  vein,  with associated cel lu lar 
inf i l t rate (J) .  The blue l ine indicates al ignment with the OCT scan. 
 
In CFA control mice, vessels assessed by TEFI, FFA and OCT showed a 
normal, non-inflamed appearance. In contrast in the EAU eyes, TEFI 
detected several abnormal, inflamed vessels that were also identified on the 
corresponding infrared SLO image, FFA and OCT. Two large superficial 
retinal vessels were observed on the OCT scan (Figure 10G-H) and their 
corresponding appearance assessed on flat-mount. Interestingly, the 
abnormal vascular signal, enlargement and distortion of surrounding retinal 
tissue on OCT correlated with a dense perivascular infiltrate that surrounded 
the vessel, whilst the vessel lacking substantial perivascular accumulation of 
cells was small, dense and had preserved adjacent layers on OCT. 
 
In many mice, including wildtypes, retinal vessels were occasionally 
observed running below the inner nuclear layer. Involvement of these vessels 
in EAU resulted in a dramatically different appearance on OCT (Figure 10I-
J), with attenuation of signal in most of the thickness of the retinal tissue with 
evidence of fluorescein leakage on FFA. Whilst it is not possible to detect 
oedema on retinal flat-mounts, myeloid and T-cells were found to be closely 
associated with these vessels. Given that such changes can be detected on 
OCT, the evolution of vasculitis and its effects upon surrounding retina might 
be further delineated in vivo using this technique. 
 
Interesting other features, not recognised as classically part of EAU were 
observed. One example is of a vascular abnormality that looked similar to the 
intraretinal neovascularisation observed in chronic retinal degenerations.30 
Noticed during FFA imaging of a mouse at day 36 post-induction, the lesion 
had both an atypical angiographic and OCT appearance (Figure 11).  A 
video of the 3D reconstruction of this lesion, demonstrating the vascular 
arrangement can also be seen at: 
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(http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.006
3002) 
 
 
 
F igure 11. OCT imaging assists the identif ication and characterisation of novel features 
developed during the EAU model.  Fundus f luorescein angiography (FFA) on an eye at 36 
days post- induct ion of  EAU revealed an abnormal i ty  in i t ia l ly  bel ieved to l ie with in the 
spectrum of vascul i t is  (A) .  Ret inal  f lat-mount revealed an atypical  vascular lesion ar is ing 
along the course of a large vessel (B) .  3D reconstruct ion of the region (enclosed by the white 
box),  wi th CD4+ & CD8+ cel ls (green) d isplayed (C) .  Magnif ied v iew of the FFA (D)  correlates 
with a combined col lagen IV (red) and br ightf ie ld project ion image viewed from the subret inal  
space towards the v i t reous (E) .  The black patch corresponds to RPE adherence dur ing ret inal  
separat ion and vessels pass through th is region (example indicated by white arrowhead) 
having ar isen from the ret ina after penetrat ing the outer nuclear layer ( in b lue) -  h ighl ighted 
in the reconstruct ion (F) .  OCT demonstrates a unique, dense signal appearance (G) ,  
inconsistent with more widely observed vascul i t ic  changes in EAU. The green arrow in (A)  
indicates the locat ion and or ientat ion of  the OCT scan The arrangement seen on sagit ta l  
reconstruct ion (H)  might part ly  explain the appearance, which could be consistent with 
inf lammatory- induced intraret inal  te langiectasia,  vascular reorganisat ion or neovascular buds. 
Lect in B4 stain ing is d isplayed (white).   
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3.4 The development of retinal features during EAU can be 
tracked by OCT 
 
Whilst in humans, repeated Spectralis OCT scans can be locked to an 
identical location, this process proves difficult as a result of optical 
constraints in the mouse. However, features can be manually followed in a 
single eye and OCT holds the potential to follow the dynamic intraretinal 
changes during EAU (Figure 12).  
 
  
 
Figure 12.  OCT can track the development of t issue changes over t ime during the course 
of EAU.  Each column i l lustrates the development of  a feature from the same eye of an animal 
at  a constant,  manual ly located region on OCT for a l l  four main features. Timepoints at  15, 
26, 36 and 60 days post- induct ion of  EAU are shown.  
 
Due to the intrinsic variability of the model, the timing and severity of 
changes varies between animals, but a general trend to early inflammation 
and late reduction in disease is evident. Following peak disease at day 26, 
vitreous opacities appear to clear, as do perivascular changes. Deep retinal 
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folds only develop late, are associated with vessels and do not appear to 
regress in the timeframe examined. The changes at the optic disc are 
dynamic and also regress following peak disease. Note that it would be 
impossible to directly quantify the degree of vitreous or intraretinal 
involvement using TEFI and it is likely that histology would lose the 
component of disc enlargement secondary to oedema. 
 
3.5 A minimally subjective OCT-based EAU scoring system 
correlates well with conventional histological assessment  
 
A scoring system was developed which required a standardised method of 
imaging. Each eye underwent eight scans - two transecting the disc 
perpendicular to each other, four at the 30-degree edges whilst centred on 
the optic disc, one far superior and one far inferior shot. This was felt to be 
the optimal balance between a comprehensive and yet feasible assessment. 
One example is shown in Figure 13. Whilst this set of scans requires around 
ten minutes per animal and an equivalent amount to process, this is far less 
than processing, sectioning, staining and scoring histological specimens. 
 
 
Figure 13. An example of the standard scoring series.  Eight shots were obtained from an 
eye at d26 EAU. Horizontal  (A)  and vert ical  (E)  scans through the opt ic d isc,  one scan at 
each of the four edges centred on the disc (B-C, F-G)  and far superior (D)  and infer ior (H)  
scans were captured. 
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The OCT scoring system was derived from an analysis of current histological 
schemes and an appreciation for the developmental time course of OCT 
changes (Figure 12). The system was constructed to remove subjectivity 
where possible and thus reduce inter-observer variation. The result involves 
measuring four variables – vitreous change, disc swelling, large vessel 
involvement and structural reflective changes. A worked example is shown in 
Figure 14.  
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Figure 14. A worked example of the OCT-based scoring system.  Using al l  e ight scans, 
each eye is scored across four domains and the raw results d isplayed. The number of 
d iscrete v i t reous opacit ies separate from the ret ina is counted in the scan that shows the 
largest number (A ) .  Clusters that would receive scores are i l lustrated in the red box. A 
vert ical  and hor izontal  average of d isc swel l ing is measured using the on-machine software 
between the terminat ions of the layer corresponding to the outer p lexi form layer (B ) .  Across 
the s ix non-disc scans, the proport ion of a l l  abnormal vessels of  the tota l  t ransected by al l  
scans is calculated (C ) .  The infrared scan can guide vessel locat ion on the OCT B-scan 
(green arrow indicates posi t ion) Non-disc scans are f inal ly  d iv ided into ten equal vert ica l  
segments and the proport ion contain ing any abnormal i ty ( including inf lamed vessels,  
excluding v i t reous changes) are counted out of  a tota l  of  60 (D ) .   
 
It was necessary to transform the raw scores, to provide a sensible working 
range and weight each characteristic to provide the greatest correlation 
between histological and OCT scores (Table 10). This was derived 
empirically by examining scores in the initial pilot cohort (Figure 6). 
Additionally, analysis of disc swelling using on-machine measurements is 
complicated. As each machine and optical adaptation will alter, the disc 
enlargement score is expressed relative to a cohort of CFA control mice. This 
cohort would only need to be run once, to calibrate the baseline for the 
particular machine. Other scores assessing the vitreous, vessels and 
structure were created to be minimally subjective. Whilst much information 
could be extracted from a detailed sub-analysis of the intraretinal changes in 
structure, this was not thought to be practical during application as a scoring 
tool. 
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SUB-
SCORING 
CATEGORY 
DESCRIPTION RAW 
SCORE 
RANGE 
PER 
EYE 
ALTERATION 
FACTOR 
 
EAU 
SCORE 
RANGE 
 
Vitreous 
involvement 
 
Absolute count of discrete opacities 
in the vitreous space up to a 
maximum of 150. The count from 
the worst affected scan is used. 
0–150 None 0–150 
 
Disc 
enlargement 
 
 
On-machine measure of the linear 
distance between the termination of 
the outer plexiform layer equivalent 
on either side of the disc. For each 
eye, average the results of the 
horizontal and vertical disc scans. 
Relative 
value to 
control 
CFA 
group 
(Measure/average 
CFA control group 
measurement)2 
then 
multiplied by 35 
25.6–92.0 
(CFA control 
group 
average 
of 1695 units 
in this cohort) 
Vascular 
involvement 
 
Number of abnormal vessels as a 
ratio of total vessels scanned based 
on OCT appearance. Two disc 
centred scans excluded. 
0–1 Multiply by 300 0–300 
 
Structural 
change 
 
Using six scans (non-disc centred) 
only, each is divided into 10 equal 
vertical segments. The total number 
not completely normal are counted, 
ignoring vitreous changes. 
0–60 
 
Multiply by 1.5 0–90 
Maximum final EAU score range for this cohort: 25.6–632 
 
Table 10. Range and processing of f inal OCT scores.  Weight ing was determined by 
correlat ion to h isto logy, of  which vascular change was most paral le l .  On average most scores 
wi l l  l ie  between 20 and 600 points,  dependent upon cal ibrat ion of the disc score. The range 
for the cohort  in these exper iments is presented. 
 
Quantitative analysis was possible by combining data from all three cohorts 
to show the time-course of EAU scores generated using OCT, TEFI and 
CD45 immunolabelled histology (Figure 15A-C). Scoring was performed by 
three masked assessors and the averaged results are displayed. The data 
from each system are presented in raw form and not normalised to one 
scheme. All three reflect the expected course of EAU and correlate 
significantly with each other (Figure 15D–F). OCT scores correlated well with 
histology (Pearson R2 = 0.6392, P<0.0001, n =31 eyes), affirming the 
hypothesis that inflammatory changes in the limited 30-degree field of OCT 
are directly proportional to whole eye changes sampled by histology. 
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Figure 15. OCT-based scoring correlates well  with established measures.  Combined data 
from the cohorts across the ent i re t ime-course for A)  OCT, B)  h isto logical  and C)  TEFI 
d isease scores. D) Correlat ion between OCT and histo logy is present.  E-F)  Other correlat ions 
between OCT, TEFI and histo logy. Mean + SD shown. One-way ANOVA (P<0.0002 for each),  
with Tukey post hoc test for mult ip le comparison (*  = P<0.05, **  = P<0.01, ***  = P<0.001).  
Pearson correlat ion and l inear regression of the values are displayed. 
 
The overall conclusion was that the OCT scoring system correlated well with 
the gold standard of histology for EAU. There are several advantages to the 
technique as mentioned, including the possibility for repeated examination of 
intraretinal changes in the same eye. By removing the need for a parallel 
cohort for the assessment of disease severity when other analyses such as 
flow cytometry or Western blot are required, OCT also permits a reduction in 
animal numbers in line with the principle of the 3R’s of animal 
experimentation. Additionally a severity score matched to the very eye used 
for such subsequent analysis, can partly mitigate the wide variation in 
severity between animals with EAU. 
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3.6 OCT-based EAU scores were validated in an 
interventional experiment 
 
Whilst the scoring system has been shown to correlate during an 
observational series, it was unknown whether this would hold true during an 
independent and interventional experiment. As part of the main project, a 
head-to-head study was performed, injecting AAV8 expressing either murine 
IL-10 or GFP control. Nine C57BL/6J mice were injected with either vector 
randomised to an eye. One week later, EAU was induced and the OCT 
scoring series acquired at day 26, before histological processing of the eyes.  
 
 
Figure 16. The OCT-based scoring system was validated in an interventional experiment.  
Comparison between the cal ibrat ion cohort  and an experiment in ject ing AAV8-CMV-mIL-10-
IRES-eGFP and AAV8-CMV-hrGFP control  vector one week pr ior to the induct ion of EAU. 
OCT imaging was performed at day 26 and the same eyes taken for h isto logical  CD45 
scor ing. A)  The correlat ion from this experiment reveals a s igni f icant and even better f i t  
between the OCT and histo logical  scores than the correlat ion in the in i t ia l  cal ibrat ion 
experiments (B) .  Pearson correlat ion shown. Each point  represents one eye. 
 
Disease was scored by two masked assessors (Figure 16). The previously 
observed correlation was seen and was even tighter, perhaps due to less 
inter-observer variation or as a function of the intervention. This provided 
confirmation that the system was valid over a range of applications and was 
suitable for further use. 
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3.7 Electroretinography of EAU in the C57BL/6 mouse is 
confounded by the induction protocol 
 
Electroretinography was performed in collaboration with Dr Livia Carvalho. A 
pilot study showed electroretinogram (ERG) changes at day 40 post-
induction of EAU (Figure 17A-B), with reduced b-wave amplitude compared 
to wildtype mice (n=7 EAU, 3 control). As an ERG defect was identified, the 
OCT cohorts were assessed by ERG and also demonstrated progressive 
loss of b-wave amplitude, indicating possible photoreceptor or bipolar cell 
dysfunction from 15 days post-induction onwards (Figure 17C). Surprisingly, 
the control cohort that received the same dose of subcutaneous CFA and 
intraperitoneal pertussis toxin only developed comparable ERG changes 
(Figure 17D). Whilst the mean b-wave amplitudes of the CFA controls were 
always higher than the EAU cohort, there was no statistical difference at any 
timepoint. Expressing the values as a percentage of the original baseline 
ERG did not provide any additional insight (Figure 17E). Photopic readings 
showed an identical pattern to the scotopic throughout (data not shown).  
 
The progressive amplitude suppression in the control group was unforeseen. 
Structural appearances of the retina by OCT, TEFI and histology were as 
expected. It is possible that either the CFA, or the Pertussis toxin was 
leading to inhibition of the ERG. As Pertussis toxin in vitro can inhibit G-
protein signalling, it was felt to be the most likely candidate, by directly 
inhibiting phototransduction components such as Transducin173 but no 
studies have previously documented the effects upon the retina in vivo. It is 
unusual though that the effects persisted to 36 days after injection. Due to 
time constraints, a repeat study with a Pertussis toxin alone cohort has not 
been performed. The implications of this study will be discussed in later 
chapters. 
 
As b-wave amplitudes began to resolve at day 60pi, it was possible that a 
window of opportunity existed, where the side effects of the induction were 
resolving and the persistent ERG reduction from structural damage in EAU 
was evident. ERG was performed on three additional WT mice and the mean 
plotted against the raw values of the other cohorts (Figure 17F). As complete 
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groups there was no statistical difference, but compared to this reference, 
67% of the CFA group eyes were equal to or greater than the WT mean, 
against 17% with EAU. This suggests that if repeated or with greater animal 
numbers a difference might be seen, at a timepoint when it is likely the 
effects of the induction have ceased, particularly if the low values in the CFA 
group are erroneous outliers. 
 
Figure 17. The scotopic electroretinogram shows reduced b-wave amplitude during 
C57BL/6  EAU, but this may be a result  of the induction protocol .  A cohort  of  mice at day 
40 post- induct ion of  EAU was compared to wi ldtype (WT) mice. A) Representat ive averaged 
scotopic t races are shown for three indiv idual animals,  i l lustrat ing reduced ampl i tude in EAU. 
B)  Pooled results for the cohort  show a s igni f icant d i f ference. Each point  represents one eye. 
Mann-Whitney U test used. The OCT cohort  underwent ERG at each t imepoint and C)  scotopic 
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ERG b-wave ampl i tudes show a progressive reduct ion over t ime, with part ia l  recovery by day 
60pi.  D) The cotemporaneous CFA (+Pertussis toxin) control  cohort  a lso showed simi lar 
reduct ion in the b-wave. This could not be corrected for by plot t ing as a change from basel ine 
ERG (E) .  Three WT mice underwent ERG contemporaneously with day 60pi mice (F)  and the 
mean b-wave ampl i tude of 311µV is shown as a dotted l ine. As groups there was no stat ist ical  
d i f ference between EAU and CFA, al though a greater percentage of the lat ter reached the 
mean WT value or above. Means + SD shown. Al l  t races were analysed at a scotopic f lash 
intensi ty of  0.03cd.s/m2. 
 
3.8 OCT is possible, but not as suited to the B10.RIII model 
of EAU 
 
It was uncertain if OCT was a possible assessment method in the B10.RIII 
strain model of EAU, which develops severe vitritis, retinal detachments and 
posterior synechiae - all of which would be expected to affect OCT scan 
quality. Of six eyes examined, only one eye had posterior synechiae that 
precluded examination. A representative example of a mouse without 
posterior synechiae is shown below (Figure 18). All three modalities of OCT, 
TEFI and histology correlate with large retinal folds clearly imaged. Uniquely, 
OCT reveals the presence of subretinal fluid - known to occur in this model. 
This feature (Figure 18E, red arrow) is typically lost during histological 
processing, but is an important marker of severe disease.  
 
In view of the perceived limitations and low use of the strain in this project, no 
further work was performed. Two years later an OCT based grading system 
was published by another group.174 The difficulties of imaging this model 
were evident, as distinct features were not incorporated into the scoring 
system. Overall retinal thickness was used as a gross measure instead. It 
would be possible to examine the model in post-peak disease when the 
vitritis has resolved. The technique would then be highly pertinent to 
investigating severe chronic inflammatory changes are known to result in 
tissue remodelling and angiogenesis.24   
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Figure 18. OCT can detect pathology during the severe form of EAU induced in the 
B10.RII I  mouse strain.  Despite marked vi t r i t is  and extensive ret inal  d isrupt ion, i t  was st i l l  
possib le to obtain reasonable scans in the B10.RII I  stra in model.  Widespread ret inal  fo lds 
conf irmed by TEFI (A)  and histo logy (B and C)  could be ident i f ied on the infrared scout image 
(D)  and imaged by OCT in cross-sect ion (E).  The fo lds correspond to changes in the outer 
nuclear layer in both t issue sect ions (C)  and OCT (E) ,  wi th only the lat ter demonstrat ing l ikely 
subret inal  f lu id (red arrow), which would be lost dur ing f ixat ion and histo logical  processing.  
 
3.9 Chapter summary 
 
The detection and analysis of key features during EAU in the C57BL/6 
mouse is possible using OCT. Vitreous infiltration can be quantified and does 
not significantly degrade the quality of the retinal images. Optic disc 
enlargement can be measured and is a dynamic feature over the course of 
the disease. Deep retinal features, such as folds are demonstrable and 
matched histology on flat-mounts used to dissect their associated cellular 
phenotype. Vasculitis can also be imaged, with the appearance dependent 
upon vessel depth within the tissue. Incorporating all of these features, a 
scoring system has been created and shown to significantly correlate with 
established histological disease scores. This scoring system was 
subsequently validated in an interventional experiment. 
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4 Results 2: Flow cytometry as a quantitative 
scoring system for endotoxin induced uveitis 
 
Endotoxin-induced uveitis (EIU) is primarily an acute response to injected 
lipopolysaccharide (LPS) and as a model of human uveitis per se, it serves 
best to elucidate mechanisms rather than as a direct clinico-pathological 
correlate. It has however been used to emulate mechanisms of human 
anterior uveitis, particularly following the known association with gram-
negative bacterial infection and predominant anterior segment infiltration.32 
Unlike EAU, there is minimal tissue damage and disease is self-resolving. 
 
In this project EIU was employed as it provides several advantages over 
EAU, namely it elicits a narrower range of pro-inflammatory signals and it is 
rapid. It takes up to 24 hours to reach peak disease, compared to 26 days, 
so different therapeutic approaches could be tested more swiftly. Although 
the immunological mechanisms are not identical, it has been shown that 
many EAU therapeutic agents such as IL-10 and TNF receptor fusion 
proteins can also suppress EIU.34,107 With this in mind, once basic 
parameters are optimized in EIU, they can be applied back to the EAU 
model. 
 
To date in the literature, whilst flow cytometry has been used for investigating 
some features of the model, only histology has been routinely used to assess 
the outcome (scoring) of murine EIU. As with most semi-quantitative 
analyses, studies have typically used limited numbers of semi-thin paraffin 
sections taken across each eye and then performed subjective cell counts of 
haematoxylin-staining cells in a random selection of only the aqueous or 
vitreous spaces. Building on the experience of flow cytometry for EAU, it was 
decided to investigate the technique as a routine outcome measure for 
EIU.42,159  
 
We decided to induce EIU by intravitreal injection of 1ng LPS from E.coli 
which generated larger numbers of infiltrating CD11b+Ly6G+ cells than 
systemic induction. The severity of this procedure is less, as acute peritonitis 
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and septic shock are not induced in the mice. Animals were culled 16-18 
hours later and this will be referred to subsequently in the text as ‘standard 
EIU induction.’  
 
Briefly, eyes with EIU are dissected in 50µl PBS, the aqueous humour is 
washed out and the retina and enclosed vitreous removed. These are 
aspirated into a tube and mechanically dissociated, before being spun 
through a specific 60µm pore diameter 96-well filter plate. The cornea, iris, 
ciliary body, lens and RPE/choroid are not needed and can be used for 
matched alternative analyses, such as ELISA or qPCR. Dissociated cells are 
retained in the 96-well plate and form a cell pellet after the first spin. The 
supernatant can also be removed at this stage for other analyses and 
matched to the subsequent EIU score. Antibody staining and washes are 
performed in the same 96-well plate. Anti-CD11b and anti-Ly6G are the 
minimum recommended choice of antibodies. Where possible anti-Ly6C and 
a live-dead stain are included. We use a flow cytometer with a compatible 
automated plate loader, which also improves the efficiency of the technique. 
A standard curve of polystyrene beads is run for each experiment, which 
allows the calculation of an absolute cell count for the whole sample. The 
absolute count of CD11b+Ly6G+ cells was used as the single routine 
outcome score, as it is known that these neutrophils are the predominant and 
key cell type in EIU.32  
 
4.1 Defining the standard EIU model using a flow cytometry 
based approach 
 
Hypopyon was routinely obtained using this EIU technique, which reflects the 
severe end of the disease spectrum when compared to the equivalent clinical 
observation of anterior uveitis in humans (Figure 19A). The gating strategy 
included sequential gating on CD11b+ then Ly6G+ and Ly6C+, permitting 
enumeration of neutrophils and monocytes respectively.43 Flow cytometry 
plots are displayed for an eye undergoing ‘standard EIU induction’ of 1ng 
LPS in 2µl, culled after 18hrs. (Figure 19B). In the normal mouse eye there 
are few CD11b+Ly6G+ cells. Following standard EIU induction, a mean of 
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around 20,000 cells is detected per eye at 18 hours (Figure 19C).  Technical 
refinements to the model itself can also be assessed, as many groups use 
different injection volumes and doses of LPS.33,175,176 As part of our own 
evaluations, the delivery volume and dose of LPS was varied. Reducing the 
delivery volume to 1µl led to reduced disease, but increasing the dose to 
200ng LPS with a constant volume of 2µl did not result in an increase in 
infiltrate (Figure 19C). 
 
 
Figure 19. Characterisation of EIU using quantitative f low cytometry.  Fol lowing standard 
EIU induct ion with a 2µl intravi t real  in ject ion of 1ng LPS from E.col i ,  by 18-hours A)  most 
eyes have developed hypopyon (sedimented leukocytes in the anter ior chamber;  red arrow) 
s imi lar to that seen in severe human anter ior uveit is .  B)  The AC, ret ina and v i t reous can be 
dissociated for combined analysis by f low cytometry.  A representat ive example of f low plots 
shows that sequent ia l  gat ing by CD11b stain ing al lows the ident i f icat ion of d ist inct  Ly6G+ and 
Ly6C+ populat ions. Calculat ion of an absolute cel l  count is  possible using a standard curve. 
C)  Taking th is CD11b+Ly6G+ cel l  count (neutrophi ls)  as the measure of EIU severi ty,  an 
average count of  20,000 is obtained fo l lowing standard EIU induct ion with 1ng LPS in 2µl ,  and 
is c lear ly d i f ferent iated from eyes not receiv ing LPS. Alter ing condit ions of  the EIU model 
i tsel f  can be assessed. At the standard 2µl volume, increasing the dose of  LPS further to 
200ng has minimal ef fect.  Del iver ing 1ng in 1µl  however leads to reduced disease, overcome 
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by using 200ng in 1 µl .  Kruskal-Wal l is  test with Dunn’s mult ip le comparison test.  *=P<0.05, 
**=P<0.01, ***=P<0.001. n=5-6 per group.  
 
Whilst CD11b and Ly6G are the only phenotypic markers required for simple 
assessment, the flow cytometry panel can be extended. An expanded 
composition within standard EIU was determined, showing that CD4 and 
CD8 T-cell content was negligible and only a small number of CD94+ cells 
were identified, which should represent NK and NKT cells. The population 
classified as CD45+ but negative for additional markers and labelled as 
‘other’ may comprise resident microglial cells (Figure 20A-B).  
 
 
Figure 20. Composition of the infi l trate in EIU can be distinguished by f low cytometry 
whilst qPCR on matched tissues can assess the transcription of multiple chemokines .  
Flow cytometry al lows the s imultaneous analysis of  subtypes, ident i fy ing mainly 
CD11b+Ly6G+, CD11b+Ly6C and CD94+ cel ls.  A)  Samples were f i rst  gated on CD45+, and 
then expressed as percentage of th is populat ion. n=6. B)  The same data displayed as a pie 
chart ,  to h ighl ight the predominant CD11b+Ly6G+ populat ion. As only the AC, ret ina and 
vi t reous are used for cel l  counts,  the remaining i r is ,  c i l iary body (CB) and RPE/choroid were 
used for C)  quant i tat ive RT-PCR for key chemokines in EIU relat ive to β-act in and normal ised 
to eyes with no disease. n=3 per group, with technical  t r ip l icates. Means + SD shown. 
 
Finally by using matched iris, ciliary body and RPE from eyes analysed by 
flow cytometry, RNA transcripts for TNF, KC and CCL2 could be detected by 
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quantitative RT-PCR. All three were elevated and are known to contribute to 
cellular recruitment and blood-ocular breakdown (Figure 20C). 
 
4.2 Timecourse and compartmental analysis of EIU 
 
The infiltrate in EIU can be further scrutinised by keeping the anterior 
chamber infiltrate separate from the retina/vitreous. This is performed by 
careful dissection, puncturing the cornea and evacuating the aqueous 
humour separately, before extracting the retina. Similar appearances by flow 
cytometry are seen (Figure 21A). Following standard EIU induction a near 
equal division of numbers is seen, with a trend towards a greater 
CD11b+Ly6G+ count in the AC (Figure 21B).  
 
Live-Dead discrimination is routinely performed in flow cytometry using dyes 
such as DAPI, 7AAD or propidium iodide. We used proprietary fixable live-
dead 780nm stain to examine the viability of cells detected in EIU. One 
caveat is that dead cells can non-specifically stain with antibody, however 
this was not observed to be substantial after comparing samples tested with 
and without live-dead discrimination, where no dead cells were seen to stain 
for multiple incompatible markers as might be expected. Subsequently, live-
dead staining was used routinely to look at the viability of subsets. To 
observe if changes in cellular viability occurred over the duration of 
recruitment into the eye, an early timepoint of 6-hours was also included. 
Interestingly a greater number of CD11b+Ly6G+ cells in the retina were dead 
than in the AC and the percentage was higher at 18-hours, though it is 
possible that the increased processing time might affect this (Figure 21C). 
With monocytes a similar pattern was seen, however a higher proportion of 
cells were dead in the retina at 6 hours (Figure 21D). 
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Figure 21. Compartmental sub-analysis of the EIU model is possible using f low 
cytometry.  Standard EIU was induced with a 2µl intravi t real  in ject ion of 1ng LPS from E.col i .  
When dissected at 18-hours for analysis,  the AC was kept separate from the v i t reous and 
ret ina. A)  Representat ive f low plots showing gat ing for CD11b then Ly6G or Ly6C, display 
each populat ion c lear ly ident i f ied in both compartments.  B)  Absolute AC and ret ina/v i t reous 
counts of  indiv idual eyes from two separate exper iments for CD11b+Ly6G+ and 
CD11b+Ly6C+ cel ls.  There is an approximately even spl i t  between compartments. n=6. Vi ta l  
dyes can be uniquely used with f low cytometry to gauge the l ive and dead status of cel ls  in 
the inf i l t rate.  C)  Relat ive comparison between the percentage of dead CD11b+Ly6G+ cel ls in 
the AC and ret ina at an ear ly and standard t imepoint.  More dead cel ls  are seen in the ret inal  
compartment.  D)  There is a more even pattern for CD11b+Ly6C+ cel ls ,  but greater v iabi l i ty  in 
the AC at 18-hours. E)  An extended t imecourse of l ive CD11b+Ly6G+ cel ls at  2,  6,  12 and 18-
hours post- induct ion for the two compartments.  This demonstrates a rapid increase, with  
negl ig ib le cel l  numbers at 2-hours, but a near p lateau by 6-hours. F)  Whole eye counts for 
s impl ic i ty i l lustrate the re lat ive change with Ly6G+ cel l  inf i l t rat ion ear ly and increasing 
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numbers of Ly6C+ cel ls towards a later stage, in l ine with the known pattern of  monocyte 
accumulat ion in EIU. Means + SD shown. Kruskal-Wal l is  test with Dunn’s mult ip le 
comparisons. *=P<0.05, **=P<0.01, ***=P<0.001. 
 
A timecourse was undertaken to understand the effect of time upon EIU 
dynamics and cellular composition. At 2-hours no infiltrate could be detected, 
but by 6-hours, near-maximal numbers of CD11b+Ly6G+ cells were present 
in both the AC and retinal compartments (Figure 21E). Looking at combined 
counts, from 6 hours onwards, the overall number of CD11b+Ly6G+ cells 
does not markedly change, but the CD11b+Ly6C+ cell number dramatically 
increases by 18-hours (Figure 21F). This is consistent with previous 
published studies and proposed to be monocytes entering to clear dying 
neutrophils.175  
 
4.3 Validation of flow cytometry for EIU from interventional 
experiments 
 
This EIU scoring protocol has been applied extensively to work detailed in 
subsequent chapters. As examples to support the validity of the approach, 
three different experiments are outlined in Figure 22. In the first, the effect of 
systemic Dexamethasone upon subretinal detachment alone prior to EIU was 
tested and found not to affect the degree of infiltration. The lack of a 
significant difference is clearly seen, alongside an accurate description of the 
wide biological and technical variation that exists (Figure 22A).  
 
 
Figure 22. Examples of f low cytometry applied to interventional EIU experiments.  2mg/kg 
systemic Dexamethasone was administered at the t ime of subret inal  in ject ion of a mixture of 
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PBS and AAV8-hrGFP to determine i f  i t  af fects the degree of EIU induced a week later.  A) 
Flow cytometry quant i tat ively conf i rmed i t  had no effect ,  nor was one apparent dur ing 
subgroup analysis.  B)  Another exper iment assessed the effect of  intracameral administrat ion 
of Lent iv i rus expressing ei ther GFP or murine IL-10 upon EIU. Flow cytometry reproduced the 
expected result  obtained previously convent ional h isto logy. C)  An intervent ional exper iment 
administered concurrent doses 200ng of recombinant human IL-10 at the t ime of EIU 
induct ion. Suppression of both the mean value and bio logical  var iat ion of  inf i l t rat ing cel l  
counts was demonstrated. Mann-Whitney U test,  *=P<0.05, ***=P<0.001. Means + SD shown. 
 
The second experiment was a repeat of published work suppressing EIU by 
gene transfer of murine IL-10 by intracameral delivery of Lentivirus.34 As 
seen when assessed by histology in the published paper, a significant 
reduction in cells was seen in the AC (Figure 22B). Finally, the effect upon 
EIU of direct administration of recombinant human IL-10 into the AC was 
investigated.  Marked suppression with reduced neutrophil numbers was 
seen, again in line with published data obtained using histology (Figure 
22C).177  
 
4.4 Chapter summary 
 
Flow cytometry can be used to score the severity of EIU in place of 
conventional histological counts. A quantitative assessment is possible and 
using CD11b+Ly6G+ gating, the exact number of neutrophils ascertained. 
The standard range of disease for EIU was characterised, with a mean 
infiltrate of 20,000 neutrophils at 18-hours. Key cellular populations were 
identified as Ly6G+ neutrophils, Ly6C+ monocytes and CD94+ cells such as 
NK and NKT cells. The benefit of matched residual tissues was 
demonstrated through the detection of TNF, KC and CCL2 upregulation in 
RPE and iris/ciliary body homogenates. Live-dead discrimination revealed 
greater viability of cells in the anterior chamber compared to the posterior 
compartment. A timecourse demonstrated the rapid ingress of neutrophils 
from 6-hours post induction, with numbers of Ly6C+ monocytes only 
increasing by 18-hours. Finally, three interventional experiments 
demonstrated the successful application of this technique. 
  
                                                                                                                   103 
5 Results 3: Refinement of vectors and AAV 
production for ocular immunomodulation 
 
Ocular gene therapy as a field and the development of AAV vectors have 
been geared towards the correction of inherited monogenic disorders. The 
first clinical trials in the eye used AAV2 to replace the RPE65 gene in 
deficient patients.48-50 None of the patients had significant pre-existing ocular 
inflammation and no obvious immune-related complications developed 
during the trials. However, during early experiments looking at modulating of 
models of ocular inflammation such as EAU, it became apparent that the 
AAV vector preparations generated, whilst adequate for monogenic gene 
therapy rescues, were not optimal for immunomodulation. 
 
Several refinements were investigated, such as changing production 
procedures to obtain cleaner and more pure AAV preparations. The 
consequences of endotoxin contamination were explored and new vector 
production methods were developed to address the endotoxin issue. 
Avoiding the subretinal route was one aim, achieved by introducing the use 
of an engineered AAV serotype into the lab. Finally some key assumptions, 
such as the direction of secretion of transgenes from the RPE and the benefit 
of Dexamethasone treatment were examined. The intention was that these 
refinements would make successful suppression of intraocular inflammation 
more likely. 
 
5.1 Improving the AAV production and purification process 
 
Following the failure of mIL-10 to supress EAU after expression using 
subretinal AAV9, a reassessment of the quality of AAV preps was made (see 
results chapter 4, Figure 36). A trial run using a new AVB-medium based 
column seemed to lead to less toxic retinal changes, though the titre and 
efficiency of production was less. This relatively simple change appeared to 
be beneficial and so other issues were identified and changes instigated. For 
exact details of the production and purification process see Materials & 
Methods. 
                                                                                                                   104 
 
 
Figure 23. Alterations leading to the refined AAV production process.  Key changes 
inst igated are A)  l is ted for reference. B)  An example of t i t re-matched AAV8-CMV-mIL-10-
IRES-eGFP analysed by SYPRO Ruby gel.  The three v ira l  capsid proteins VP1-3 are 
indicated. Other s ized bands represent non-vira l  protein contaminants.   
 
Several of the refinements to the production process for AAV manufacture in 
the lab are summarised in Figure 23A. The decision was made to switch to 
using the AVB column permanently. Previously AAV9 was purified using 
sequential Sephacryl (size separation) and then Poros (anion-exchange) 
medium based columns. Whilst these lead to high titre preps, the relatively 
unselective and crude separation based only on size and a broad window of 
protein charge results in multiple contaminating proteins. The majority of 
these are likely to derive from HEK-293T cell components used to generate 
the AAV and would be expected to be highly immunogenic and biologically 
active. Additionally, columns would be reused around thirty times, which 
whilst regenerated with buffer and washed at each stage, is still likely to 
accumulate contaminants.  
 
AVB-medium is a commercially available compound by GE Healthcare 
engineered to bind the AAV2 capsid with high affinity, but is not antibody 
based. Whilst the exact binding residues are commercially sensitive, it has 
been stated as also able to bind AAV1 and AAV5. In our hands AAV8 binds 
well and AAV9 less so, though still to a usable degree. Having trialled a pre-
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packed 5ml column, disposable 1ml sized columns were settled upon for use 
a maximum of three times. When compared by SYPRO Ruby total protein 
stain on a denaturing polyacrylamide gel, the greater purity - with essentially 
only the VP1-3 AAV capsid proteins visible – can be seen compared to 
Poros/Sephacryl separation (Figure 23B).  
 
To enable efficient purification without loss of titre, it was decided to change 
to using AAV8. In terms of speed and cellular transduction profiles, it is very 
similar to AAV9, except it is not known to infect Muller cells. A two-plasmid 
system was possible using the commercially available pDP8.ape plasmid. 
Traditional three-plasmid transfection – genomic, capsid and helper – 
requires three separate plasmid preparations, each with the risk of 
contamination or plasmid mutation at each stage. Requiring one plasmid 
fewer not only reduces these issues, but there is evidence that improved viral 
titres are achieved due to optimised ratios of components.178 Furthermore 
pDP8.ape can be relatively cheaply purchased at high GLP grade quality, 
superior to any achievable in the lab and was done so from Plasmid Factory 
GmBH, Germany. 
 
At the same time as AAV9-mIL-10 was observed to lead to retinal loss, the 
issue of possible endotoxin contamination arose. Endotoxin, or 
lipopolysaccharide is a cell wall component derived from Gram-negative 
bacteria and a common environmental contaminant. The AAV9 viral 
preparations were tested and whilst the non-toxic AAV9-CMV-hrGFP prep 
was positive at 300 EU/ml, the toxic AAV9-CMV-mIL-10 was heavily 
contaminated at over 100,000 EU/ml. It is possible this may have led to the 
changes observed and the immune status of the eye is likely to be altered by 
LPS. 
 
It was decided to alter the production process so all AAV preps used for in 
vivo work would test below 2.5EU/ml. This limit was empirically chosen, 
based on an extrapolation of the FDA maximum permitted levels on devices 
used upon humans. It should therefore be suitably low. All testing was 
performed using the Limulus Amoebocyte Lysate (LAL) method, which is the 
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industry gold standard. An assessment of the endotoxin contamination status 
of viral preps and key reagents used in the facility was made (Table 11). 
 
Sample type Subtype Number 
tested 
Above 2.5 
EU/ml 
AAV AAV9 (Poros purified) 4 + 
AAV8 (Poros purified) 4 + 
AAV2 (Heparin column purified) 1 + 
AAV2 (clinical grade) 1 - 
Lentivirus Standard ultracentrifugation purified 3 + 
Water Milli-Q water 2 - 
Simple distilled water 2 + 
Tap water 1 + 
PBS Standard tablet produced 1 + 
Gibco tissue culture 1 - 
Mega-preps Invitrogen standard kit 2 + 
Qiagen standard kit 3 + 
Qiagen endofree kit 2 - 
Reagents PEI 2 - 
PBS-MK buffer 2 - 
Standard Fetal Bovine Serum 3 + 
Gibco Performance Plus Fetal Bovine Serum 1 - 
Purification equipment Akta FPLC machine washings 2 + 
AVB column flow-through – 10 volumes 2 + 
 
Table 11. Endotoxin status of several vectors, reagents and equipment used for AAV 
production in the lab.  Di f ferent numbers of each sample type was tested using Charles River 
Endosafe s ingle-use tubes at a cut of f  of  2.5EU/ml.  Results were consistent in each group 
and i t  is  indicated i f  the resul ts were posi t ive or negat ive at th is concentrat ion. Of note al l  
vector preparat ions were posit ive, except the GMP-produced cl in ical  vector.  Several  
a l ternat ive endotoxin- low reagents were also tested and subsequent ly integrated into the 
ref ined process. 
 
All glass equipment was subsequently dry heat baked for 8 hours at 270°C to 
inactivate all endotoxin, as standard autoclaving is ineffective. Reagents and 
buffers were tested by LAL prior to use. 0.5M Sodium hydroxide wash was 
used to partially sanitise the fast-protein liquid chromatography (FPLC) 
machine before each run, though the only certain method for prevention of 
endotoxin contamination is to prevent any initial introduction. Genomic 
plasmid isolation was altered to use a commercial Endotoxin-free mega-prep 
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kit (Qiagen) as plasmids were all positive above 2.5EU/ml using standard 
kits. Standard Fetal bovine serum (FBS) used for tissue culture of HEK-293T 
cells in AAV production is typically not quality assured for endotoxin, but can 
be specially obtained as Gibco Performance Plus. This is guaranteed as 
below 5EU/ml. Following introduction of these measures and disposable AVB 
columns, viral preps of AAV8 at 1x1012gc/ml negative for endotoxin at 
2.5EU/ml were reliably attained. 
 
One aspect important to the accurate use of AAV is thorough matching of 
control and intervention preps to the same titre of genome copies. Until this 
point the ‘Dot-blot’ protocol using southern blot hybridisation of DNA against 
a known standard curve was employed. This was widely used but accepted 
to be crude, with over half an order of magnitude observed in test-retest 
variation in our hands. To improve upon this, a new protocol was introduced 
based upon qPCR using primers binding in the ITR region. Using this more 
robust quantification of titre-matching was possible, with good repeatability 
observed in extensive subsequent application (Selina Azam, personal 
communication). 
 
It is well known that subretinal detachment leads to ocular inflammation and 
can even affect retinal function detected by ERG for several weeks 
after.179,180 To circumvent these potential limitations a new AAV vector called 
ShH10 was investigated, which had recently become available in the lab as a 
gift from Prof John Flannery of Berkeley University, USA. It was engineered 
by in vivo evolution to primarily target Muller cells following intravitreal 
injection. Whilst work in the lab confirmed this pattern in mouse pups, the 
transduction profiles had not been assessed in the adult mouse. 
 
ShH10-CMV-eGFP was produced and purified using the same clean AVB 
column-based process with good titres of 1x1013gc/ml obtained. 2µl of vector 
suspension containing 1x1010gc ShH10 was injected into either the subretinal 
space or the vitreous cavity and eyes were sectioned after one day, one 
week and 3 weeks. Co-staining was performed for CD45 (Figure 24). At one 
day, no GFP signal is visible, but CD45+ cells are seen around the sclera 
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after subretinal injection, likely reflecting an acute response to reflux of 
ShH10 around the eye. At one week following subretinal injection GFP 
expression can been seen in RPE and photoreceptors around the region of 
the bleb. No GFP fluorescence was seen in the ciliary epithelium, in contrast 
to intravitreal injection where the ciliary body is fully transduced, as well as 
corneal endothelium and an occasional inner retinal cell. By three weeks, 
occasional columns of GFP positive Muller cells are seen predominantly 
around retinal vessels, but transduction of Muller cells was not as extensive 
as described in pups.57 By three weeks the subretinally injected eyes show 
higher levels of expression in the RPE and photoreceptors still without any 
ciliary epithelium involvement. Interestingly CD45+ cells are only evident in 
the sclera, but were not seen following intravitreal injection. 
 
All these refinements were employed to produce the AAV8 and ShH10 
vectors used in work described in all other chapters. In the following sections 
the effect of ocular endotoxin, a novel technique for removing unpackaged 
capsids, an assessment of the directionality of viral mediated transgene 
secretion and the effects of dexamethasone on subretinal injection will be 
described. 
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Figure 24. Intravitreal and subretinal delivery of ShH10 lead to different patterns of cell  
transduction in the adult mouse.  Representat ive examples from a t ime-course of 1 day, 1 
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week and 3 weeks fo l lowing in ject ion of 1x101 0gc of ShH10-CMV-eGFP. Al l  were f ixed with 
4%PFA, sta ined with ant i  CD45-Alexa 546 and imaged by confocal microscopy. At one day 
post- in ject ion, no GFP expression is seen, but scleral  CD45+ cel ls  are seen in the subret inal  
in jected group. At one week, mi ld photoreceptor and RPE transduct ion is seen with subret inal  
del ivery,  whi lst  intravi t real  in ject ion leads to c i l iary epi thel ium, corneal endothel ium (white 
arrow) and the occasional inner ret inal  cel l  becoming GFP+. By three weeks, strong 
photoreceptor and RPE expression is evident f rom subret inal  in ject ion, with no c i l iary 
epi thel ia l  t ransduct ion seen at any stage. With intravi t real  ShH10-CMV-eGFP at three weeks, 
the same cel l  types as at one week are seen, with now occasional columns of Mul ler cel ls  
(red arrow), typical ly around the locat ion of inner ret inal  vessels.  Scale bars = 100µm. 
Unmarked are same magnif icat ion as control  image. DAPI (b lue),  GFP (green),  CD45 (red).  
GC= Gangl ion cel l  layer,  INL-Inner nuclear layer,  ONL-outer nuclear layer,  OS-photoreceptor 
outer segments, RPE-ret inal  p igment epi thel ium.  
 
5.2 Injecting endotoxin contaminated material has detectable 
effects upon the eye 
 
Whilst systemic or intraocular injection of refined lipopolysaccharide from 
E.coli or Salmonela is used to elicit the model of endotoxin-induced uveitis, 
the effects of typical environmental endotoxins are unknown. Universal 
standard endotoxin is an internationally agreed mix of different bacterial 
endotoxins, used to emulate typical contaminants. The National Institute for 
Biological Standards and Control kindly provided a sample of this. Endotoxin-
low (<2.5EU/ml) AAV8-CMV-hrGFP was spiked with 2000 EU universal 
standard endotoxin or with carrier only and injected into the subretinal space 
of adult WT mice. TEFI at 24hrs shows subtly different retinal appearances, 
with a greater degree of possible retinal oedema in the endotoxin group 
(Figure 25A). Flow cytometry on dissociated retinae confirm elevated 
numbers of CD11b+Ly6G+ cells, likely to reflect acute neutrophil infiltration 
(Figure 25B). 
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Figure 25. Endotoxin posit ive AAV8 leads to acute neutrophil  infi l tration, but no 
changes in transgene expression .  Endotoxin-free AAV8-CMV-hrGFP spiked with PBS or 
2000 EU of universal  standard endotoxin was in jected into the subret inal  space. A)  At 24hr 
subt le d i f ferences in ret inal  appearance were evident by TEFI.  B)  F low cytometry showed a 
stat ist ical ly  s igni f icant increase in ret inal  CD11b+Ly6G+ cel ls with endotoxin.  Mann-Whitney 
U test,  P=0.0022. Another cohort  was lef t  for 7 days pr ior to analysis of  GFP signal by f low 
cytometry.  The expectat ion was for increased levels of  expression in the presence of 
endotoxin.  C)  No di f ferences however were observed for e i ther GFP+ cel l  count or median 
f luorescence intensi ty (MFI).  Means +/-  SD shown. 
 
It has been reported that the ITR regions of the AAV2 genome used for 
almost all gene therapy applications has NFκB-binding regions. This means it 
is potentially responsive to inflammatory signalling, that certainly appears to 
modestly increase transcription from the ITRs themselves.181 As TLR4 
signalling downstream of LPS can trigger NFκB activation, the effect of 
endotoxin upon AAV-mediated transgene expression was tested. Subretinal 
injection of endotoxin spiked AAV8-CMV-hrGFP and control was assessed at 
one week, where high levels of expression should be occurring (Figure 25C). 
No difference in either the number of GFP+ cells or the median fluorescence 
intensity appeared different. Whilst the experimental design might not be 
optimised to detect a small difference, it is unlikely for a dramatic effect upon 
transcription to exist. 
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Previous endotoxin contaminated AAV preparations for gene therapy of 
monogenic disorders did not lead to obvious inflammation in mice. As all of 
these were delivered using the subretinal route, no changes may have been 
seen if there was either a deviant innate response to LPS or sequestration in 
this space. To investigate this issue, eyes were injected with purified 1ng 
LPS from E.coli to ensure maximal stimulation and the greatest chance to 
detect infiltration. The same dose was injected intravitreally as a control. Six 
hours after injection, eyes were sectioned and stained with anti-CD45. In the 
intravitreal group, typical changes of EIU were seen, with anterior chamber 
cells (Figure 26A), which were predominantly polymorphonuclear (Figure 
26B). The cells can be seen associated with the iris, having likely emerged 
from iris vessels (Figure 26C) and are also present in the vitreous cavity 
(Figure 26D), where they are believed to emerge from the region of the optic 
nerve head (Figure 26E). 
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Figure 26. Histological differences are evident between responses to intravitreal and 
subretinal delivery of endotoxin.  Eight eyes were in jected with 1ng LPS ei ther v ia the 
intravi t real  or subret inal  route. Six hours later they were cryosect ioned, sta ined with 
immunof luorescent ant i -CD45 ant ibody and imaged using ei ther confocal or f luorescent l ight 
microscopy. As expected, fo l lowing intravi t real  in ject ion A)  the anter ior chamber is f i l led with 
CD45+ cel ls l ikely emerging from the i r is ,  which is heavi ly inf i l t rated. B)  On higher 
magnif icat ion the polymorphic nuclei  are consistent with neutrophi ls .  C)  Cel ls are present in 
the angle and other resident cel ls  are seen at the corneal l imbus. D)  In the poster ior 
chamber,  cel ls  are present in the v i t reous, adjacent to inner ret inal  vessels.  E)  At the disc,  
CD45+ cel ls were also seen (x40 confocal image inset) ,  as th is is  a l ikely region for access 
into the eye. Fol lowing subret ina l  del ivery,  no cel ls  were obvious in the AC or v i t reous. 
Consistent ly,  cel ls  were observed instead in the choroidal /scleral  complex around the F)  
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ci l iary body, G)  opt ic nerve head and  H)  poster ior ret ina. Where not annotated, scale bars = 
25µm.  
 
In contrast, no CD45+ cells could be seen within the eye in any subretinal 
LPS injected eyes at the same timepoint. CD45-staining cells were seen in 
the scleral/choroidal regions in almost every eye, often near the ciliary body 
(Figure 26F), always around the optic disc (Figure 26G) and typically in mid-
equatorial regions near the injection site (Figure 26H). Whilst this could 
purely reflect an acute response to reflux of LPS into the sub-tenon’s space 
following injection, it is interesting that no retinal infiltrate is seen, suggesting 
that subretinal injection leads to a different response to intravitreal injection. It 
is possible that there is retardation of exposure and so after a longer delay 
examination might yield different results. In either instance, it is fair to 
conclude that the potential to miss subtle responses to endotoxin has been 
greater due to use of the subretinal route, but it is still unclear what the long-
term consequences are. 
 
A small study compared a 2µl subretinal injection with 1ng LPS from E.coli 
and PBS control (n=4 eyes each group). At one month post-injection eyes 
were embedded in paraffin, sectioned and stained with haematoxylin and 
eosin. No gross structural differences could be seen, in terms of outer 
nuclear layer cell dropout, thinning, retinal folds or photoreceptor outer 
segment loss. It would have been worth repeating with universal standard 
endotoxin, which contains a mixed population of LPS more reflective of 
environmental contamination instead of purified single strain LPS, but supply 
was limited. 
 
Differences between reported cellular tropism, the distribution and speed of 
transduction of AAV serotypes exists throughout the field and literature. It 
might be that unrecognised, but highly variable levels of endotoxin 
contamination could lead to the observed disparities. For example, ShH10 
was originally reported as achieving widespread Muller cell transduction at 
three weeks. In our hands only sparse islands of transduced cells around 
vessels are achieved. Differences exist between purification methods – in our 
lab endotoxin-free AVB column purification is used, as opposed to caesium 
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chloride gradients, without endotoxin testing. One hypothesis was that 
endotoxin and/or other cellular contaminants could cause inflammation and 
degradation of the inner limiting membrane following injection, which would 
then allow more ShH10 to penetrate the retina and transduce Muller cells. 
 
 
Figure 27. Spiking ShH10-CMV-eGFP with endotoxin does not overtly affect the extent or 
type of retinal cells expressing GFP.  Three weeks fo l lowing intravi t real  del ivery of  1x101 0gc 
ShH10-CMV-eGFP spiked with 1ng LPS from E.col i  or  PBS carr ier control ,  eyes were 
enucleated, sect ioned and imaged. A)  In a l l  eyes the c i l iary body epithel ium was completely 
t ransduced, as were B)  Mul ler cel ls  in the region of the opt ic nerve head. C)  GFP expression 
was found in Mul ler cel ls across the rest of  the ret ina; no obvious di f ferences between groups 
could be appreciated. n=6 eyes per group. DAPI counterstain (b lue).  Sect ioned at 16µm 
thickness. Scale bars = 100µm. 
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To test this hypothesis, ShH10-CMV-eGFP with and without a 1ng LPS spike 
was delivered by intravitreal injection into C57BL/6 mice. Three weeks later 
eyes were assessed (Figure 27). No differences in the extent or degree of 
GFP expression in Muller cells were apparent. Whilst this makes it unlikely 
that the presence or absence of endotoxin is responsible for the differences 
in reported ShH10 transduction, it could be that other unidentifiable 
components such as HEK-293T cell debris could still have an effect. This 
would be difficult to test in a controlled way. 
 
A final experiment assessed the possibility of long-term structural damage as 
a result of subretinal delivery of endotoxin. Four eyes were injected with PBS 
and four with 1ng LPS from E.coli in 2µl. They were examined by paraffin 
section after six weeks. Minimal structural changes or photoreceptor nuclei 
loss were seen with H&E staining in either group, suggesting that there is no 
long-term effect upon cellular viability. One caveat is that eyes were injected 
with purified LPS that may not reach the same dose or diversity of species as 
that achieved during standard environmental contamination. 
 
5.3 Testing a novel AAV genome-containing capsid 
enrichment technique 
 
It has been well established that during recombinant AAV production, many 
assembled capsids do not contain any genomic insert. For AAV2 it has been 
calculated that using typical production techniques 96.5% of particles are 
‘empty’.66 In terms of immunomodulation, highly antigenic capsid protein that 
does not contribute to the therapeutic effect is highly undesirable. 
Furthermore, evidence suggests that using the subretinal route in the eye, 
the capacity to prevent systemic response to AAV is dose dependent. At high 
titres of AAV, systemic responses to capsid proteins can be seen, which 
prevent effective treatment of the contralateral eye.76 
 
Based upon the concept of a difference in surface protein charge between 
full and empty AAV a technique using a gradient over an anion exchange 
medium was proposed. AAV5 was trialled first, as personal communication 
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from another group had claimed some success using this serotype and a 
similar approach. A 20-plate preparation of AAV5-GFP was made and initially 
purified using an AVB-column and the endotoxin-free production process 
(Figure 28A). The entire three fractions from the elution peak were pooled 
and diluted 1:10 with distilled water. A 5ml Sepharose QXL column was used 
and loaded with the AVB-purified vector, washed and then eluted with a 
gradient of 250mM sodium chloride buffer from 30% to 100% over 50ml 
(Figure 28B). The absorbance spectrum confirmed one large initial peak and 
then another two semi-distinct peaks. 1ml fractions from across all three 
peaks were tested by both qPCR to determine the number of genome copies 
and SYPRO Ruby gel (as Figure 23B) with densitometry restricted to VP1-3 
bands as a measure of capsid protein. These two readings had background 
readings subtracted and were then normalised to a pre-elution fraction. The 
relative amounts are plotted superimposed over the corresponding fractions 
where tested (Figure 28C). They indicate that capsid proteins are relatively 
evenly distributed throughout all three peaks in proportion to the absorbance 
trace. Genome copies however, are predominantly located in the first peak. 
This disconnect implies that most full packaged AAV is in the first peak and 
the empty capsids have been separated to lie mainly in the third peak. 
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Figure 28. An enrichment of genome-containing capsids is possible using Sepharose 
QX L  medium and AAV5.  Apply ing the new technique on a twenty 15cm-plate batch of AAV5-
CAR-GFP, the f i rst  stage is a standard AVB pur i f icat ion. A)  Three fract ions represent ing the 
major i ty  of  the absorbance peak from the AVB column (blue arrow) are pooled and B)  run on 
a GE Sepharose QX L column and eluted using a sal t  gradient (red = conductance).  C)  The 
result ing absorbance trace shows a pattern of three main peaks. Twenty 0.5ml fract ions were 
taken across the run and a subset analysed by both ITR qPCR determinat ion of v ira l  genome 
number (b lue) and SYPRO Ruby protein gel  with densi tometr ic quant i f icat ion of VP1-3 bands 
(red).  The conclusion is that the rat io of  genome copies to capsid protein is h ighest in the 
f i rst  peak, suggest ing that a greater number of  empty capsids are present in the lat ter peaks. 
D)  Electron microscopy with uranyl acetate counterstain was used as another method to 
determine the percentage of fu l l  capsids. I t  has previously been shown, as the examples 
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i l lustrate,  that empty capsids col lapse to develop a pi t  that sta ins darkly with uranyl  acetate.  
E)  Representat ive example taken from the depleted peak (b lue) showing predominant ly empty 
capsids. F) The equivalent example from the enr iched f i rst  peak with mainly fu l l  capsids 
(orange).  G)  Sepharose QX L trace showing the locat ion of f ract ions pooled for the re levant EM 
assessments. H)  A masked count of  three random f ie lds from three di f ferent images each 
sample is p lot ted for the two peaks. Two-tai led unpaired T-test,  ***=P<0.001. Mean + SD 
shown. Blue traces = UV absorbance (mAu),  red = conductance (mS/cm), beige = Akta Pr ime 
set percentages for B (high sal t)  buffer.   
 
To confirm these findings, electron microscopy of two pooled fractions from 
the first and third peaks were analysed. Empty capsids can be distinguished 
as the concave centre resulting from capsid conformation in the absence of a 
genomic core stains with Uranyl acetate counterstain (Figure 28D). 
Representative examples are shown for the depleted (Figure 28E) and 
enriched peaks (Figure 28F). As the first peak could be taken alone for in 
vivo use, separation out of the empty capsids seen in the deplete peak is a 
form of enrichment. The relative percentages of capsids were enumerated by 
blinded counts over multiple fields from the two peaks (Figure 28G) and a 
significant difference in the percentage of packaged capsid AAV from 30% to 
70% (Figure 28H). This allows an estimate of enrichment of full capsids by 
30%. AAV5 transduces RPE and photoreceptors after subretinal detachment, 
but less efficiently than AAV8, and with a slower onset and a lower final level. 
As a result, the possibility for a similar enrichment of AAV8 was investigated, 
as this was the current vector of choice. 
 
A 20-plate preparation of AAV8 was AVB purified and again run through the 
Sepharose QXL column using the same protocol. This time only one distinct 
absorbance peak was acquired, suggesting that no demonstrable separation 
had occurred (Figure 29). Analysis of fractions by qPCR and SYPRO ruby 
gel confirmed the finding, with both distributing evenly across the peak. A 
cotemporaneous publication illustrates the separation of AAV8 using a CIM-
QA column, a similar type of medium, but with the smaller size monoliths 
used to allow finer resolution of protein separation.182 At the time of writing 
separation of AAV8 into two peaks corresponding to full and empty capsids 
has been possible using the developed protocol, but with a GE MonoQ 
column (Selina Azam, personal communication).  
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Figure 29. The genome-containing-capsid enrichment process using a Sepharose QX L 
column is not able to separate full  and empty AAV8 capsids.  A twenty 15-cm plate prep of 
AAV8-CMV-IL-1ra was pur i f ied by AVB column and then A)  run across the gradient program 
on a GE Sepharose QX L column. Only one absorbance peak could be seen, imply ing no 
s igni f icant separat ion had occurred, or minimal empty capsids were present.  B) ITR qPCR 
determinat ion of v ira l  genome number (b lue) and SYPRO Ruby protein gel  with densi tometr ic 
quant i f icat ion of VP1-3 bands (red) conf i rmed th is f inding. No obvious enr ichment was evident 
and so electron microscopy assessment was not performed.  Blue traces = UV absorbance 
(mAu),  red = conductance (mS/cm), beige = Akta Pr ime set percentages for B (high sal t)  
buffer.  
 
Due to the time and resource constraints of employing this process, it was 
not integrated into the routine production scheme, but retained as a final 
refinement once an optimal suppressive target and method has been 
developed. 
 
5.4 Perioperative high-dose corticosteroid does not affect the 
subsequent success of EIU suppression 
 
Previous evidence indicates that subretinal injection alone can cause 
widespread microglial activation and an increase in detectable 
myeloperoxidase from the eye (Ulrich Luhmann, unpublished observations). 
Following the observed trend towards worsening of EAU and EIU after 
subretinal injection of even control vector, one hypothesis was that the early 
innate immune responses to retinal detachment were worsening the outcome 
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and preventing AAV-mediated immunosuppression. During optimisation of 
the EIU model, it was ascertained whether systemic Dexamethasone 
administration at the time of vector delivery could attenuate this potentially 
nullifying effect (Figure 30). 
 
 
Figure 30. High dose systemic Dexamethasone at the t ime of subretinal injection does 
not alter the degree of EIU induced a week later.  2mg/kg water soluble Dexamethasone 
was administered into the per i toneal space of C57BL/6J mice 24hr before, immediately pr ior 
to and 24hr fo l lowing subret inal  in ject ion.  A)  Representat ive TEFI images of the in ject ion s i te 
of  PBS subret inal- in jected mice receiv ing Dexamethasone and controls fa i l  to demonstrate 
any change in ret inal  appearance at one week. B) CD11b+Gr1+ inf i l t rat ive cel l  counts of PBS, 
AAV8-Nul l  and AAV8-hrGFP in jected eyes were unaffected in subsequent ly induced EIU with 
1ng LPS from E.col i .  There was no trend upon subgroup analysis.  Mean + SD shown. 
 
2mg/kg Dexamethasone was given as an intraperitoneal dose the day 
before, the time of and the day after subretinal injection. EIU was induced 
one week later. No obvious change in retinal appearance could be detected 
by TEFI and flow cytometry of eyes from mice treated with and without 
Dexamethasone did not differ in CD11b+Ly6G+ cell count. Perioperative 
corticosteroids are used routinely in clinical practice and are known to 
suppress active ocular inflammation, but it is not known if they affect the 
resident rather than infiltrating immune cells, and this may explain the lack of 
effect in the experiment. Whilst technical refinements in timing and readout 
might reveal a small benefit, it was felt unlikely to lead to dramatic effect and 
so not pursued further. 
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5.5 EAU does not trigger a systemic response against 
subretinal delivered AAV8 
 
The absence of systemic response to AAV2 when injected into the subretinal 
space has been well established in both pre-clinical studies and clinical 
trials.48-50,76,183 The effect of pre-existing or subsequent independent ocular 
inflammation upon this poorly understood form of ‘immune privilege’ is 
unknown. One hypothesis is that the subretinal space contains viral antigens, 
preventing systemic exposure, rather than an active immune deviation 
process. If so, then intraocular inflammation with the accompanying infiltrate, 
retinal damage and degradation in blood-ocular barriers may lead to 
exposure and subsequent responses. To model this in mice, EAU was 
induced following subretinal delivery of AAV8-CMV-mIL-10-IRES-eGFP in 
one eye and AAV8-CMV-hrGFP in the other. No local suppression of disease 
had been observed as discussed in results chapter 4. Serum and spleens 
were collected at peak disease on day 26 and analysed for ELISPOT 
responses to AAV8 capsid and the development of neutralising antibodies 
(Figure 31). 
 
 
Figure 31. No systemic antigen-specif ic immune responses are detected after EAU 
induction following subretinal delivery of AAV8.  1x101 0gc AAV8-CMV-mIL-10-IRES-eGFP 
was in jected into the subret inal  space of both eyes. A week later EAU was induced and serum 
and lymph nodes harvested at day 26. A)  IFNγ -re lease assay for CD8+ T-cel ls responsive to 
AAV8 capsid was performed, with posi t ive and naïve negat ive controls.  The number of  
d iscrete spots sta in ing was counted. No signi f icant response was detected for a l l  f ive animals 
tested. B)  Neutral is ing capsid-directed ant ibodies from serum were determined by their  abi l i ty  
to prevent AAV8-CMV-eGFP from transducing HEK-293T cel ls in  v i t ro .  With appropr iate 
posi t ive and negat ive controls,  none of the f ive mice tested had detectable levels of  
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neutral is ing ant ibody. Three di lut ion and technical  dupl icates were performed. 1:100 di lut ion 
is i l lustrated. Means + SD shown. 
 
Positive controls were obtained from mice injected subcutaneously with 
AAV8-CMV-hrGFP one month earlier, whilst naïve wildtype mice were used 
as negative controls. ELISPOT responses were tested against re-stimulation 
with whole virus capsids (Figure 31A). Of the five mice tested from an 
experiment where eyes were injected alternately with AAV8-CMV-hrGFP and 
AAV8-CMV-mIL-10, none demonstrated significant responses. It is possible 
that systemic exposure of IL-10 may have affected responses, but elevated 
levels have not been detected in the serum of injected mice when cytokines 
were expressed previously.110 The ELISPOT result was mirrored by 
neutralising antibody assessment where serum was incubated with intact 
AAV8-CMV-hrGFP prior to addition to HEK-293T cells in culture. After three 
days the percentage of GFP expression was enumerated by flow cytometry 
(Figure 31B). As mice are known to predominantly develop a humoral 
response to AAV, this last finding is perhaps more critical than the ELISPOT 
result.77 
 
5.6 Soluble transgene-encoded proteins are likely to be 
delivered into the eye, rather than secreted into the 
choroidal circulation 
 
Tracing soluble, secreted proteins delivered by AAV transduction of ocular 
cells is a problematic but important issue. All AAV serotypes infect RPE after 
subretinal administration. When using transmembrane or intracellular 
transgenes it is clear that the transduced cells themselves will develop 
elevated concentrations. With secreted targets such as IL-10 or soluble TNF-
receptors, it is critical that the transgene product leaves the RPE to reach 
other appropriate sites in the eye. Whilst an effect on the RPE may provide 
some benefit, it is likely that other cells, such as microglia or infiltrating 
myeloid cells, will need to be affected to achieve full disease suppression. As 
most of these inflammatory cells traffic to the retina, vitreous and ciliary body, 
secretion from the RPE would need to reach these sites and not be directed 
exclusively basally to be washed rapidly away in the choroidal circulation. 
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To assess if exclusive basal secretion of viral mediated transgene occurs in 
the RPE, two experiments provide evidence – in vivo and in vitro - in mouse 
and human cells respectively. Firstly, lentivirus carrying murine IL-10 was 
injected into the subretinal space before induction of EAU a week later. 
Although no attenuation in infiltrating cell counts was seen (Figure 32A), 
matched supernatants taken from either homogenised retina and vitreous or 
RPE/choroidal complex were tested for murine IL-10 by ELISA. Delivered 
into the subretinal space, lentivirus is well known to infect only RPE. The 
detectable elevation of mIL-10 in the Lentivirus.mIL-10 injected retina 
compared to the PBS injected control retina is likely to represent secretion 
apically from the RPE (Figure 32B). Whilst there may be slight cross-
contamination of RPE/choroidal to retinal samples, dissection along the 
subretinal plane is normally very reliable. Further support arises from 
homogenisation of the RPE, where levels are approximately equal to that in 
the retina, implying that a significant proportion of the IL-10 produced ends 
up secreted apically. 
 
 
Figure 32. Subretinal Lentivirus-mIL-10 delivery provides support for the successful 
secretion of transgene product from RPE into retina and vitreous. One week fo l lowing 
subret inal  in ject ion of neat Lent iv irus-SFFV-murine IL-10 or PBS, EAU was induced. At day 
26 eyes were careful ly  separated by dissect ion into ret ina, v i t reous, AC f lu id and RPE-
choroidal complex. A)  Ret ina, v i t reous and AC f lu id were pooled and spun down to extract 
leukocytes. The supernatants were retained for ELISA. Flow cytometry was performed for a 
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var iety of  markers.  No stat ist ical ly  s igni f icant suppression in inf i l t rate was observed. B)  
Matched ret inal  supernatants and homogenised RPE/choroid samples underwent ELISA for 
mIL-10. Lent iv i rus is known to only transduce RPE, so detectable levels in the ret ina above 
the levels in PBS in jected eyes can only have or ig inated from the RPE, imply ing secret ion of 
IL-10 to the apical  s ide. As a comparable,  s igni f icant increase was seen in both groups 
treated with Lent iv irus, th is level of  secret ion is l ikely to be substant ia l .  Kruskal-Wal l is  test 
with Dunn’s mult ip le comparison **=P<0.01, *=P<0.05. Mean + SD shown.   
 
Further support arises from work performed with human embryonic stem cell 
and induced pluripotent stem cell-derived RPE cultures. These experiments 
were performed in collaboration with Dr Anai Gonzalez-Cordero. 
Differentiated RPE was cultured in transwells with apical and basal reservoirs 
and grown as monolayers to tight confluence. Examples of the monolayers 
achieved are shown (Figure 33A). Good polarisation was confirmed by both 
detecting apical Ezrin staining on immunohistochemistry (Figure 33B) and 
polar secretion of VEGF as expected in a predominantly basal direction by 
ELISA (Figure 33C). 
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Figure 33. Polarised human ES and iPS-derived RPE confirm apical secretion of murine 
IL-10 and p75-Ig protein following ShH10 transduction.  Human ES-derived and iPS-derived 
RPE cel ls were plated in 0.22µm mesh size transwel ls and grown to conf luence. A)  A 
representat ive image of ES-der ived RPE stained for the membrane marker Phal lo id in,  
demonstrates polygonal RPE morphology of consistent cel l  type and conf luence. B)  Confocal 
imaging of iPS-der ived human RPE demonstrates a conf luent and polar ised monolayer 
sta ined for Ezr in -  a protein that local ises apical ly to the RPE microvi l l i .  Supernatant f rom the 
apical  and basal compartments were col lected from transwel ls at  a ser ies of t imepoints 
fo l lowing the addit ion of  ShH10 carry ing mIL-10, mouse p75-Ig or eGFP control .  C)  Human 
VEGF is known to be secreted basal ly by RPE. This was conf irmed using ELISA and results 
were corrected for tota l  protein to e l iminate any general ised effects of  d i lut ion. Whi lst  tota l  
amounts var ied between transwel ls,  in a l l  samples the apical-basal rat io indicated at least 
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3.5-fo ld h igher levels in the basal compartment.  This is  further evidence the cul tures were 
sui tably polar ised. D)  ES-der ived RPE transduced by ShH10-CMV-mIL-10 generated 
detectably h igher levels of  mIL-10 in the apical  compared to basal compartment by almost 10-
fo ld at  a l l  t imepoints post- infect ion. This was stat is t ical ly  s igni f icant by two-way ANOVA, 
P=0.0075. E)  A s imi lar result  was obtained by ShH10-CMV-p75-Ig,  where again, the major i ty 
of  produced transgene was found in the apical  compartment,  though th is d id not qui te reach 
stat ist ical  s igni f icance by two-way ANOVA, P=0.16. Numbers in bold above bars = rat io of  
largest to smal lest  concentrat ion. Species-specif ic  ELISA and BCA determinat ion of tota l  
protein were performed at three di lut ions and with technical  t r ip l icates. GFP controls by 
ELISA did not d i f fer  f rom background blank wel ls. 
 
Transwells were infected with ShH10-CMV-eGFP, ShH10-CMV-mIL10 or 
ShH10-CMV-mouse p75-Ig and medium sampled from both apical and basal 
compartments across multiple timepoints. ShH10 was used as in vitro it 
appears to result in the highest level of expression in human ES or iPS-
derived RPE (Anai Gonzalez-Cordero, personal communication). The use of 
mouse transgenes ensured minimal complicating background when testing 
with species specific ELISA. Transwells were filled with an equal volume of 
medium at each re-feed. In further potential demonstration of polarity 
however, the volume would distribute so that the basal compartment would 
accumulate almost double that of the apical. Presumably fluid is pumped 
through the RPE in a basal direction as occurs in vivo.   
 
Both mIL-10 and p75-Ig were detected predominantly in the apical 
compartments (Figure 33D-E). ELISA readings were corrected for total 
protein content, in case the changes in volume affected these results. With 
only two targets it is impossible to confirm if this is a transgene-specific effect 
dependent upon signal sequence, or less likely a generalised effect of AAV-
driven expression. Nevertheless, the previously held hypothesis that all 
transgene product is lost into the choroid appears unlikely.  
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5.7 Chapter summary 
 
Multiple refinements to the manufacture and purification of AAV have been 
introduced, to obtain purer material that should provide the best chance for 
successful ocular immunomodulation. Endotoxin contamination has been 
addressed during AAV production and its consequences defined. The lack of 
systemic responses to AAV8 in the context of EAU was identified. New 
serotypes of AAV8 and ShH10 have been investigated and a novel technique 
for removing empty capsids was trialled. Intravitreal ShH10 was shown to 
transduce ciliary epithelium, corneal endothelium and a reasonable number 
of Muller cells. This is the most extensive cellular transduction achieved from 
the intravitreal route used in any study of gene therapy for uveitis to date. 
Finally, the propensity for AAV-transduced RPE to beneficially secrete 
soluble transgene proteins apically was confirmed using human stem cell 
derived cultures. 
  
                                                                                                                   129 
6 Results 4: Gene transfer of IL-10 into 
experimental models of intraocular 
inflammation using modern AAV serotypes 
 
Several publications have shown the suppressive effect of interleukin-10 (IL-
10) upon EAU following viral gene transfer93,110. To continue the work 
performed in these earlier studies, the efficacy of more recently developed 
AAV serotypes was examined. The hypothesis is that the faster onset of 
transduction, higher levels of expression and wider cellular tropism would 
prove superior to the previously used AAV2. This original serotype 
predominantly transduces RPE and takes over three weeks to reach near 
maximal levels of expression. Serotypes such as AAV8 exceed the levels 
achieved by AAV2 even by one week. This advantage could allow 
intervention in active inflammation, rather than prophylactic treatment only 
when drug-induced remission had been achieved. This is the eventual 
translational goal and was approached by using animal models of uveitis. 
 
6.1 Defining the parameters of the EAU model for modulation 
by gene therapy 
 
An initial requirement was to establish the parameters of the C57BL/6 EAU 
model in our facility. The severity of the EAU model is affected by many 
variables, which need to be defined in order to achieve effective induction 
and as consistent disease as possible. The genetic background of mice, 
housing conditions, commensal microbiota and dose of RBP-3 peptide can 
all affect both the severity and timecourse of EAU. Identifying the parameters 
of disease achieved as a result of these variables was necessary to 
effectively employ the model. Disease was identified and classified using 
CD45-immunolabelled histology (Figure 34A) and TEFI. Peptide was 
synthesised and trialled over a range of DMSO concentrations to obtain an 
optimal mix that provides complete peptide solubility and the greatest amount 
of disease. Whilst workable, complete dissolution of peptide into a liquid 
suspension was only consistently achieved at 35%. Below this it remained as 
a gel which was possible, but technically awkward to work with. Unfortunately 
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at high levels, the DMSO resulted in minimal EAU potentially due to the 
inhibitory effects of DMSO upon T-cell activation.184 Therefore a 10% 
maximum concentration was used for all subsequent work (Figure 34B). 
Delineating the exact EAU timecourse achieved is important as both strain 
variations and microbiome often determined by the local animal facility can 
affect EAU severity and timing. Without this peak disease might be missed in 
subsequent experiments. Using TEFI to chart progression, day 26 was 
chosen as the peak disease timepoint of EAU (Figure 34C-D). Using the 
same dataset, a correlation was confirmed between the two eyes of each 
individual animal. Whilst a disparity between eyes was frequent, there was 
less variation between the two eyes of the same mouse (intra-animal 
variation) than between eyes of different mice (inter-animal variation). This 
highlighted that where possible paired analyses between intervention and 
control are preferable (Figure 34E).  
 
                                                                                                                   131 
 
Figure 34. Local parameters of the C57BL/6  EAU model.  Induct ion of EAU used 500µg 
IRBP1 - 2 0  in complete Freund’s adjuvant,  with 25µg pertussis toxin.  A)  Representat ive CD45-
DAB (brown) and haematoxyl in sta ined sect ions of eyes at peak EAU demonstrat ing inf i l t rate 
and structural  damage. Scale bar = 50µm. The IRBP pept ide is typical ly d issolved in a 10% 
di lut ion of DMSO. B) Due to solubi l i ty  issues, a range of DMSO from 15% to 35% was tested 
and showed reduced disease with increasing DMSO percentage. Kruskal-Wal l is  test with 
Dunn’s mult ip le comparison, *=P<0.05, n=3. Topical  endoscopic fundal imaging (TEFI) was 
used to further character ise the EAU model.  C)  A representat ive t imecourse i l lustrates 
progression between day 19 and 36 post- induct ion, with disc swel l ing, vascul i t is  and ret inal  
lesions. D)  Pooled TEFI scores from three masked scorers for mult ip le eyes fo l lowed over the 
course of EAU. A second-order polynomial  f i t  is  shown, which highl ights peak disease at day 
26. n=10. E)  Left  and r ight eyes of the same animal dur ing EAU, show a s igni f icant 
correlat ion imply ing less intra-animal than inter-animal var iat ion. Spearman correlat ion. 
Means + SD shown.  
                                                                                                                   132 
 
EAU in the presence of AAV transduced retina was assessed to observe if 
any dramatic loss of transduced cells occurred in this context. Following 
subretinal AAV8-CMV-hrGFP injection, EAU was induced and eyes 
examined by a variety of techniques including TEFI, SLO and histology (see 
Materials & Methods). As expected the control eyes without EAU 
demonstrated normal appearances on TEFI and SLO imaging, with 
superiorly located GFP signal arising from the RPE and photoreceptors 
(Figure 35). Histology revealed confluent transduction of the RPE and a 
majority of the photoreceptors in the region of the subretinal detachment.  
 
 
Figure 35. The effect of EAU upon AAV transduced retina.  Representat ive examples of 
eyes in jected superior ly in the subret inal  space with 2µl  of  1x101 0gc AAV8-CMV-hrGFP.  The 
top row is f rom an eye 3 weeks post- in ject ion, with a normal TEFI and infrared ( IR) 
appearance. GFP signal can be seen using the 488 channel of  the HRA2 scanning laser 
ophthalmoscope. Matched histo logy shows the expected and previously reported RPE and 
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photoreceptor t ransduct ion. The lower rows are from eyes 26 days after the induct ion of EAU. 
Disc swel l ing, vascul i t is  and a green hue can be seen by TEFI.  GFP channel shows patches 
of reduced signal and histo logy shows loss of the expected number of GFP+ photoreceptors 
compared to control .  Using CD45 label led histo logy, another example in a region of extensive 
structural  damage and inf i l t rat ion again demonstrates some loss of t ransduced photoreceptors 
with re lat ively intact s ignal f rom the RPE. Scale bars = 50µm. 
 
In eyes at peak EAU, TEFI demonstrated classical clinical changes of 
vasculitis (perivascular cuff), disc enlargement and retinal lesions. This 
corresponded to disruption in GFP signal on SLO. By histology the 
transduced RPE remains predominantly intact, though the density of GFP+ 
photoreceptors appears reduced in regions of structural change (Figure 35). 
Using sequential slides from the same eye, CD45+ cells are visible in the 
subretinal space, associated with the inflammatory retinal folds where GFP 
signal in the photoreceptors has been lost. It is unclear if these findings 
represent preferential loss of transduced rods and cones or only reflects 
generalised damage to the retina during EAU. Regardless, it appears likely 
that a potent suppressive effect is required from any target gene delivered, or 
the disease process may eliminate the very cells responsible for its 
production.  
 
6.2 Murine IL-10 supplementation by AAV9 in EAU  
 
Subretinally delivered AAV2 carrying murine IL-10 had been shown to 
suppress EAU when delivered three weeks prior to the onset of EAU.110 This 
period is required as AAV2 takes many weeks to reach maximum 
expression. AAV9 is a new serotype in use in the lab. It is known to be 
expressed strongly by one week and transduces RPE, photoreceptors and 
occasional Muller cells following subretinal injection.185 As the first 
experiment, high dose AAV9-mIL-10-IRES-GFP was injected with a AAV9-
CMV-hrGFP control. AAV2-CMV-mIL-10-IRES-eGFP was used to compare 
to previous work. All vectors were left for 3 weeks, to allow a fair comparison 
with AAV2 before the induction of EAU. 
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At peak disease on day 26, eyes were examined by TEFI and CD45-labelled 
immunohistochemistry (Figure 36A). Surprisingly the AAV9-mIL-10 cohort 
was markedly abnormal, with extensive outer layer retinal loss and choroidal 
changes, not seen in the GFP control or AAV2 groups. Successful 
expression had been confirmed by fundal imaging for GFP (Figure 36B) 
after injection, whilst elevated levels of mIL-10 were established using ELISA 
(Figure 36C). As expected, AAV9 resulted in higher final levels than AAV2 
despite the extensive retinal loss. Final histological EAU scoring showed 
statistically significant worsening in the AAV9-mIL-10 group relative to 
unprocedured eyes (Figure 36D). AAV2 failed to suppress disease, but in 
this experiment AAV2-mIL-10 was compared to AAV9-hrGFP and had been 
delivered at a higher titre than before to maximise any potential effects. 
Electroretinograms consolidated the findings, with AAV9-mIL-10 injected 
eyes demonstrating a statistically significant reduction in B-wave amplitude, 
consistent with tissue damage during EAU giving rise to significant retinal 
loss (Figure 36E).  
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Figure 36. AAV9 mediated expression of mIL-10  leads to increased severity of EAU and 
associated retinal cell  loss.  Double 2µl  subret inal  in ject ions of 5x101 1gc/ml t i t re-matched 
AAV9-CMV-mIL-10-IRES-GFP, AAV9-CMV-hrGFP or AAV2-CMV-mIL-10-IRES-GFP was 
performed three weeks pr ior to EAU induct ion. A)  Representat ive images of TEFI and CD45-
DAB histo logy. Extensive ret inal  loss and abnormal choroidal  appearances were seen in the 
AAV9-mIL-10 cohort ,  compared to AAV9-hrGFP control .  Scale bars = 50µm. B)  Successful  
GFP expression was conf irmed by s l i t - lamp f luorescent fundus imaging at day 17 post-
in ject ion, whi lst  ELISA of whole eye homogenates detected elevated levels of  mIL-10 from 
AAV2 and AAV9-mIL-10 vectors.  n=3, with technical  t r ip l icates. One-way ANOVA and Tukey’s 
mult ip le comparison test,  **=P<0.01, ***=P<0.001. D)  F inal  CD45 histo logical  EAU scores 
demonstrate stat ist ical ly  s igni f icant worsening with AAV9-mIL-10 compared to uninjected 
eyes. A trend towards worsening is seen even with AAV9-hrGFP and AAV2-mIL-10. E)  
Electroret inography demonstrates marked suppression of the scotopic B-wave in the AAV9-
mIL-10 cohort ,  consistent with both EAU and extensive ret inal  damage. Kruskal-Wal l is  test 
with Dunn’s mult ip le comparison, *=P<0.05. Means + SD shown.  
 
Unexpectedly AAV9-mIL-10 was highly detrimental to the eye. Similar 
findings had not been seen before using AAV9. AAV9-hrGFP and AAV2-mIL-
10 did not show the same dramatic appearance though all vectors had a 
trend towards worsened EAU. The observed changes could be a result of 
high level expression of mIL-10 itself causing toxicity, or due to a non-protein 
specific effect of expressing secreted transgenes from AAV. It was also 
uncertain if the AAV9-mIL-10 vector specifically was only toxic in the context 
of simultaneous EAU and so a small dose-titration experiment was 
performed without disease induction. 
 
TEFI performed on AAV9-mIL-10 injected eyes after one month again 
revealed similar retinal damage and appeared to be titre-dependent (Figure 
37A). Eyes were homogenised and tested by ELISA (see Materials & 
Methods) for mIL-10 and a dose-response was seen dependent upon titre. 
The onset of retinal changes appeared to coincide with the 1x107gc dose – 
the first where detectable IL-10 production is seen (Figure 37B). Flow 
cytometry on dissociated retinas was performed and an increase in CD4+ 
and CD8+ T-cells was also seen with higher titre (Figure 37C).  
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Figure 37. The AAV9-mIL-10 vector induces dose-dependent retinal changes and T-cell  
infi l tration.  Double 2µl  subret inal  in ject ions of varying t i t re AAV9-CMV-mIL-10-IRES-eGFP 
pur i f ied by Sephacryl  and Poros columns were assessed after 32 days. A)  TEFI shows 
progressive ret inal  changes with increasing total  genome copies of AAV. PBS is shown to 
control  for  the effect of  ret inal  detachment.  B)  Eyes were homogenised and tested for mIL-10 
levels by ELISA. This showed an effect ive elevat ion in ocular mIL-10, when a 2µl  in ject ion of 
above a 1x107gc/ml t i t re was performed. C)  Other eyes underwent f low cytometry af ter ret inal  
d issociat ion. A trend towards higher numbers of CD4+ and CD8+ T-cel ls is  seen with 
increasing t i t re.  D)  TEFI appearances of eyes in jected with di f ferent t i t res of AAV9-mIL-10, 
pur i f ied using an AVB column. This method does not provide as high a t i t re,  but contains less 
cel lu lar contaminants,  result ing in less marked ret inal  changes. 
 
With possible toxic changes seen in the retina, the quality of AAV 
preparations being used was examined. The viral facility was optimised for 
monogenic rescue projects and had not extensively produced AAV for 
immunomodulation applications that might be more sensitive to 
contaminants. As an initial trial, purification was performed using an AVB 
column – an affinity-based separation medium. This is believed to give 
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cleaner preparations, but was not designed for use with AAV9 and so lower 
titres were obtained, with a maximum of 2x1010gc from a 20-plate prep.  
 
Less clinical toxicity was observed, with improved retinal appearances seen 
on TEFI for equivalent titres (Figure 37D). This manner of production 
however, was not satisfactory due to the inefficient yield of virus. At this point 
it was decided to fully re-assess the entire AAV production process and the 
many resultant changes are detailed in results chapter 3. 
 
6.3 Refined production generated AAV8-mIL-10 avoids overt 
retinal toxicity but does not suppress EAU 
 
As described multiple alterations were made to the viral production facility to 
enable optimal AAV production. Briefly this included removal of endotoxin 
contamination, a two-plasmid transfection process, routine purification using 
disposable AVB columns and improved titre-matching using a PCR based 
technique. The serotype used was also switched to AAV8. This is because it 
allows high-titre purification by binding strongly to AVB medium, be 
generated using a two-plasmid system and has similar transduction 
characteristics to AAV9. Specifically it is known to transduce RPE and 
photoreceptors but not Muller cells.  
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Figure 38. Refined production process AAV8-CMV-mIL-10 sti l l  fai ls to suppress EAU.  
Fol lowing the ref ined AAV product ion process descr ibed in results chapter 3,  AAV8-CMV-mIL-
10-IRES-eGFP or AAV8-CMV-hrGFP was produced and 0.5µl of  5x101 2gc/ml in jected into the 
subret inal  space. One week later EAU was induced then terminated at peak disease at 26 
days later.  A)  Representat ive TEFI images of eyes from the three intervent ion groups, shows 
l imited di f ferences between the groups. B)  In v ivo  scores for the cohort  using the OCT-based 
EAU scor ing system developed in results chapter 1 shows a trend towards worsened EAU. C)  
CD45 histo logical  EAU scores show worsened disease in the AAV8-mIL-10 group compared to 
uninjected eyes. D)  ELISA of whole eye homogenates from eyes in jected in the same cohort  
conf irms elevated levels of  mIL-10 in the intervent ion group only.  Kruskal-Wal l is  test,  
*=P<0.05. E)  Summary graph of CD45 histo logy EAU scores from this and the previous AAV9 
experiment,  wi th F)  pooled data to demonstrate the effect of  mIL-10  overexpression. One-way 
ANOVA with Tukey’s mult ip le comparison test.  **=P<0.01, ***=P<0.001. Means + SD shown. 
 
                                                                                                                   139 
Using the newly produced vectors, the initial experiment was repeated using 
AAV8-CMV-mIL-10-IRES-eGFP and AAV8-CMV-hrGFP. TEFI appearances 
did not reveal the atrophic changes seen before with AAV9, implying 
previous findings might have been specific to that serotype or contaminants 
from the original production process (Figure 38A). The newly developed 
OCT-based EAU scoring system was employed and showed a trend towards 
worsened disease in AAV8 injected eyes (Figure 38B), confirmed by CD45 
histology scores (Figure 38C). Successful supplementation of mIL-10 was 
identified by ELISA on whole eye homogenates (Figure 38D). Pooling data 
from both AAV9 and AAV8 experiments, (Figure 38E-F) significant 
worsening of EAU was observed in both GFP and mIL-10 expressing 
vectors, compared to uninjected eyes. The difference between GFP and mIL-
10 was not statistically significant and so it is not possible to conclude that 
the effect of mIL-10 is responsible.  
 
It is known that retinal detachment leads to an increase in multiple 
inflammatory cytokines and microglial activation.179 One hypothesis at this 
stage was that the subretinal injection resulted in a larger increase in 
inflammation than the degree of suppression obtained from mIL-10. Timing of 
intervention is also important and cytokines such as IL-10 may lead to 
different effects given prior to established inflammation, rather than during 
disease. Different forms of IL-10 also exist and three main types have been 
investigated widely in the literature. Murine, human and viral IL-10 share 
similar properties, but differ with respect to their potential pro-inflammatory 
effects. For example, viral IL-10 lacks the predominantly stimulatory regions 
and is felt to possess superior immunosuppressive qualities.  
 
To address these three issues, a novel engineered serotype known as 
ShH10 was obtained from Prof. John Flannery (Berkeley, USA). It was 
characterised as described in results chapter 3 and produced using the 
refined production process. ShH10-viral IL-10 was produced and delivered 
using the intravitreal route, which is suspected to be less destructive than a 
subretinal injection, albeit at the risk of greater systemic absorption of vector. 
The relative simplicity of an intravitreal injection also makes it tractable 
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clinically to intervene in eyes with established EAU, which may otherwise 
suffer from hypotony and vitritis that would make subretinal injection 
technically challenging, and would increase adverse outcomes. 
 
EAU was induced in a cohort of C57BL/6J mice and at day 14 two doses of 
ShH10-viral IL-10-IRES-GFP were injected. Eyes were analysed at day 26, 
by which time expression would be obtained from the ciliary epithelium, 
corneal endothelium and occasional Muller glia. TEFI did not show 
differences in retinal appearance compared to PBS injected controls (Figure 
39A), despite the presence of 500pg/ml in retinal supernatants (Figure 39B). 
Flow cytometry confirmed the absence of effect upon changes in key 
infiltrating cellular populations (Figure 39C). 
 
 
Figure 39. Intravitreal injection of ShH10-viral IL-10 during established EAU does not 
change final disease outcome.  EAU was induced and at day 14, intravi t real  in ject ion of 2µl  
PBS, 2x101 0gc (h igh dose) or 2x109gc ( low dose) ShH10-CMV-vIL-10-IRES-GFP was 
performed. A)  At peak disease on day 26 TEFI appearances do not show dramatic d i f ferences 
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between groups. Fol lowing dissociat ion ret inal  samples were analysed by f low cytometry with 
supernatants used for ELISA. B)  v IL-10 was detectable in both high and low dose groups. 
Kruskal-Wal l is  test with Dunn’s mult ip le comparison, P=0.03. C)  F low cytometry shows no 
s igni f icant a l terat ion in cel l  counts of  CD4, CD8 T-cel ls,  CD11b+Ly6G+ (neutrophi ls or MDSC) 
or CD11b+Ly6C+ (monocyte) populat ions.  Whi lst  no suppression of d isease was achieved, 
there was equal ly no worsening in d isease despite intravi t real  administrat ion of up to 2x101 0 
v ira l  genome copies dur ing acute EAU. Means + SD shown. n=16 eyes. 
 
It was clear that further investigation would be required to identify and correct 
issues affecting successful suppression of EAU by viral gene transfer of IL-
10. As the priority was to discern why expressing IL-10 using newly 
developed AAV serotypes did not reduce intraocular inflammation, a simpler 
model was employed to reduce the number of potential variables. Endotoxin-
induced uveitis (EIU) is a non-antigen based model of acute ocular 
inflammation that occurs rapidly, allowing assessment within 24 hours. 
Triggered by ocular TLR4 ligation, the pro-inflammatory signalling pathways 
involved are much more narrow than EAU and so arguably the opportunity 
for successful suppression is greater. This has been corroborated by 
publications showing attenuation of EIU using lentivirally delivered mIL-10.34 
 
6.4 EIU can be used to efficiently screen factors affecting 
effective suppression by viral gene transfer  
 
Prophylactic delivery of the refined AAV8-mIL-10-IRES-GFP vector was 
tested first with EIU induced by intravitreal administration of 1ng LPS a week 
after subretinal injection. No suppression in neutrophil (defined as 
CD11b+Ly6G+) infiltration was seen, even though detectable 
supplementation of mIL-10 was identified by ELISA (Figure 40A-B). The lack 
of correlation between infiltrative cell number and mIL-10 level implies that 
either mIL-10 has no dose-response effect or levels are outside the 
therapeutic range (Figure 40C).  
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Figure 40. Subretinal administration of AAV8-CMV-mIL-10-IRES-eGFP does not affect 
EIU.  One week fo l lowing 2µl subret inal  in ject ion of t i t re-matched 2x109gc ref ined AAV8, 1ng 
of LPS was administered into the v i t reous cavi ty and 18hr later,  AC, v i t reous and ret inal  cel ls  
were dissociated and analysed by f low cytometry.  A)  There was no effect  upon EIU severi ty 
as measured by granulocyte inf i l t rat ion, despite B)  an 18-fo ld e levat ion in IL-10 protein level  
detected by ELISA of matched RPE/choroid homogenate. Mann-Whitney U test,  P=0.024. C)  
No signi f icant correlat ion was detected between mIL-10 levels and degree of inf i l t rat ion. 
Pearson correlat ion. Means + SD shown. 
 
 
To address the issue of dose, route and vector effects, mIL-10 was delivered 
from variety of vectors and routes, including intravitreal ShH10, subretinal 
AAV8, AAV9 and lentivirus. ShH10-CMV-eGFP was used as a control. EIU 
was induced a week later and analysed by flow at 18-hours (Figure 41A). No 
significant differences were seen between numbers of infiltrating neutrophils 
(CD11b+Ly6G+). A range of concentrations of mIL-10 was recovered from 
matched retinal supernatants (Figure 41B). Comparing dose to disease 
severity, there was no correlation, indicating that over a range of doses from 
10pg/ml to 10ng/ml mIL-10 has no effect upon EIU, when delivered by a 
variety of viral routes (Figure 41C).  
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Figure 41. Murine IL-10  expressed from different AAV serotypes fails to suppress EIU at 
any dose achieved.  A wide range of ocular mIL-10 was achieved by in ject ing di f ferent 
serotypes, t i t res and routes. ShH10-CMV-mIL-10 ( IV),  AAV9 (double subret inal) ,  AAV8 (s ingle 
subret inal) ,  Lent i -mIL-10 (s ingle subret inal) .  ShH10-CMV-eGFP (IV) and uninjected eyes were 
used as a control .  A)  No change in the number of CD11b+Ly6G+ cel ls was seen between any 
group. B)  Elevated levels of  mIL-10 were conf i rmed in a l l  intervent ion groups by ELISA. Three 
di lut ions and technical  dupl icates. Al l  OD values were on the l inear part  of  the standard 
curve. C)  No correlat ion was ident i f ied between mIL-10 level  and cel l  count,  imply ing lack of 
ef f icacy across a range from 10pg/ml to 10ng/ml.  Pearson correlat ion, R2=0.0005, P=0.91. 
Means + SD shown.  
 
This result was unexpected and hard to reconcile with previously published 
work.34 Before making a conclusion about the effect of mIL-10, the prior 
experiment of intracameral lentivirus and EIU was repeated exactly, but 
using the disease readout of flow cytometry developed in results chapter 2. 
Injecting lentivirus in this manner leads to transduction of the corneal 
endothelium, iris, trabecular meshwork and ciliary body. Suppression was 
seen in the anterior chamber, but not in the vitreous/retinal compartment 
(Figure 42A). Additionally no difference in mIL-10 levels could be detected 
between the therapeutic vector and eGFP control injected eyes (Figure 
42B). Diseased eyes were not tested by mIL-10 ELISA during the initial 
publication and suppression was seen by histology in both compartments 
(Figure 42C). The potential implication is that either EIU itself or the GFP 
vector induced endogenous production of mIL-10.  Interleukin-10 is known to 
increase during normal EIU.186 It could be that the suppressive effects result 
from conditioning of resident cells in the two weeks prior to EIU induction.  
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Figure 42.  Intracameral Lentivirus expressing murine IL-10  attenuated AC cell  counts 
only during EIU when analysed by f low cytometry. Eyes received 4µl intracameral 
in ject ions of  Lent iv irus expressing GFP or mIL-10 .  Two weeks later EIU was induced and eyes 
taken for f low cytometry at  12 hours post- in ject ion. A) Absolute counts of  CD11b+Ly6G+ cel ls 
in the AC, Ret ina/Vitreous and the two-combined demonstrate a reduct ion in the AC only.  
Mann-Whitney U test.  P=0.03. B)  This is  despite no detectable di f ference in mIL-10 levels in 
AC f lu id at  the end of the exper iment.  C) Histological  scores from previously publ ished data 
for comparison.3 4 Mean + SD shown.  
 
To clarify several variables, the experiment was repeated again, but including 
eyes injected with lentivirus without the induction of EIU. This cohort failed to 
demonstrate the AC suppression previously seen (Figure 43A). Matched 
ELISA data for mIL-10 levels reveals details of changes during EIU (Figure 
43B). Firstly, prior to the induction of disease a detectable elevation in mIL-
10 exists relative to PBS and GFP control at baseline. During EIU levels in 
the AC do not significantly change in any groups. Larger amounts of IL-10 
are observed in the retinal compartment during EIU compared to the 
matched eye AC samples, with a trend to greater levels in the Lenti.mIL-10 
group. Despite now detectable elevations there is no suppression of disease. 
Pooling data from both experiments confirms no overall effect of mIL-10 
expression (Figure 43C).  
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Figure 43. The experimental repeat and addition of a PBS control demonstrates no 
signif icant suppression of EIU by Lenti .mIL-10 ,  despite detection of elevated mIL-10 
protein levels in the eye.  Eyes received 4µl intracameral in ject ions of PBS or Lent iv irus 
expressing GFP or mIL-10. Two weeks later EIU was induced and eyes taken for f low 
cytometry at  12 hours post- in ject ion. A)  Absolute counts of  CD11b+Ly6G+ cel ls in the AC, 
Ret ina/Vitreous and the two-combined shown no s igni f icant suppression. Kruskal l-Wal lace 
test.  P>0.30. B)  ELISA for mIL-10 on ocular supernatants detects s igni f icant ly e levated levels 
af ter Lent i .mIL-10 in the AC. Kruskal l -Wal lace test.  P=0.02. The induct ion of EIU appears not 
to af fect levels of  mIL-10. C)  Pooled cel l  counts including the previous experiment f rom 
Figure 42 conf irm no s igni f icant suppression by Lent i .mIL-10 .  Means + SD shown.  
 
There is clearly large variation between experiments and the previous work 
was not fully repeatable. As levels were not assessed in that paper, it is hard 
to compare the required therapeutic dose. Additionally, the caveat of using a 
different form of assessment – flow cytometry vs histology – should be 
considered when comparing results. As the first repeat showed AC 
                                                                                                                   146 
suppression without a difference in mIL-10 level, it is possible that mIL-10 
requires below-detection concentrations to suppress disease. To investigate 
the different effects of other species of IL-10, viral IL-10 derived from 
Epstein-Barr virus was delivered to the eye using ShH10. It was thought 
possible that the different structure, lacking pro-inflammatory regions might 
prove superior in efficacy to mouse IL-10. 
 
A week after intravitreal injection of ShH10-CMV-vIL-10-IRES-GFP, EIU was 
induced and eyes examined 18 hours later by flow cytometry. A reduced 
CD11b+Ly6G+ count was seen in the AC (Figure 44A) but not the retina, 
accompanied by detectable levels of vIL-10 (Figure 44B). An R&D-
manufactured cytokine and chemokine panel proteome profiler was used 
with pooled AC fluid supernatants from vIL-10 and GFP control groups 
(Figure 44C). Densitometry of the signals in the detectable range revealed 
reduced levels of multiple proteins in the vIL-10 group, relative to GFP. Only 
C5a was increased with treatment (Figure 44D). It is not well established 
with this technique how the significance of effect size should be estimated. 
Arising from AC fluid, it is indiscernible which contributions the infiltrating 
cells or ocular tissues each make. Certainly the near global suppression, 
rather than a particular pattern of neutrophil specific protein reduction makes 
this data less convincing.   
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Figure 44. ShH10 delivered viral IL-10 does not reliably suppress EIU.  ShH10-CMV-vIL-
10-IRES-eGFP was t i t re matched to ShH10-CMV-eGFP and 1x101 0gc del ivered v ia 2µl  
intravi t real  in ject ion. After one week EIU was induced and eyes analysed 18-hours later.  A)  In 
the f i rst  exper iment,  suppression was seen in the AC (P=0.009),  but not in the ret ina. Mann-
Whitney U test.  B)  This was accompanied by detectably e levated levels of  vIL-10 in the AC. 
C)  Pooled AC supernatants from f ive eyes were tested by R&D proteome prof i ler .  D)  
Densitometry was used to assess relat ive changes between eGFP and vIL-10 groups. Al l  
detectable cytokines or chemokines appeared reduced to var iable degrees in the vIL-10 
cohort ,  except C5a complement component which was elevated. The exper iment was 
independent ly repeated, but th is t ime no therapeut ic ef fect  was seen. Pooled results including 
concurrent PBS in jected controls conf irm no s igni f icant ef fect  upon CD11b+Ly6G+ cel l  
number in e i ther the E)  anter ior chamber or F)  ret inal  compartment.  G)  A stat ist ical ly  
s igni f icant e levat ion in CD11b+Ly6C+ cel l  number was seen in the ret inal  compartment in the 
vIL-10 treated group compared to PBS. Kruskal-Wal l is  test with Dunn’s mult ip le comparison, 
P=0.019. Means + SD shown. 
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The experiment was independently repeated but again the first result could 
not consistently be reproduced, suggesting a small, negligible or highly 
variable effect. Data from both experiments was pooled (Figure 44E-F). 
There was however a significant increase in CD11b+Ly6C+ cells in the 
retinal compartment, during vIL-10 expression (Figure 44G). This could 
reflect a more generalised response against the ShH10 vector transduction 
and not just an effect of vIL-10 itself, as discussed in results chapter 3.  
 
6.5 Recombinant protein confirms the efficacy of human but 
not murine IL-10 in EIU 
 
A wide range of viral vectors, routes and doses had failed to suppress EAU 
and EIU using IL-10. Repeating previous published work had also failed to 
validate the original results consistently. Furthermore, inconsistent data was 
seen even between sequential repeats of the same recent experiments, 
implying either the therapeutic effect was small or unknown variables exist. 
To identify issues, and reduce variables recombinant protein was used to 
treat EIU. A strong positive control was also required. One key publication 
had shown the beneficial effect of local delivery of recombinant human IL-10 
in EIU, scored by histology.177 We sought to use flow cytometry and compare 
these findings to those obtained using murine IL-10. 
 
Different doses of recombinant human and murine IL-10 or PBS control we 
injected into the vitreous cavity at the same time as EIU induction. Whole 
eyes were dissociated and analysed 18-hours later (Figure 45A-C). Human 
IL-10 demonstrated a potent dose-response, significantly suppressing EIU at 
200ng and above. Murine IL-10 showed a trend towards suppression, but 
this was not statistically significant and failed to exhibit any dose-response 
behaviour. To confirm this was not due to biological inactivity or defect in the 
recombinant mIL-10 protein, the data shown is pooled from experiments 
using product from two different manufacturers (Biolegend and Cell 
Signalling technologies). Subgroup analysis showed no difference between 
the two, reinforcing the results obtained. Furthermore, elevated levels of mIL-
10 could be detected in ocular supernatants from injected eyes at 18-hours 
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post EIU using a murine IL-10 specific ELISA (Figure 45D). Further evidence 
that mIL-10 is not suppressive is that increasing mIL-10 concentration is 
significantly correlated with increasing CD11b+Ly6G+ cell number (Figure 
45E). Biological activity of mIL-10 was also confirmed by quantitative RT-
PCR, where mIL-10 injected eyes had lower levels of KC transcripts than 
PBS injected controls (Figure 45F). As this is a prototypic neutrophil chemo-
attractant, lower levels should typically result in less infiltration. 
 
 
Figure 45. Unlike recombinant murine IL-10, human IL-10 suppresses EIU in a dose-
dependent manner.  Using f low cytometry as a readout,  1ng LPS was intravi t real ly in jected 
with PBS or d i f ferent doses of recombinant murine and human inter leukin-10. Eighteen hours 
later ret ina, v i t reous and aqueous f lu id f rom each eye were dissociated and analysed by f low 
cytometry.  A)  Representat ive dot p lots of  eyes with EIU, gated f i rst  by CD11b. Only the 400ng 
human IL-10 group has marked reduced counts of  Ly6G or Ly6C+ cel ls.  B)  Over a range of 
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doses murine IL-10 fa i ls  to s igni f icant ly suppress CD11b+Ly6G+ inf i l t rat ion, though a 
general ised trend towards lower counts than PBS exists.  C)  Human IL-10 exhibi ts a strong 
dose-response suppression of EIU, which is stat ist ical ly  s igni f icant at  200 and 400ng. Data 
shown is pooled from 3 independent exper iments,  using two di f ferent batches of cytokines 
each from two di f ferent manufacturers.  Kruskal l -Wal lace with Dunn’s mult ip le comparison 
test.  *=P<0.05, **=P<0.01. D)  To conf irm the presence of murine IL-10, e levated levels in 
ret inal  supernatants from in jected eyes were conf irmed by ELISA. Mann-Whitney U test,  
*=P<0.05. E)  Furthermore, the level  of  mIL-10 was inversely proport ional to the degree of 
suppression. Pearson correlat ion. F)  Relat ive qPCR for KC normal ised to β -act in on whole 
eye homogenates 18 hours after PBS and mIL-10 in ject ion. Mann-Whitney U test,  
***=P<0.001, n=3. Means + SD shown.  
 
These discoveries may begin to reconcile some of the previously observed 
findings. It is known that human and murine IL-10 differ by 27% amino acid 
sequence with the latter also N-glycosylated, however they have been 
broadly regarded as similar in action and used relatively interchangeably in 
much of the literature.119 The limited effect, if any of murine IL-10 in EIU may 
have been responsible for the uncertain and highly variable findings between 
different experiments. As human IL-10 was clearly effective, it was decided to 
use this endpoint as a positive control and essentially reverse-engineer 
successful suppression using AAV. The human IL-10 sequence was cloned 
behind the CMV promoter and produced as an ShH10 vector.  
 
All three forms of interleukin-10 – human, murine and viral – encoded in 
ShH10 were delivered by intravitreal injection. A week later EIU was induced 
and eyes analysed at 18-hours. No statistically significant suppression 
relative to PBS or ShH10-CMV-eGFP was seen in either the AC or retinal 
compartments (Figure 46A-B). At one week ShH10 mediated expression is 
predominantly from the ciliary epithelium and corneal endothelium. Whilst a 
change would have been likely to be seen in the anterior chamber, it is 
possible the dose of human IL-10 may have been too low. From the analysis 
of recombinant protein consistent suppression was only seen after an initial 
dose of 200ng. Whilst this would have decreased by the 18-hour timepoint, it 
was uncertain if ShH10 mediated delivery of human IL-10 would ever 
achieve the same dose range.   
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Figure 46. ShH10-mediated transfer of mouse, human or viral  IL-10  does not suppress 
EIU at 18-hours following injection one-week prior.  2µl  intravi t real  in ject ion of PBS, 
1x109gc ShH10-CMV-eGFP or t i t re-matched ShH10-CMV-murine IL-10, human IL-10 or v ira l  
IL-10 was performed. One week later EIU was induced and at 18-hours eyes dissected into 
AC and ret ina/v i t reous. Flow cytometry analysis shows no stat ist ical ly  s igni f icant change from 
PBS or GFP control  in A)  the anter ior chamber or B)  poster ior compartment.  Means + SD 
shown. 
 
To gauge the decay and relative changes in concentration following bolus 
human IL-10 injection in EIU, a kinetic experiment was performed. All 
samples were standardised and analysed simultaneously to minimise error 
and variation, with samples split evenly across the same ELISA plates and 
run on one 96-well plate for flow cytometry. Suppression of CD11b+Ly6G+ 
cell number by human IL-10 beyond 6 hours was seen (Figure 47A). At 18-
hours, AC and retinal compartment supernatants were tested by ELISA for 
EIU eyes injected with either 200ng recombinant hIL-10 protein or one week 
post intravitreal ShH10-CMV-hIL-10 administration (Figure 47B). 
Surprisingly at this point, levels were similar or fractionally higher in the viral 
derived group. Looking at the ELISA levels over the course of time, initial 
recovery at 2hours in the AC was around 15ng/ml, so significantly higher, but 
by 18-hours levels have rapidly decayed to below those obtained from steady 
ShH10 mediated production (Figure 47C). The trend to higher levels in the 
AC following both viral delivery and intravitreal recombinant protein delivery 
may reflect the natural path of fluid egress in the eye. Aqueous humour 
produced by the ciliary body is likely to wash hIL-10, with some vitreous 
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contribution, through the pupil, into the AC and out of the eye via either the 
trabecular meshwork or uveoscleral outflow pathways. 
 
 
 
F igure 47. A comparative t imecourse of recombinant protein demonstrates comparable 
levels at 18-hours post injection to ShH10-derived human IL-10 in the eye.  Eyes receiv ing 
intravi t real  in ject ion of  1x101 0gc ShH10-CMV-human IL-10 were induced with EIU after one 
week. During the same session other eyes induced with EIU and co- in jected with ei ther PBS 
or 200ng recombinant human IL-10. Eyes from this cohort  were analysed at 2,  6 and 18-
hours. ShH10-in jected eyes were terminated at 18-hours post–EIU. Eyes were separated into 
AC or ret ina/v i t reous compartments.  Simultaneously analysis was performed for a l l  samples, 
spl i t  evenly across ELISA plates and stained and analysed by f low cytometry in the same 96-
wel l  p late.  A)  Pool ing data from two other independent exper iments,  a t imecourse of typical  
EIU and that t reated with intravi t real  recombinant human IL-10 is shown. At a l l  t imepoints 
human IL-10 treated eyes show lower cel l  counts.  n=4-6 eyes per point .  B)  Human IL-10 
ELISAs at 18-hours for AC and ret ina/v i t reous compartment supernatants.  Recombinant 
protein has decayed to approximately the same level  produced by ShH10 del ivery.  C)  
Compartment separated ELISA data over t ime, with mean levels from ShH10 product ion at 18 
hours marked. Means + SD shown. ELISAs performed at three di lut ions, with technical  
t r ip l icates.  
 
High levels of human IL-10 are achieved following recombinant protein 
injection, with little reduction from 2 to 6hrs, but rapid decay such that at 18 
hours levels of hIL-10 are significantly lower than that achieved by ShH10 
delivery. Clearly viral expression can achieve similar concentrations at this 
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late stage, but as no suppression of EIU is seen, either the early 2 to 15hr 
period is the crucial window where high levels of IL-10 are required, or the 
presence of virally transduced cells attenuates the suppressive effect.  
 
6.6 The suppressive effects of IL-10 upon EIU may be 
affected by the timing after induction 
 
The kinetic data and progressive characterisation of the EIU model in our 
hands highlighted the effect of changing cell populations and cell viability 
over time (see results chapter 2) Total numbers of CD11b+Ly6G+ cells 
were similar between the 6 and 18 hours post EIU induction, with a trend to 
greater numbers in the 6hr group. CD11b+Ly6C+ cells however, increased 
dramatically in number by 18 hours. It is possible that different mechanisms 
and biological interactions are occurring at this late point. Certainly it has 
been proposed that Ly6C+ monocytes may be recruited as a form of 
resolution to clear dead neutrophils recruited at peak EIU.32 In this context, 
human IL-10 may not be effective. We decided to repeat the initial 
experiment using ShH10-CMV-human IL-10, but assessed at 6hrs post EIU 
induction.  
 
Whole eye suppression of CD11b+Ly6G+ and Ly6C+ cells was observed 
when tested at 6hrs (Figure 48E-F). Elevated levels of human IL-10 were 
confirmed from ocular supernatants (Figure 48G). To ascertain if the effect 
was real, supernatants were run on an R&D proteome profiler as before and 
relative differences to the eGFP group were calculated by densitometry 
(Figure 48H). Most pro-inflammatory agents were suppressed, but the 
greatest magnitude of reduction was seen particularly for proteins involved in 
neutrophil chemotaxis such as IP-10, KC, CCL2, and MIP2.  
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Figure 48. ShH10-derived human IL-10 suppresses EIU at the 6-hour t imepoint,  with 
corresponding reduction in key neutrophil  chemokines.  Intravi t real  in ject ion of  1x101 0gc 
t i t re-matched ShH10-CMV-hIL-10 or ShH10-CMV-eGFP was performed. One week later EIU 
was induced and eyes examined 6-hours later.  A)  Representat ive histo logy from ShH10-CMV-
eGFP in jected eyes at 1 week, demonstrat ing transduced B)  c i l iary epi thel ium, C)  corneal 
endothel ium (arrow) and D)  occasional gangl ion cel ls and astrocytes. Flow cytometry conf i rms 
reduced whole eye counts of both E)  CD11b+Ly6G+ and F)  CD11b+Ly6C+ cel ls in the human 
IL-10 treatment group. G)  ELISA conf irms signi f icant ly e levated levels of  human IL-10 
compared to the GFP control .  Mann-Whitney U test,  *=P<0.05, **=P<0.01. Means + SD 
shown. H)  R&D proteome prof i ler  of  pooled whole eye supernatants from f ive animals,  show 
decreased levels of  several  detectable chemokines predominant ly involved in neutrophi l  
recrui tment with ShH10-human IL-10 treatment.  A 50% reduct ion was arbi t rar i ly  chosen as 
s igni f icant.  NC = No change.  
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The experiment was independently repeated with additional controls. PBS 
was used as there may be a worsening with GFP control virus, that might 
make the intervention look effective. Mouse IL-10 was used to discern if 
human IL-10 was truly more effective. Unexpectedly, no reduction in the 
number of CD11b+Ly6C+ or Ly6G+ cells was observed relative to PBS or 
GFP control (Figure 49A). A similar, if not higher level of human IL-10 was 
detected by ELISA (Figure 49B), but no correlative effect upon cell count 
seen (Figure 49C).  
 
 
Figure 49. Repeat experiment of ShH10-human IL-10 with additional controls fai ls to 
reproduce the suppression of EIU at the 6hr t imepoint.  2µl  of  PBS or 5x101 2gc/ml ShH10 
CMV-eGFP, human or mouse IL-10 was del ivered into the v i t reous cavi ty.  A week later EIU 
was induced and terminated 6hr post- induct ion. A)  F low cytometr ic  counts of  the whole eye 
are not stat ist ical ly  d i f ferent between PBS or v ira l  intervent ion groups. Kruskal-Wal lace test 
P=0.59. Despite B)  detectably e levated levels of  human IL-10, there is a lso no correlat ion C)  
between inf i l t rate and IL-10 levels.  Pearson correlat ion. D)  Pooled data from both 
experiments demonstrates that the ShH10-GFP cohort  has worse EIU than PBS, such that in 
isolat ion ShH10-mIL-10 and hIL-10 would look to be suppressive. Relat ive to PBS there is no 
suppression. Only 200ng recombinant human IL-10 suppresses beyond PBS control .  E)  ELISA 
on ret inal  supernatants conf i rms the presence of human IL-10 in treated samples. Mann-
Whitney U test,  *=P<0.05, **=P<0.01. Means + SD shown.  
 
Combining both data sets, with representative data from recombinant mouse 
and human IL-10, the initial suppressive effect looks due to the exacerbation 
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that ShH10-CMV-eGFP appears to have caused (Figure 49D-E). Relative to 
PBS only recombinant human IL-10 injected eyes reduce disease, whereas 
both ShH10-derived murine and human IL-10 show reduced disease 
compared to GFP only.   
 
6.7 Levels of ShH10-derived human IL-10, comparable to 
those of suppressive recombinant protein fail to attenuate 
EIU 
 
The absence of effect similar to recombinant protein could still be due to 
dose if it is the early timepoint where high levels of IL-10 are required. To 
examine this, two approaches using ShH10-CMV-human IL-10 were taken 
and compared to a control of PBS. Intravitreal ShH10 was used but left for 
three weeks to improve the number of Muller cells transduced and improve 
levels of IL-10. Double subretinal injection was confirmed as leading to RPE 
and photoreceptor transduction (see results chapter 3). Together these 
account for the largest proportion of ocular cells possible to be transduced 
with viral gene transfer. The resulting levels of human IL-10 should therefore 
be the highest possible. If despite this no effect is seen, it may be that 
constitutive tonic signalling from constitutive virally-mediated IL-10 production 
may result in different effects to that of a single bolus dose and require 
complex regulation of expression to succeed. It would then be clear that IL-
10 should not be prioritised further in the context of current AAV-based 
therapy.  
 
No adverse effects at high doses of recombinant protein were seen (Figure 
45C). As proof of principle, the highest possible dose of ShH10-CMV-human 
IL-10 was double injected into the subretinal space and allowed three weeks 
to reach maximum expression levels. EIU was induced and assessed at the 
6hr timepoint (Figure 50A). Compared to PBS, there was no suppression of 
EIU for both cell types (Figure 50B-C). Levels of human IL-10 achieved by 
ELISA on ocular supernatants were the highest detected so far, with a mean 
of 200ng/ml (Figure 50D). No correlation between levels and cell count could 
be seen however (Figure 50E). This is higher than the recombinant protein 
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dose known to suppress disease at 6hr, which has a mean of 40ng/ml 
(Figure 50F) with both samples tested in the same volume.  
 
 
Figure 50. Levels of human IL-10 comparable to suppressive recombinant protein doses 
can be obtained using subretinal ShH10, but no therapeutic effect is seen upon EIU. 
Furthermore, a local infi l tration of CD8+ cytotoxic T-cells is detected.  3 weeks fo l lowing 
paired eye double subret inal  in ject ions of PBS or 1x101 0gc ShH10-CMV-human IL-10, EIU was 
induced and analysed at 6hrs.  A)  Representat ive f low plots of  sequent ia l  gat ing strategy, on 
l ive cel ls then CD11b+ gated, spl i t  into Ly6G+ and Ly6C+ populat ions. B)  No signi f icant 
suppression is seen upon CD11b+Ly6G+ or C)  CD11b+Ly6C+ whole eye cel l  counts.  D)  hIL-
10 ELISA upon supernatants conf i rms highly e levated levels in the v ira l  del ivery group. 
Wilcoxon signed rank test,  P=0.007. E)  No correlat ion is seen between levels of  hIL-10 and 
CD11b+Ly6G+ cel l  counts.  200ng recombinant hIL-10 protein at  6 hours is known to 
s igni f icant ly suppress EIU vs. PBS. F)  Data from a previous experiment are plot ted next to 
the current ELISA results.  Whi lst  some var iat ion exists between ELISA plates, i t  is  c lear that 
v ira l  der ived levels are at  least as high, i f  not greater.  Mann-Whitney U test,  P=0.012. G)  Of 
note, a s igni f icant e levat ion in CD45+CD8+ T-cel ls was seen in the ShH10-hIL-10 group. This 
is  l ikely to represent an ant i -v ira l  or IL-10 speci f ic  response. No correlat ion existed between 
CD45+CD8+ counts and hIL-10 levels.  Wilcoxon signed rank test,  P=0.008. Means + SD 
shown. 
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A significant infiltration of CD45+CD8+ T-cells was seen in ShH10 injected 
eyes (Figure 50G). This could be a confounding factor as it may represent a 
cytotoxic T-cell response to either ShH10 transduced cells or as a function of 
the effects of hIL-10 signalling. 
 
The experiment was repeated with intravitreal injection of ShH10 but left 
unmanipulated for three weeks, to improve expression from Muller cells and 
increase overall levels without introducing additional inflammation from 
retinal detachment. Again, no suppression of EIU was seen (Figure 51A-B), 
despite levels of hIL-10 around 40ng/ml in ocular supernatants - compared to 
the mean of 5ng/ml if left one week (Figure 51C). This is the likely maximum 
achievable level using ShH10 and the intravitreal route, however is 
approximately the same level achieved as that of recombinant protein at 6hr 
(Figure 51D). The implication is that either the tonic nature of continuous 
production from ShH10 or the very presence of the virus is sufficient to 
abrogate the suppressive function of human IL-10. In this experiment, no 
significant CD8+ T-cell infiltration was seen as a confounding factor (Figure 
51D). 
 
 
Figure 51. Extending the t ime to three weeks following intravitreal injection of ShH10-
human IL-10 achieves higher transgene levels, but sti l l  does not suppress EIU.  2µl  PBS 
or 1x101 0gc ShH10-CMV-human IL-10 was in jected into the v i t reous cavi ty.  Three weeks later 
EIU was induced and whole eyes analysed by f low cytometry and ELISA at 6hr.  A)  No 
suppression was seen in l ive CD11b+Ly6G+ or B)  CD11b+Ly6C+ cel l  counts.  C)  ELISA for 
human IL-10 on ocular supernatants demonstrates a s igni f icant e levat ion in levels,  with a 
mean of 40ng/ml,  compared to 5ng/ml when lef t  one week. Mann-Whitney U test,  P=0.005. D)  
No elevat ion in CD45+CD8+ T-cel l  counts was seen, imply ing no s igni f icant local  cytotoxic T-
cel l  response was evident.  Means + SD shown. 
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In this final experiment, levels of hIL-10 in the eye were matched to a known 
concentration that suppresses EIU. That no attenuation of disease was seen 
implies the final dose at 6 hours is not a crucial factor. It is possible that the 
kinetics of IL-10 signalling is important, or the responses to virus itself may 
affect the unknown mechanism for suppression of recruitment of 
CD11b+Ly6G+ cells. 
 
6.8 IL-10 is not an optimal target for the suppression of 
intraocular inflammation by gene transfer 
 
Due to the of lack of consistent results using IL-10 and the potential 
differences between mouse and human IL-10, the original experiment that 
proposed local EAU immunomodulation by AAV transfer of mIL-10 was 
repeated.110 It was possible that as AAV2-mediated gene transfer achieves 
lower levels of expression, an idiosyncratic property of low-dose mIL-10 
might be identified. Alternatively, relatively lower levels of expression using 
AAV2 might avoid cellular responses that may have confounded successful 
attenuation of EAU.  
 
 
Figure 52. Repeat of AAV2 mediated delivery of mIL-10  with the addition of f low 
cytometric analysis fai ls to reproduce the reported suppression.  In an exact repeat of  
publ ished work, double 2µl  subret inal  in ject ion of 1x101 0gc/ml t i t re-matched AAV2-CMV-eGFP 
and AAV2-CMV-mIL-10-IRES-eGFP was performed in C57BL/6J  mice. After three weeks EAU 
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was induced and mice cul led at  day 23. A)  H&E histo logy EAU scores, as used in pr ior 
assessment,  show no stat ist ical ly  s igni f icant d i f ferences between groups. Scor ing was 
performed masked to treatment group. n=6 mice. Mean + SD shown. B)  F low cytometry 
assessment of  d issociated ret inae from six eyes of each group conf i rms the lack of ef fects 
upon lymphocyte or myeloid cel l  inf i l t rat ion. Means shown. n=6 mice. C)  Ret inal  supernatants 
were pooled from six eyes of each group and run on a mult ip lex bead array for several  mouse 
cytokines. Whi lst  only s ingle readings, e levated mIL-10 was detected (red) conf i rming 
successful  t ransgene expression. Other pro- inf lammatory cytokines are higher in the IL-10 
group. ND = Not detected. 
 
Repeating the experiment comparing AAV2-GFP and AAV2-IL-10, no 
difference in histological EAU scores, or flow cytometric analysis of infiltrating 
cells could be identified (Figure 52A-B). To confirm successful expression, 
retinal supernatants from eyes used for flow cytometry were pooled and 
analysed by multiplex bead array (Figure 52C). Elevated levels of mIL-10 
were detected at peak disease relative to AAV2-GFP in the intervention 
group. Additional pro-inflammatory cytokine measurement identified higher 
levels in the IL-10 group, which only supports the lack of suppression. 
 
 
Figure 53. Administration of intravitreal recombinant human IL-10 at peak EAU fails to 
suppress EAU.  PBS or 200ng in 2µl was in jected into the v i t reous cavi ty at  days 17 and 21-
post induct ion of EAU. A)  TEFI of  paired eyes at peak disease on day 26 fa i ls  to demonstrate 
s igni f icant reduct ion in d isease. B)  Masked CD45-stained histo logy EAU scores conf irm th is 
f inding. Paired T-test,  P=0.19. n=8. Mean + SD shown. 
 
As a result of this experiment, the assertion that local treatment with IL-10 in 
the effector phase of EAU is effective was examined. The new findings of 
efficacy in EIU led to the use of human rather than mouse IL-10. To gauge its 
effect upon EAU in the absence of confounding factors from AAV itself, 
200ng recombinant human IL-10 in a 2µl intravitreal injection was 
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administered to mice at day 17 and 21 post-induction. At peak disease on 
day 26 TEFI was performed (Figure 53A). No reduction in EAU disease 
appearance or histological disease score was evident (Figure 53B). This 
result combined with the preceding experiments implies that IL-10 does not 
readily suppress EAU, even before the issue of viral-mediated transfer 
arises. 
 
6.9 Chapter summary 
 
In conclusion, the lack of robust effects upon EAU and EIU suggest that IL-
10 is unlikely to offer an option to pursue for therapeutic purposes. Whilst 
several publications have reported suppression using murine IL-10, we were 
unable to reproduce the results using lentivirus, AAV2 or modern AAV 
serotypes including AAV9, AAV8 and ShH10. Recombinant human IL-10 was 
shown to be effective in attenuating EIU but required a bolus dose of 200ng. 
The same effective ocular concentrations could be matched and even 
exceeded using ShH10, but through this route of delivery no suppression of 
EIU was attained. The disparity may be a function of the dynamics of IL-10 
signalling or more likely due to the nature of viral gene delivery.  
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7 Results 5: Targeting TNF to suppress ocular 
inflammation by AAV-mediated gene transfer 
of soluble receptors 
 
TNF is central to the disease process in EAU, through the recruitment and 
licencing of inflammatory macrophages within the retina to produce nitric 
oxide and mediate tissue damage.127,187 Furthermore, its role in human 
disease is underscored by the potent effect of TNF inhibitors used widely in 
clinical practice for uveitis.10,11  
 
There are two receptors for TNF and soluble forms occur naturally. Soluble 
TNF-receptor 1 (known also as p55) preferentially binds soluble TNF whilst 
soluble TNF-receptor 2 (known as p75) preferentially binds transmembrane 
TNF.188 Systemic administration of recombinant human p55 fusion protein 
has been used to successfully attenuate murine EAU.133 Other groups have 
also reported successful attenuation of EAU in the Lewis rat following the 
expression of soluble TNF receptors from non-viral gene transfer to the 
ciliary muscle.60  
 
Monomeric murine soluble TNF receptor 1 and 2 (p55 and p75 respectively) 
sequences were already available within the group and had been sub-cloned 
into the pD10 CMV-promoter plasmid followed by an IRES-eGFP fragment.  
Whilst TNF is biologically active as a trimer, it was envisaged that monomeric 
soluble receptor binding could still block its ligand interaction with viable 
membrane bound receptors. As it had been reported that monomeric soluble 
TNF receptors were able to block the cytotoxic activity of TNF in vitro,189 it 
was felt that this would be a reasonable target to over-express in the eye and 
test the principle of gene transfer in uveitis using recently developed 
pseudotyped AAV vectors.  
 
In EAU the major source of tissue damage arises from the reactive oxygen 
species produced by macrophages. Different signals are required which 
converge upon the induction of nitric oxide synthetase (iNOS). Typically in 
EAU it is IFNγ that triggers macrophages to produce TNF, which then acts in 
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an autocrine manner leading to iNOS production. Other signals including 
TLR4 activation by lipopolysaccharide also lead to activation. To confirm the 
presence of nitric oxide production from macrophages in the EAU model in 
our facility, slides were stained with an anti-nitrotyrosine antibody (Figure 
54). The antibody detects 3-nitrotyrosine residues that arise from the action 
of peroxinitrite – a reactive oxygen species generated by nitric oxide and 
superoxide anions from macrophages.190 Nitrotyrosine was detected 
throughout the diseased retina and only in areas where CD11b+ cells were 
co-located.  
 
 
Figure 54. TNF-licenced nitr ic oxide synthetase induction in myeloid cells during EAU 
leads to detectable nitrotyrosine residues and structural damage.  Cryosect ions from eyes 
at peak C57BL/6 EAU were stained for Nitrotyrosine (green),  CD11b (red) and DAPI (b lue).  A)  
Widespread ret inal  destruct ion is accompanied by ni t rotyrosine stain ing. Regions of choroidal  
s ignal are also present.  B)  Stain ing is l imited to regions of CD11b+ cel l  inf i l t rat ion, where 
peroxin i t r i te is  produced and damaged adjacent ret inal  cel ls .  C)  CD11b+ vi t reous cel ls a lso 
produce ni t rotyrosine stain ing on surrounding debris.  Scale bars = 25µm. 
 
7.1 Gene transfer of monomeric soluble TNF receptors by 
AAV8 fails to attenuate EAU 
 
Following refinement of AAV8 production, 1x1010 genome copies (gc) of 
CMV promoter-soluble p55-IRES-eGFP expressing vector was injected 
prophylactically into the subretinal space to test its effect upon EAU. At peak 
disease, TEFI shows multiple discrete lesions and visible GFP signal in the 
control group (Figure 55A). These lesions appeared to correlate with retinal 
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folds containing CD11b+ cells and have been seen before in EAU without 
gene transfer, though not frequently. Histological scoring of an independently 
repeated experiment, failed to demonstrate a difference in EAU disease 
score (Figure 55B).   
 
  
Figure 55. AAV8 expression of soluble p55 monomeric receptor does not affect 
infi l tration or CD4 polarisation in EAU compared to GFP control.  A cohort  of  eyes 
received 2µl subret inal  in ject ions of 1x101 0gc AAV8-CMV-GFP or AAV8-CMV-p55 a week pr ior 
to EAU induct ion. A)  Representat ive TEFI images at day 26 show GFP in the v is ib le spectrum 
and mult ip le ret inal  lesions, shown to be CD11b+ cel l -contain ing outer nuclear layer fo lds by 
histo logy ( inset) .  B) An independent cohort  scored by histo logy fa i ls  to demonstrate 
suppression. C)  Absolute cel l  counts as analysed by f low cytometry in another cohort ,  does 
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not d i f fer between groups. D)  Intracel lu lar cytokine sta in ing of CD4+ cel ls.  The trends did not 
reach stat ist ical  s igni f icance. Mann-Whitney U test.  Mean and SD shown. 
 
When absolute cell counts for each combined retina, vitreous and anterior 
chamber were assessed by flow cytometry, there was no significant 
difference in lymphocyte or inflammatory monocyte number between the 
groups (Figure 55C). Intracellular cytokine staining showed only a slight 
trend towards increased IL-17A+ helper T-cell polarization (Figure 55D), but 
the absolute number of cells was low, so this finding should be interpreted 
cautiously. Any true increase in TH17 polarisation could be explained if there 
is paradoxical stabilization or enhancement of TNF signaling as a result of 
p55 overexpression.130 Increased TNF activity might be expected to enhance 
TH17 cell numbers, as evidence from anti-TNF therapy in human 
autoimmune disease demonstrates a reduction in TH17 cell counts.191,192  
 
The possibility of differential effects between the subtypes of soluble TNF 
receptor was raised and so the AAV8-CMV-p75-IRES-eGFP was tested. It 
would be expected to have a greater affinity for binding transmembrane TNF, 
but might also trigger reverse-signaling through TNF. The effect this might 
have locally in the eye has not been studied. Publications looking at effects 
on human monocytes are unclear and demonstrate either stimulatory or 
inhibitory effects dependent on context.193,194 In T-cell interactions with 
monocytes, tmTNF appears to mediate activation. In endothelial cell co-
cultures with monocytes, reverse-signaling appears to prevent monocyte 
activation and secondary cell death.  
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F igure 56. Expression of p75 fai ls to suppress EAU and increases the number of 
CD11b+Ly6C+ cells in the eye.  One week fo l lowing subret inal  in ject ion of 1x109gc t i t re-
matched AAV8 CMV-p75-IRES-eGFP or CMV-hrGFP, EAU was induced. At peak disease (day 
26) the eyes were analysed by f low cytometry.  A trend towards greater numbers of cel ls  was 
evident in the p75 group, which reached stat ist ical  s igni f icance for CD11b+Ly6C+ cel ls.  
Mann-Whitney U test,  P = 0.03.  
 
Following subretinal injection of titre-matched p75-expressing vector and 
GFP control, EAU was induced and eyes again analysed by flow cytometry. 
A generalized trend towards greater numbers of infiltrate was present and 
this was statistically significant for CD11b+Ly6C+ monocytes (Figure 56). 
Due to the potential worsening of disease, the experiment was not repeated. 
One hypothesis was that reverse signaling on the RPE could have led to 
increased chemokine or indeed TNF production. sTNFR could bind to tmTNF 
expressed by RPE cells and deliver a pro-inflammatory reverse-signal, 
worsening the outcome of EAU. Obtaining an accurate measure of active 
TNF in the context of soluble p55 and p75 may have been helpful, but is 
technically challenging.195 As neither monomeric soluble TNF receptor 
suppressed EAU, before concluding that these were ineffective targets, other 
confounding factors were considered. 
 
7.2 Neither immunological differences between eGFP and 
hrGFP, nor the presence of the IRES construct explains 
the failure to suppress EAU 
 
As suppression had not been achieved using p55 or p75, or using IL-10 (see 
results chapter 4) alternative factors were sought prior to further EAU 
experiments. At this stage a report emerged in the field highlighting specific 
issues with eGFP expressing AAV in the macaque eye, where progressive 
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inflammation occurred.196 Supported by studies from other fields, eGFP has 
been shown to possess a highly antigenic eight amino acid H2-Kd restricted 
region at the C-terminus.197,198 It was thought to be potentially responsible for 
many of the observed findings.  
 
In the constructs tested thus far, all therapeutic transgenes were tagged with 
an IRES-eGFP, whilst due to availability, the control vector always used 
hrGFP. To exclude the confounding factor of an adaptive immune response 
specific to eGFP abrogating any suppressive effect of the therapeutic vector 
a separate experiment was commenced. Two weeks following subretinal 
injection with 1x1010gc AAV8-CMV-eGFP or AAV8-CMV-hrGFP, EAU was 
induced and scored at peak disease by CD45 immunolabelled histology 
(Figure 57A). No difference was detected and so this was not felt to be a 
significant factor. 
 
 
 
F igure 57. eGFP compared with hrGFP expression does not signif icantly alter the 
severity of EAU and the presence of an IRES-GFP segment does not markedly reduce the 
level of the preceding transgene.  Mice were in jected with 1x109gc t i t re-matched AAV8-CMV-
eGFP or AAV8-CMV-hrGFP. A)  Two weeks later EAU was induced and eyes scored by 
histo logy in a masked fashion. No stat ist ical ly  s igni f icant d i f ference was seen between the 
two groups. n=6 eyes, Wilcoxon matched pairs test P=0.15. pD10 plasmid encoding ei ther B)  
CMV-sTNFR1 (p55) or C)  CMV-mouse IL-4 with and without an IRES-eGFP segment were 
transfected into HEK-293T cel ls at  three di f ferent concentrat ions. 48 hours later supernatants 
were tested by ELISA for the transgene products at  three di lut ions and in tr ip l icate. Total  
protein was corrected for by BCA protein assay. Whi lst  a trend towards lower levels with an 
IRES-eGFP present,  the effect is  not large or stat ist ical ly  s igni f icant by Two-way ANOVA. 
Data are from two independent experiments.  n=5 minimum per group.  
 
Another potential factor was the presence of the IRES-eGFP tag. It was 
repeatedly observed that the amount of eGFP produced was inversely 
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proportional to the size of the preceding gene (Dr S. Barker, personal 
communication). As the IRES results in a longer, single mRNA transcript it 
was unclear if this reduced the overall expression of the preceding 
transgene. This could lead to reduced levels of therapeutic protein which 
might result in lack of efficacy.  
 
To test this hypothesis, the IRES-eGFP tag was cloned out from several 
plasmid constructs for comparison. Each pair was then matched by 
spectrophotometry and transfected into HEK-293T cells at a range of 
concentrations. 48 hours later supernatants were tested by ELISA with total 
protein correction. Secreted protein was chosen as the final endpoint to 
account for any confounding post-transcriptional or post-translational factors. 
No marked difference was identified using either matched p55 (Figure 57B) 
or IL-4 constructs (Figure 57C). Despite these findings, where eminently 
possible the IRES-eGFP tag was removed to avoid any uncertainty. 
 
7.3 Avoiding retinal detachment by using ShH10 vector still 
does not permit the suppression of EAU by monomeric 
p55 
 
It is known that detachment of the retina by subretinal injection is highly 
inflammatory, with elevated TNF, IL-1β and CCL2 detectable in the eye by 
48hrs.179 The subretinal route is favoured for AAV delivery due to the cell 
transduction characteristics and well-established lack of systemic immune 
response. However, in terms of local immunomodulation, the widespread 
microglial activation, gliosis and structural trauma caused by subretinal 
injection may alter the balance too far to overcome, let alone permit 
immunosuppression. Other cotemporaneous experiments using subretinal 
delivery had also failed to yield suppression, and so an alternative route was 
sought.  
 
One solution pursued was to employ a newly available AAV serotype - 
ShH10. This was engineered to specifically transduce Muller glia following 
intravitreal injection.57 In our hands it was found to transduce ciliary 
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epithelium and corneal endothelium, with occasional Muller cell transduction 
around vessels (see results chapter 3). CMV-p55 monomer without IRES-
eGFP was produced with the ShH10 capsid and titre-matched to an ShH10-
CMV-eGFP control vector. 
 
2µl intravitreal injections of ShH10 vectors were performed one week before 
induction of EAU. At peak disease on day 26, eyes were imaged by TEFI 
(Figure 58A) before the aqueous, vitreous and retina were dissected, 
dissociated and analysed by flow cytometry (Figure 58B). The pooled 
supernatants following dissociation of each eye in 200µl PBS were tested by 
p55 receptor ELISA (Figure 58C). 
 
 
Figure 58.  Prophylactic ShH10 mediated expression of monomeric p55 receptor does not 
affect infi l tration in EAU compared to GFP control,  despite detectably elevated levels in 
the t issue. Eyes received 2µl intravi t real  in ject ions of 2x101 0gc ShH10-CMV-p55 or ShH10-
CMV-eGFP virus a week before EAU induct ion. A)  TEFI images at day 26 show minimal 
d i f ferences between the two groups, ref lected in B)  Absolute cel l  counts by f low cytometry 
from dissociated ret ina and AC f lu id.  This is  despite C)  an approximate 3-fo ld increase in p55 
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levels compared to GFP control  v irus detected in ret inal  supernatants by ELISA. Mann-
Whitney U test.  *=P=0.016. Mean +SD shown. 
 
TEFI revealed equivalent appearances and there was no difference in 
lymphocyte or monocyte cell counts between control and the p55 monomer. 
ELISA confirmed the production of p55, although levels were elevated by 
approximately three-fold only compared to GFP. The maximum titre possible 
had been administered (1x1010gc), but only left for 1 week prior to induction 
of EAU. It would have been possible to increase the levels allowing full Muller 
cell transduction at 3 weeks. It was decided to first test the approach using a 
different inflammatory model. 
 
7.4 Endotoxin-induced uveitis is not suppressed by ShH10-
mediated soluble p55 and TNF inhibition can cause 
worsened infiltration 
 
Endotoxin-induced uveitis was selected as a rapid and alternative model to 
test the approach of AAV mediated TNF inhibition. It is essentially only a 
TLR4 mediated acute inflammatory insult and so might be more amenable to 
suppression than the multiple pathway orchestrated disease of EAU. It also 
is used as a model of anterior uveitis, with minimal retinal involvement and so 
if the anterior ocular compartment is more amenable to successful gene 
therapy this might be apparent. 
 
Whilst controversy exists, with some groups reporting TNF inhibition worsens 
EIU severity,199 others claim that it results in suppression of disease.32,176 
Effects are context-dependent and although systemic inhibition is likely 
beneficial, the effect of local therapy remains unclear. It has been shown that 
non-viral gene transfer of p55-Ig fusion protein can suppress EIU in rats.107 
and so this approach was felt to be reasonable. 
 
ShH10 was chosen as ciliary body and corneal endothelial transduction are 
attained after one week. These tissues are closer to the anterior chamber 
and so it was envisaged that a greater concentration of therapeutic protein 
would be obtained in that region. ShH10-CMV-p55 monomer without IRES 
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tag was produced and 1x1010gc injected into the vitreous cavity. A matched 
ShH10-CMV-eGFP control was used. Seven days later intravitreal injection 
of 1ng LPS was performed. The eyes were dissected and analysed by flow 
cytometry at the 18-hour timepoint. No difference in either neutrophil (Figure 
59A) or monocyte (Figure 59B) infiltration could be identified between 
groups. A two-fold increase in concentration of p55 protein in the ocular 
supernatants compared to GFP control was obtained (Figure 59C) and 
successful transduction of the ciliary epithelium was confirmed in the GFP 
cohort by histology (Figure 59D).  
 
 
 
F igure 59.  ShH10 expression of monomeric p55 receptor does not affect EIU at double 
the control level.  Eyes received 2µl intravi t real  in ject ions of 2x101 0gc ShH10-CMV-p55 or 
ShH10-CMV-eGFP virus one week before EIU induct ion and analysis at  16hr.  A) There was no 
stat ist ical ly  s igni f icant d i f ference in the number of  CD11b+Ly6G+ or B)  CD11b+Ly6C+ cel ls 
compared to the GFP control .  This is  despite C)  AC levels of  p55 were approximately double 
the GFP control  by ELISA. Mann-Whitney U test,  P=0.0024. D) Successful  t ransduct ion of the 
c i l iary epi thel ium (white arrow) was conf irmed by confocal microscopy on sect ioned ShH10-
CMV-eGFP in jected eyes. Mean + SD shown.  
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It was concluded that either the p55 levels attained were not sufficient, or EIU 
was not amenable to therapy by the modulation of TNF with soluble p55 in 
this context. Recombinant soluble p55 was not easily available, and so to 
determine if any degree of inhibition was possible, a limited amount of 
recombinant human p55-Ig fusion protein was obtained (A kind gift of D 
Copland, University of Bristol). This is quite different from the monomer, 
consisting of two human p55 receptors linked by an Fc region, but might still 
provide evidence to support the use of TNF inhibition in EIU. p55-Ig was 
injected concurrently with the induction of EIU in a limited set of mice and 
terminated at 18-hours. Upon dissection, it was discovered that all eyes (4/4) 
had diffuse, large haemorrhages throughout the retina (Figure 60A) an 
observation not seen in any EIU eyes before. 
 
 
Figure 60. Administration of recombinant human p55-Ig at the induction of EIU leads to 
retinal haemorrhage and worsened infi l tration.  Mice were in jected in the v i t reous cavi ty 
with 1ng LPS mixed with ei ther PBS or 4µg recombinant human p55-Ig fusion protein.  Eyes 
were analysed by f low cytometry 18hr later.  A)  In the p55-Ig group, a l l  4 eyes had di f fuse 
ret inal  haemorrhages, as shown dissected and viewed f rom the subret inal  space. B)  A 
s igni f icant increase in the number of  inf i l t rat ing CD11b+Ly6G+ cel ls was seen, without change 
in C)  the CD11b+Ly6C+ compartment.  Mann-Whitney U test,  P=0.002. Means + SD shown. 
 
Flow cytometry confirmed worsened EIU with a significantly elevated number 
of neutrophils compared to contemporaneously injected PBS controls 
(Figure 60B). There was no difference in the number of CD11b+Ly6C+ cells 
(Figure 60C). Explaining these findings is challenging. The dose of 
recombinant protein delivered was high to ensure a response, but may have 
been non-specifically toxic. Alternatively, potent TNF inhibition may indeed 
be detrimental and lead to increased disease. The findings point toward the 
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presence of biological activity from the p55-Ig fusion, albeit detrimental in this 
experiment. It was decided to reassess the monomeric forms in vitro before 
continuing further and check their activity with a functional readout.  
 
7.5 In vitro assessment confirms the superior efficacy of 
soluble p75-Ig fusion dimer over the monomeric form 
 
All experiments had demonstrated either no improvement in disease scores 
or a worsened outcome with p75 overexpression. Returning to the literature, 
several publications using plasmids encoding multimeric variants of p55 had 
been shown to suppress EAU in the rat.60,107 Whilst the most widely used 
target is one conjugated to a murine IgG Fc fragment, isolated soluble p55 
receptor was shown to suppress EAU.107 One difference is that the human 
receptor was used in this study, which has only around 64% homology to the 
murine protein (UCSD Signalling gateway). There may also be an issue of 
dosage, as measurement in intraocular fluid showed that 5ng/ml was able to 
suppress disease, whereas we obtained around 0.15 ng/ml with murine p55. 
 
The presence or absence of the Fc-fusion may provide another explanation 
for the discrepancy between study results. There are reports that human 
sTNFR have a dose-dependent effect upon TNF activity, acting to neutralise, 
buffer and stabilise active trimers.130 In that study, p75 had a greater effect 
upon preventing recombinant TNF induced cytotoxicity than an equivalent 
dose of p55. In a model of lethal sepsis in mice triggered by systemic 
endotoxin, the human p75 monomer was compared to the Fc-linked dimer.200  
The dimer had a 50-fold stronger affinity and a 1000 times greater efficiency 
at preventing TNF induced cell death in vitro. Unlike the monomer, it could 
prevent endotoxaemic death when administered at doses as low as 10µg. 
When the monomer was administered, even up to 260µg, it failed to provide 
any benefit over control IgG. Furthermore, unlike the dimer, it actually 
increased circulating serum TNF levels ten-fold, possibly due to the 
stabilising effect upon the active TNF trimers as had been described in 
vitro.130 
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To interrogate these issues further, a soluble TNF fusion protein was sought. 
The only freely available sequence for cloning into the pD10 plasmid for AAV 
production, was that of a murine p75-Ig dimer.161 This was prepared and 
compared to the murine p75 monomer using an in vitro WEHI-164 
cytotoxicity assay. This mouse fibrosarcoma cell line rapidly undergoes 
cytotoxic cell death in response to active TNF. Recombinant protein was 
obtained by transfecting equal amounts of the plasmids encoding the p75 
variants into HEK-293T cells. The conditioned medium from these cells were 
mixed with recombinant murine TNF and then added to the WEHI-164 cells. 
Cell death was accurately calculated by flow cytometry with the fluorescent 
live-dead dye 7AAD (Figure 61).  
 
 
Figure 61. WEHI-164 cytotoxicity assays confirm the neutralising effect of p75-Ig in vitro  
and the negligible action of monomeric p75.  1µg of CMV-p75 or CMV-p75-Ig plasmid was 
transfected into HEK-293T cel ls,  the supernatant col lected after 48hrs and 0.22µm f i l tered. 
2.5ng recombinant murine TNF was combined with th is condit ioned media or that f rom un-
transfected HEK-293T cel ls for 30mins at room temperature. This was added to 80% conf luent 
wel ls of  the WEHI-164 cel l  l ine. 24 hours later wel ls were spun down and 7AAD added to sta in 
dead cel ls.  F low cytometry was performed and 10,000 events col lected for each sample. A)  
Medium lacking TNF and with TNF alone def ine the range of the assay from ~25% to ~60%. 
Neat medium from un-transfected cel ls  has no effect upon the assay. Neat p75 monomer (red) 
and 1:2 di lut ion are no di f ferent to the control .  Neat p75-Ig (purple) and 1:2 di lut ion however 
both s igni f icant ly suppress cel l  death from TNF. One-way ANOVA with Tukey’s mult ip le 
comparison test.  **=P<0.01, ***=P<0.001. B)  The same data expressed as percentage 
suppression in cel l  death. Technical  t r ip l icates performed. n=4, pooled from two independent 
experiments.  Means + SD shown. 
 
The data describes the superior effect of the p75-Ig dimer on preventing 
WEHI-164 cell death compared to the p75 monomer, implying more effective 
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suppression of TNF. It was not possible to easily determine if the p75 
monomer enhanced TNF effects, as cytotoxicity was already at the upper 
limit of the assay. This clear result, which was independently repeatable led 
to the production of AAV8 and ShH10 encoding CMV-p75-Ig with no IRES 
tag. 
 
7.6 Prophylactic AAV8 mediated p75-Ig dimer delivery to the 
eye still fails to detectably suppress EAU 
 
Though the subretinal route was not favoured initially, it was required to 
reliably achieve higher levels of transgene. This was felt to be important as 
the therapeutic mechanism involved neutralising TNF and so a greater 
amount of p75-Ig would be assumed to lead only to improved blockade. Two 
weeks following prophylactic AAV8 delivery of either p75-Ig or eGFP control, 
EAU was induced and scored by histology at peak disease (Figure 62). By 
CD45-labeled histology, no suppression could be seen compared to GFP 
control virus. TNF was below the level of detection in both groups using 
ELISA on pooled ocular fluid from six mice. One possibility is that TNF does 
not contribute to the same degree in the C57BL/6 model, compared to other 
models of EAU and so any beneficial effect would not be seen. 
 
 
 
F igure 62. Prophylactic p75-Ig expression from subretinal delivery of AAV8 fails to 
suppress histological EAU scores.  Two weeks after subret inal  in ject ion of  1x101 0gc of 
AAV8-CMV-p75-Ig or AAV8-CMV-eGFP, EAU was induced. A)  TEFI images at day 19 do not 
show obvious di f ferences aside from high levels of  GFP that spi l l  in to the v is ib le spectrum. B)  
At day 26 of EAU the eyes were taken for sect ioning, sta in ing and masked scor ing. No 
signi f icant d i f ference was evident between the groups, even by paired analysis.  Wi lcoxon 
signed rank test,  P=0.55. 
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7.7 Using the highly TNF driven B10.RIII strain model of EAU 
does not improve suppression by gene delivery of p75-Ig 
 
The B10.RIII model of EAU is known to be more severe than that induced in 
C57BL/6 mice. In particular, levels of TNF are documented to be higher and 
animals respond dramatically to systemic TNF inhibition.129,164 The 
expectation was that both more severe and TNF-driven disease would 
provide the best opportunity to observe suppression by gene transfer. 
Subretinal injection of AAV8-CMV-p75-Ig and PBS control were delivered 
prophylactically and EAU induced three weeks later. This timepoint was 
chosen to allow maximal expression of p75-Ig and for any retinal detachment 
induced inflammation to reduce. Eyes were scored by H&E stained histology 
(Figure 63). 
 
 
 
F igure 63. Prophylactic intraocular p75-Ig expression fai ls to suppress disease in the 
B10.RII I  model of EAU.  Subret inal  in ject ion of 1x101 0gc AAV8-CMV-p75-Ig in 2µl  or PBS was 
performed three weeks pr ior to the induct ion of EAU. At day 12 eyes were harvested and H&E 
histo logical  EAU scores determined. A) Representat ive histo logical  images of extensive 
ret inal  fo ld ing and damage, with PBS on lef t  and AAV8-p75-Ig on r ight.  x2.5 magnif icat ion. 
Scale bars = 400µm. B)  Paired analysis shows no s igni f icant suppression of d isease. 
Wilcoxon signed rank test,  P=0.203. n=6 mice. TNF was below the level  of  detect ion in both 
groups using ELISA on pooled ocular f lu id from six mice. 
 
Severe disease with extensive retinal folding was seen in most eyes, but no 
significant suppression was evident in the p75-Ig group compared to PBS 
controls. It is possible that the disease was too severe, or there is an intrinsic 
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issue when using the subretinal route. The immune environment might also 
compensate for the continuous inhibition of TNF resulting from prolonged 
production of p75-Ig. Alternatively local neutralisation of TNF with p75-Ig may 
not be an effective therapy.  
 
7.8 Gene delivery of p75-Ig during established EAU 
demonstrates a trend towards reduced structural damage  
 
Following the lack of effect in either prophylactic experiment, it was decided 
to trial an interventional approach, delivering p75-Ig only during established 
disease (Figure 64). This might minimise any adaptation of the local immune 
environment to persistent suppression of TNF. The approach requires the 
use of ShH10, as a subretinal injection was not thought to be advisable due 
to the increased technical difficulty in an inflamed eye and the increased 
potential to exacerbate inflammation itself.  
 
Whilst some groups have reported changes in cell number in EAU as a result 
of TNF neutralization, others show the main effect is upon limiting structural 
damage from myeloid cell activation.201 It was felt that subtle preservation in 
structure might not be clearly observed on cryosections. As a result eyes 
were analysed by paraffin sectioning and H&E staining.  
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Figure 64. Interventional p75-Ig expression by ShH10 trends towards a mild reduction of 
structural changes in EAU.  C57BL/6J  mice at  day 17 post- induct ion of  EAU were in jected 
with 2x101 0gc ShH10-CMV-eGFP or p75-Ig.  Eyes were harvested for paraff in sect ions at day 
26pi.  A)  Representat ive images of h isto logy from paired eyes, i l lustrat ing the presence of 
vascul i t is  in both, but reduced ret inal  fo ld ing in the p75-Ig group. Scale bars = 50µm. B)  The 
mean scores of  two masked assessors are plot ted for paired eyes. Whi lst  they do not reach 
stat ist ical  s igni f icance, a strong trend is seen. Wilcoxon signed rank test,  P=0.058. n=6 mice.  
 
Whilst no statistically significant difference could be demonstrated, a strong 
trend was seen and no eyes from the p75-Ig group showed worsened 
appearances compared to GFP controls. In general retinal folds were less 
frequent and less pronounced in the p75-Ig group. It is possible that the 
effect size may be real but small and so this pilot experiment would not have 
been powered adequately to detect this. This experiment is intended to be 
independently repeated as part of future work using other readouts including 
ELISA and flow cytometry. 
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7.9 Chapter summary 
 
TNF is known to be a critical pro-inflammatory cytokine in both human uveitis 
and EAU. Nitrotyrosine residues were identified in our EAU model, 
suggesting the final effector action of macrophage licencing by TNF was 
present. Monomeric soluble TNF-receptors p55 and p75 were delivered by 
subretinal AAV8, but were shown to have either no effect, or to worsen 
infiltration respectively. The potential confounding roles of eGFP vs hrGFP 
and the addition of an IRES-sequence in constructs were addressed and it 
was considered unlikely that they contributed to therapeutic failure. Avoiding 
retinal detachment using prophylactic ShH10 delivery of monomeric p55 also 
failed to suppress EAU. Testing in the EIU model, no attenuation was seen 
delivering monomeric p55. Injecting high dose recombinant p55-Ig in EIU 
though worsened the disease. Returning to in vitro investigation, the 
monomeric p75 TNF receptor was found to be inferior in its capacity to 
neutralise TNF compared its Ig-fusion dimer. This p75-Ig dimer failed to 
improve EAU when delivered by prophylactic subretinal AAV8 injection. 
Using the more severe B10.RIII model of EAU did not expose any potential 
suppressive effect either. ShH10 mediated delivery during established EAU 
showed a strong trend towards reduced structural damage, but this did not 
reach statistical significance. Local TNF neutralisation by gene transfer does 
not appear to be an optimal target to suppress EAU. 
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8 Results 6: An inflammation-responsive 
promoter can intrinsically regulate AAV-
mediated transgene expression in the eye 
 
Most promoters used in gene therapy for uveitis have been strong and 
constitutively active, such as the Chicken β-actin or CMV immediate-early 
promoters. However, some form of control is important. Tonic expression of 
most anti-inflammatory proteins is a risk for tolerance induction and likely 
down-regulation of the target pathway, rendering the treatment ultimately 
ineffective or at worse detrimental. Anti-viral or transgene directed responses 
are also suspected to be dose-dependent, particularly if AAV is delivered via 
the subretinal route.76 Limiting production of the target protein with an 
inducible, rather than continuously active promoter should therefore only be 
of additional benefit. 
 
Whilst some groups have used ‘tet-on’ and ‘tet-off’ exogenous tetracycline 
inducible systems, these are not self-regulating and inefficient as they are 
never fully silenced and often provide only low levels of expression.93 
Additionally they are based on prokaryotic DNA sequences and would be 
unlikely to be approved by regulators for human therapy. The ideal 
mechanism would intrinsically self-regulate, driving the expression of 
therapeutic transgene only in the presence of - and in proportion to - an 
acute inflammatory state. 
 
Interferon gamma (IFNγ) and tumour necrosis factor alpha (TNF) are key 
pro-inflammatory cytokines identified in both human uveitis and EAU. They 
are elevated during active disease and levels fall during resolution.129 An 
ideal inflammation-responsive promoter would respond to both cytokines 
synergistically. Interferon regulatory factor 1 (IRF1) is a protein that 
stimulates the transcription of many interferon responsive genes. The 
enhancer of the IRF1 promoter has been characterised and possesses both 
gamma-activated sequences and NFκB motifs which can activate 
transcription downstream of both IFN and TNF signalling respectively.162 As 
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a parallel strand, an NFκB-motif enhanced minimal SV40 promoter construct 
was also tested. 
 
The pGL4.Luc2 reporter plasmid was used to assess promoter activity. The 
full human IRF1 promoter sequence was amplified from genomic DNA by 
PCR. The characterised 195bp enhancer region was then cloned in front of 
the minimal SV40 promoter and duplicated several times in an attempt to 
enhance the magnitude of transcriptional response. As a control, the main 
enhancer region of the CMV promoter was cloned in front of the minimal 
SV40 promoter. A pre-synthesised 5-copy NFκB-response element 
enhancing the same SV40 minimal promoter was obtained in a plasmid 
encoding the luciferase gene. The plasmid schematics are shown in Figure 
65. 
 
 
Figure 65. Schematics of Luciferase plasmids to test inflammation-responsive 
promoters.  The pGL4-Luc2 plasmid schematic is  shown with a s ingle copy IRF1 enhancer,  
(b lue) minimal SV40 promoter (yel low) and Luci ferase ( turquoise) gene (A) .  A range of 
constructs with mult ip les of  the IRF1 enhancer region (one to four)  was generated to 
determine the number required for opt imal t ranscr ipt ion (B) .  The control  consisted of the CMV 
immediate-ear ly response element p laced upstream of the same SV40 minimal promoter (C) .  
The NFκB construct was arranged in a s imi lar fashion (D) .  
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Plasmids were initially tested in vitro by Lipofectin transfection into HEK-293T 
cells for 48hrs, prior to different conditions of stimulation with human 
recombinant IFNγ and TNF. Following this, the cells were lysed and 
substrate added in order to measure Luciferase activity. A TK-Renilla 
luciferase plasmid with constitutive activity was co-transfected to control for 
transfection efficiency.  
 
8.1 Interferon Regulatory Factor 1 promoter 
 
IFNγ-responsive promoters were identified as candidates for an 
inflammatory-inducible promoter, as IFNγ is a key pro-inflammatory cytokine, 
known to increase early in EAU, before rapidly reducing as disease ceases. 
A robust quantification of the concentration of IFNγ within the retina during 
murine uveitis is lacking. In rat EAU, levels between 50-150 pg/ml have been 
obtained from ocular homogenates at peak disease,202 whilst 10 pg/ml has 
been measured in human aqueous fluid during acute uveitis.203 Extrapolating 
from these tissue values to an in vitro dose on cell lines is inaccurate and 
unreliable, so a range of doses required testing.  
 
Identification of a cell type that responds to IFNγ was the initial step, as it is 
unclear from the literature which cell types these are in the retina aside from 
RPE. According to RT-PCR data, IRF1 is expressed in human RPE, which is 
itself known to respond to IFNγ.204 This is encouraging as it is the 
predominant cell type transduced by most serotypes of AAV. Staining 
sections from eyes at peak EAU, revealed the presence of the IFNγ-receptor 
1 (IFNγR1) predominantly on astrocytes and Muller glia (Figure 66A). This 
receptor was chosen as a marker as it is the ligand-binding alpha chain and 
tends to be constitutively expressed, unlike its heterodimeric counterpart 
IFNγR2.205 The co-localisation of IFNγR1 staining with GFAP, a cytoskeletal 
protein specific to these two cell types and produced during activation, 
affirmed this association. Sections of eyes without EAU from CFA control 
animals resulted in staining for IFNγR1 in astrocytes only (Figure 66B). It is 
likely that in EAU the receptor is up-regulated on Muller glia in response to 
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other inflammatory stimuli, consistent with work has shown the response of 
rat Muller glia to exogenous IFNγ.206  
 
To reinforce the evidence for co-localisation with GFAP on sections, Muller 
glia cultures derived from a CRALBP-GFP mouse line (a gift of Dr Claire 
Hippert) were successfully stained for IFNγR1 (Figure 66C). RT-PCR on 
these cells also confirmed the presence of transcript (Figure 66D). 
Splenocytes were extracted from a WT mouse as a positive control. Adult 
mouse cortex and the 3T3 mouse fibroblast cell line also were positive for 
IFNγR1.  
 
Testing different repeat number IRF1 constructs by Luciferase assay in HEK-
293T cells, revealed that whilst IRF1 could respond to TNF stimulation, 
(predominantly NFκB signalling) no response to IFNγ was observed (Figure 
66E). This was the case over a wide range of doses, using cytokine from 
several manufacturers (Biolegend and Invitrogen Life Sciences) and no 
additive effect could be seen when combined with TNF. Compared to 
unstimulated cells, all IRF1 constructs above a single copy led to 
approximately three-fold higher inducible responses with TNF.  
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Figure 66. IFNγ -receptor 1 was identif ied on Muller cells but the IRF1 promoter 
construct fai ls to respond to IFNγ .  Immunohistochemistry on eyes from A)  d26 EAU were 
imaged by confocal microscopy for IFNγR1 and shown to co- local ise with GFAP - a marker of  
astrocytes and Mul ler cel ls .  Microscope f i l ters were adjusted to ensure minimal b leed-through 
between colours,  with s imi lar sta in ing apparent on s ingle colour sta ined sl ides. B)  Using CFA 
control  eyes, without inf lammation, sta in ing was only detected on astrocytes, imply ing 
upregulat ion of the receptor on Mul ler cel ls .  C)  To conf irm Mul ler cel l  expression, explant 
cul tures from Rlbp1-GFP  mice also stained for IFNγR1. D)  RT-PCR conf irms the presence of 
IFNγR1 in these cul tures (Mul ler) ,  as wel l  as other t issues including mouse 3T3 f ibroblasts,  
mouse splenocytes (wbc) and mouse cortex. E)  The IRF1 promoter constructs fa i l  to respond 
to IFNγ ,  but do respond to TNF. Representat ive example of one of two independent 
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experiments performed. Two-way ANOVA with Bonferroni  post- tests.  ***=P<0.001. Mean + SD 
shown.  
 
For multiple reasons the IRF1 construct was not pursued further. No IFNγ 
response could be identified, despite the published characterisation.162 
Compared to unstimulated cells the response to TNF, even with the 4-copy 
promoter was moderate at best. The main population expressing IFNγR1 is 
also the Muller cells, which are difficult to transduce with AAV. At the time of 
initial investigation only AAV9 was available, which can transduce Muller 
cells only following subretinal injection at exceptionally high titres (Claire 
Hippert, personal communication). A degree of toxicity at this level was also 
suspected from observed loss of photoreceptors in some treated eyes. 
Subsequently ShH10 became available within the lab (see results chapter 
3), which was reported to transduce Muller cells across the eye following 
intravitreal injection in mouse pups. In the adult it was identified that only 
patches of transfected populations of Muller cells could be achieved. This 
was not thought to be of sufficient extent for effective therapy and hence not 
pursued. 
 
8.2 NFκB-motif promoter 
 
NFκB forms the archetypal pro-inflammatory signalling pathway, involved in 
both adaptive and innate immunity. The canonical activation pathway is 
activated by a variety of stimuli including TNF, Interleukin-1 and Toll-like 
receptor activation. Ultimately these act to phosphorylate and target IκB to 
the proteosome, which typically liberates p65/RelA dimers to enter the 
nucleus and stimulate transcription at NFκB-consensus motifs.207 
Furthermore similar NFκB-based constructs have been used during AAV 
therapy of the brain and so application in the eye should be feasible.96 
 
A construct with five repeats of the binding motif GGGAATTTCC at the 5’ 
end of the SV40 minimal promoter was obtained and tested by Luciferase 
reporter assay with a Renilla luciferase encoding plasmid to control for 
transfection efficiency. As a benchmark, it was tested against a construct 
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with the enhancer region of the CMV immediate-early promoter 5’ to the 
SV40 minimal promoter as described (Figure 65). 
 
Firstly, the dose-response curve to TNF was delineated over a wide in vitro 
range, as the intraocular concentration attained during murine EAU has not 
been published. In the rat, 83.5pg/ml TNF has been detected at peak EAU, 
but again how this translates to an equivalent in vitro dose is unclear.202 A 
strong trend for increasing dose-response was evident and even at 2ng/ml 
TNF the response was greater than CMV (Figure 67A). 
 
 
Figure 67. The NFκB-motif  promoter rapidly responds in a dose-dependent manner, with 
low background activity and a detectable decrease in activity after withdrawal of 
stimulation. A Luciferase reporter construct dr iven by the f ive copy NFκB-moti f  promoter was 
used to assess act iv i ty.  30,000 HEK-293T cel ls were used with a Reni l la p lasmid to control  
for  t ransfect ion eff ic iency. A)  Dose-response of TNF as a st imulant of  NFκB at 4hr,  compared 
to CMV enhancer.  Dur ing independent repeats,  h ighly var iable results were obtained. B)  The 
age of recombinant TNF fo l lowing reconst i tut ion -  despite opt imal storage under 
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manufacturer ’s recommendat ions -  was found to be important.  Three di f ferent batches 
i l lustrate di f ferent results,  despite supposed equal doses. C) By normal is ing to the 1ng dose 
result ,  whi lst  absolute TNF act iv i ty var ies, re lat ive effect of  dose clear ly demonstrates the 
pattern of response from the NFκB-promoter.  There is a l inear increase unt i l  p lateau around 
6ng. Note that even at smal l  doses, the response is greater than the CMV enhancer.  D)  A 
s imi lar pattern of  response is obtained using recombinant IL-1β ,  demonstrat ing that the 
response is NFκB and not TNF-specif ic .  E) Fol lowing the addit ion of  5ng/ml TNF, Luci ferase 
product ion is detectable above basel ine at an hour and cont inues to increase. F)  Fol lowing 
4hr st imulat ion of 5ng/ml TNF, the media is changed and TNF removed. A trend towards 
reduced promoter act iv i ty is  seen by 5 hours onwards. At 20hrs, act iv i ty has returned to 
basel ine, unl ike the act iv i ty of  the matched sample where TNF was lef t  on. Al l  exper iments 
were performed with technical  t r ip l icates and repeated independent ly at  least once. C  and D  
contain pooled results f rom three and two independent exper iments respect ively.  Mean + SD 
shown. 
 
During subsequent experimentation, large variation was seen. Much of this 
was identified as a degradation in potency of the recombinant human TNF, 
despite storage at -20°C as per manufacturer recommendation. Results from 
different aliquots of either freshly purchased TNF, or after storage for 1 or 3 
months were compared (Figure 67B). It is probable that no dose-response 
can be seen in the newer aliquots, as they were maximally stimulated. As a 
result, data from independent experiments were normalised to the 1ng/ml 
TNF value. This allowed the results to be pooled and demonstrate the 
pattern of a linear range of response and plateau (Figure 67C). To confirm 
the response was NFκB specific and not an off-target effect of TNF, the 
same experiment was performed, but using recombinant human IL-1β 
(Figure 67D). IL-1β is known to activate NFκB after binding to IL-1R and 
signalling via MyD88.208 A similar dose response was identified.  
 
Finally, the activation and deactivation kinetics of the NFκB-promoter were 
assessed. TNF was applied at 5ng/ml and Luciferase activity determined 
across the first few hours (Figure 67E). This shows that even by 2 hours 
after stimulation, a detectable increase in Luciferase can be seen. Following 
removal of TNF from the cell culture medium, Luciferase activity decreased, 
such that a large reduction in activity was evident after 5 hours and almost 
undetectable by 20 hours (Figure 67F). These temporal characteristics are 
encouraging and therefore could be viable for translational therapy.  
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The NFκB-SV40 promoter was cloned in place of the CMV promoter in the 
pD10-CMV-eGFP plasmid. Using this a viral preparation of AAV8-NFκB-
eGFP was produced and tested by application on HEK 293T cells. After 72 
hours, 5ng/ml TNF was applied in the culture medium. As it is likely that 
translation of GFP to a detectable level would take longer than Luciferase, 
yet would have a stable half-life of 26 hours, assessments were made at 24 
and 48 hours. Following trypsin dissociation the cells were analysed by flow 
cytometry (Figure 68). A clear shift in the number of cells expressing GFP 
was seen at 48hr compared to the unstimulated controls, with the 24hr 
timepoint providing intermediate values. On the basis of these results, in vivo 
testing was progressed to. 
 
 
Figure 68. HEK-293T cells infected with AAV8-NFκB-eGFP in vitro  respond to stimulation 
by TNF.  30,000 293T cel ls were plated into 96-wel l  p lates and infected with AAV8-NFκB-
eGFP for 48hrs at an MOI of 20000. 5ng/ml Human recombinant TNF in fresh D10 medium 
was added to the wel ls then analysed by f low cytometry at  d i f ferent t imepoints.  A)  
Representat ive f low cytometry plots gated by scatter prof i le f i rst .  No TNF (blue) and 48hrs 
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TNF (green) groups are displayed with GFP signal e i ther against SSC or as a histogram. B)  
Histograms normal ised to the mode for d i f ferent samples including 24hrs TNF (red).  C)  
Summary graph shows the increase in percentage of cel ls  expressing GFP with TNF over 
t ime. Stat ist ical ly  s igni f icant d i f ferences between al l  groups were evident,  with a select ion 
i l lustrated. One-way ANOVA **=P<0.01, ***=P<0.001. Mean + SD shown. The No TNF group 
was analysed at 48hrs. 10,000 events were col lected for each sample. Data are 
representat ive of two independent experiments with technical  t r ip l icates in each group.  
 
Two independent cohorts of mice underwent subretinal injection with 1x1010 
vector genomes in 2µl of either AAV8-CMV-eGFP or AAV8-NFκB-eGFP. 
Two weeks later a subset of the mice was induced with EAU. Following 
anaesthesia and dilation with 1% Tropicamide, slit-lamp fundal fluorescent 
imaging was performed at key timepoints and representative images shown 
in Figure 69. 
  
 
 
F igure 69. Unlike the CMV promoter,  which is constitutively active, the NFκB-promoter 
only leads to expression following the induction of EAU.  Two independent cohorts of  mice 
were in jected with 1x101 0  vector genomes of t i t re-matched AAV8-CMV-eGFP or AAV8-NFκB-
eGFP in the subret inal  space. Three representat ive s l i t - lamp fundal f luorescence images from 
an eye of three di f ferent mice are shown for each condit ion. Exposure t ime standardised at 
30.2s. A)  At the basel ine t imepoint,  two weeks post- in ject ion, only the CMV promoter 
demonstrates act ivat ion, though smal l  amounts of  GFP can be seen in the NFκB promoter 
eyes around the traumatic s i te of  in ject ion. B)  At peak EAU, the NFκB-promoter is  act ive, 
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although the s ignal is  less than the CMV-promoter.  C)  Histo logy conf i rms that NFκB signal is  
exclusively in the RPE (n=4) ref lect ing the presence of NFκB signal l ing, whi lst  the CMV-
promoter is  const i tut ively act ive in both photoreceptors and RPE. Images acquired with 
ident ical  confocal sett ings. D)  To demonstrate that increased t ime is not responsible for the 
act ivat ion of NFκB, control  eyes without EAU at day 26 were imaged and showed to lack GFP 
signal.  
 
At the baseline timepoint two weeks post-injection of AAV, but prior to the 
induction of EAU, the CMV promoter showed GFP signal. At this timepoint 
AAV8 would be expected to be generating high levels of expression in RPE 
and photoreceptors, but would not peak until several weeks. There was 
however, no signal in the NFκB-promoter injected eyes, except occasionally 
around the area of the needle track where traumatic inflammation may be 
occurring following injection (Figure 69A). At peak EAU on day 26, imaging 
was repeated. At this point the NFκB-promoter was active and GFP 
detectable (Figure 69B). Compared to CMV, the intensity was less. This was 
partially explained by histology, which revealed expression only in the RPE 
with the NFκB-promoter (Figure 69C). This is as potentially expected as 
NFκB signalling is robustly documented in RPE, whereas there are no 
published reports clearly demonstrating canonical NFκB signalling in 
photoreceptors. Additionally greater numbers of AAV particles are likely to 
infect the RPE. Groups reporting NFκB expression have found the signal to 
arise from microglia, rather than the photoreceptors themselves.209 However, 
microglial transduction by AAV8 has neither been seen nor reported in the 
literature. Total GFP signal from the CMV promoter is significantly greater, as 
photoreceptors also account for over ten-fold more cells than the RPE. 
Comparing the GFP fluorescence in the RPE alone, the signal does not 
appear substantially different between the groups.  
 
To control for the possibility of late expression from the NFκB promoter as a 
consequence of the AAV transduction kinetics, mice injected with AAV8, but 
not induced with EAU were examined at the same timepoint as peak EAU, a 
full 40 days post-injection (Figure 69D). Reassuringly, no signal was seen in 
the NFκB group. The CMV-promoter cohort did not appear to differ from 
                                                                                                                   191 
those with EAU, indicating a lack of induction or suppression as a result of 
inflammation with this promoter.  
 
8.3 Flow cytometric quantification establishes the dose-
response of the NFκB-promoter in EAU 
 
To objectively demonstrate the inflammation-inducible nature of the NFκB-
promoter, sixteen mice from two independent cohorts were analysed by flow 
cytometry. Following the same protocol used for histology and fundal 
imaging, mice were culled at day 26 EAU having been injected with titre-
matched AAV8-CMV-eGFP or AAV8-NFκB-eGFP two-weeks prior to disease 
induction. 
 
It was established earlier that the key cell type able to facilitate expression 
from the NFκB-motif promoter construct is the RPE. Previous work using flow 
cytometry to quantify CD45+ infiltrating cells in EAU from dissociated retina 
alone, confirmed that it reflected structural damage and is a valid measure of 
disease severity.159 Given that murine EAU is the closest model of human 
uveitis widely available, if the CD45+ cell count correlated with the degree of 
GFP induction in the RPE, this would be the closest possible validation prior 
to a clinical trial.  
 
For each eye the matched retina, vitreous and aqueous humour were 
dissected from the RPE/choroidal complex. This is typically a clear 
separation along the subretinal space. The retinal mix and RPE were 
mechanically dissociated as separate samples to achieve single cell 
suspensions. The RPE was analysed by flow cytometry for intrinsic GFP 
signal, whilst the dissociated retinal sample was stained with anti-CD45 first 
(Figure 70). 
 
There is intrinsic variability between animals and eyes during EAU, which 
naturally provides a wide range of inflammatory stimuli to test the 
responsiveness of the NFκB-promoter. Taking two eyes with mild and severe 
EAU based on TEFI, the fundal fluorescence image shows a proportionately 
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greater GFP signal with increased severity (Figure 70A). The matched flow 
cytometry plots outline the gating strategy for analysis and further show the 
association between increased CD45+ cells and GFP+ RPE cells. 
 
 
Figure 70. Flow cytometry of GFP signal and CD45+ cell  infi l tration confirms activation 
the NFκB-motif  promoter in proportion to the degree of inflammation caused by EAU.  
Mice were in jected with 1x101 0  vector genomes of e i ther AAV8-NFκB-eGFP or AAV8-CMV-
eGFP into the subret inal  space. Two weeks later,  EAU was induced, and the eyes were 
harvested for f low cytometry at  d26. The ret ina and vi t reous were dissected as one sample for 
CD45 stain ing, with the RPE/choroid as another.  A)  Representat ive fundal images and f low 
cytometry p lots f rom the eyes of mice with d i f ferent degrees of EAU sever i ty,  indicated by the 
di f ferent numbers of CD45+ cel ls in each eye and ref lect ive of the overal l  inf lammatory 
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environment.  As a result ,  the eye with more CD45+ cel ls has a greater GFP+ RPE cel l  count.  
B)  Induct ion of EAU does not af fect GFP+ RPE cel l  counts in eyes in jected with AAV8-CMV-
eGFP. C)  The NFκB-moti f  promoter produces a low level of  GFP that increases when EAU is  
induced. P<0.01, Mann-Whitney U. Mean + SD shown. D)  Using the CMV promoter,  there is 
no correlat ion between CD45+ count and GFP+ count.  n=8 eyes. E)  The NFκB-moti f  promoter 
demonstrates a s igni f icant correlat ion between increasing CD45+ cel l  count and GFP+ RPE 
count,  imply ing i t  is  regulated by inf lammation. n=23 eyes from two independent exper iments.  
L inear regression (black l ine) and Spearman correlat ion (boxes) shown.  
 
To look at the induction potential of both the CMV (Figure 70B) and NFκB-
motif (Figure 70C) promoters, the RPE GFP+ counts were plotted for eyes 
with and without the induction of EAU. This shows a lack of further increase 
in GFP+ signal resulting from EAU upon CMV-driven transcription, whereas 
the activating effect of inflammation upon the NFκB promoter is evident.  
 
The GFP+ RPE count was correlated with the corresponding CD45+ cell 
count for each eye. Again, the CMV promoter shows no correlation, with 
most cells expressing the transgene regardless of the degree of cellular 
infiltration (Figure 70D). The NFκB-promoter in contrast shows a statistically 
significant correlation. As the CD45 count increases, so does the GFP+ RPE 
count (Figure 70E). This quantitatively demonstrates the action of the NFκB 
promoter as a mechanism for self-regulated production of potential anti-
inflammatory transgenes, in the closest available model to human uveitis. 
Furthermore, expression increases in direct proportion to the degree of 
inflammatory cellular infiltrate. 
 
As outlined in the previous chapters, AAV mediated delivery of a suitable 
anti-inflammatory cytokine to treat EAU remains problematic. Incorporation of 
the NFκB promoter may aid successful suppression when a suitable target is 
identified in future work. At the end of this project, particularly as no target 
transgene driven by a constitutive promoter has been identified as effective, 
the promoter has not yet been incorporated and tested in an interventional 
study. Pending further work this will be performed. Aside from therapy, one 
alternative application is to use the construct for in vivo monitoring of the 
inflammatory environment. 
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8.4 The NFκB promoter can be used as an in vivo reporter to 
examine aspects of the EAU model itself. 
 
An area of debate exists around the post-peak, so-called ‘resolution’ phase 
of murine EAU. The inducible disease in the C57BL/6 mouse was classically 
regarded as monophasic, regressing to quiescence. It is now increasingly 
recognised that EAU does not resolve completely and at late timepoints is 
still highly dynamic. Several groups have reported vascular remodelling 25,160 
and changes in cellular infiltrate, with evidence of progressive accumulation 
of exhausted phenotype CD8+ T-cells.24  
 
To answer this question, several mice underwent subretinal injection of 
AAV8-NFκB-eGFP and then were followed through the course of EAU out to 
day 87. Representative slit lamp fluorescent fundal images are shown for 
four mice in Figure 71. As expected, there is no GFP before EAU is induced, 
but expression is seen at peak disease on day 26. By day 38, EAU usually 
has the appearance of clinical resolution, with apparent scarring around 
areas of prior vasculitis and the resolution of disc oedema. GFP intensity 
reflecting NFκB signalling in the RPE is however, undiminished and arguably 
slightly increased.  
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Figure 71. The NFκB-GFP construct confirms the presence of persistent inflammatory 
activity in the eye at t imepoints classically labelled as resolved disease.  Representat ive 
images of four eyes from a cohort  of  C57BL/6 mice (m1-4) that underwent EAU induct ion two 
weeks after subret inal  in ject ion of AAV8-NFκB-GFP. Sl i t - lamp fundal f luorescence images are 
shown for the same eye over four t imepoints – basel ine (day 0),  peak disease (day 26),  ear ly 
post-peak (day 38) and late (day 87).   
 
EAU is rarely run as far as day 87 and would be expected to be quiescent at 
this stage. Occasionally though deep retinal folds are seen at late stages, 
which have been documented to contain a mixture of myeloid and lymphoid 
cell types.25 In the eyes injected with AAV8-NFκB-GFP, GFP signal is 
certainly not diminished at day 86 and appears more intense than at any 
other stage (Figure 71). Regions of approximately the same size as the 
aforementioned retinal folds appear to form foci where the GFP signal is 
greatest, particularly in eye m3. This could reflect local activation of NFκB in 
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the underlying RPE in a process that is not yet clear. Certainly these findings 
support the emerging consensus that a form of continued inflammatory 
activity occurs in post-peak EAU. 
 
One caveat is the possibility of an anti-viral response to AAV, which could 
trigger a late stage response and inflammation that would perpetuate NFκB 
activation. Certainly in the absence of EAU, eyes injected with AAV8-NFκB-
eGFP did not express detectable levels even after four weeks, making a 
general response unlikely (Figure 69). Whilst possible that the addition of 
EAU might exacerbate a response, data in the prior chapters failed to detect 
systemic neutralising antibody or CD8 T-cell responses following subretinal 
AAV8 administration during EAU. NFκB is involved in processes other than 
inflammation, including angiogenesis. The promoter as designed would not 
be able to respond to pro-inflammatory signalling specifically and so could 
respond to these stimuli, if arising late in EAU. An antigen-directed reaction 
to eGFP or direct cellular toxicity also cannot be excluded. Publications have 
identified a strongly antigenic eight amino acid H2-Kd restricted region at the 
C-terminus of eGFP.197 Whilst this was not tested for by ELISPOT in these 
cohorts, as shown previously a head-to-head experiment against hrGFP 
failed to identify any difference in inflammation in the context of EAU. It is 
thus unlikely to have a large effect upon these results. 
 
8.5 Chapter summary 
 
The successful translation of gene therapy for uveitis to clinical trial will 
undoubtedly require refinements enabling self-regulated production of the 
therapeutic target. Based on our understanding of the key pro-inflammatory 
cytokines involved in experimental models of uveitis, IFNγ and NFκB 
signalling pathway-based promoters were chosen. Whilst the IRF1-based 
promoter failed to respond appropriately to IFNγ, the NFκB promoter 
demonstrated favourable characteristics. Strong dose-response, rapid onset 
and termination were identified in vitro using a Luciferase reporter assay. The 
promoter was then tested as AAV8-NFκB-eGFP in vitro and in vivo. It was 
inactive in the absence of disease, but led to expression in the RPE at peak 
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EAU. Using flow cytometry, the promoter was quantitatively shown to 
respond in direct proportion to the severity of inflammation, measured by 
CD45+ cell infiltration. This capacity was then used as a reporter to show that 
persistent NFκB activation occurs in the RPE during late post-peak stages of 
EAU. 
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9 Discussion 
 
This project aimed to advance the field of gene therapy for uveitis using new 
AAV serotypes, known to achieve superior levels of expression and wider 
cellular tropism. IL-10 and TNF inhibitors, two of the most commonly used 
anti-inflammatory targets were investigated but did not appear to be effective 
at suppressing intraocular inflammation in the mouse when delivered using 
AAV. An inflammatory responsive promoter was trialled for the first time in 
the eye and activated only in the presence of and in proportion to the degree 
of inflammation. New approaches for the analysis of the two commonly used 
mouse models of ocular inflammation, EAU and EIU, were developed using 
OCT and flow cytometry respectively. 
 
9.1 OCT can be used to assess and score EAU 
 
In results chapter 1, OCT was proposed as a viable method for evaluating 
mouse EAU and quantifying disease in vivo. A minimally subjective OCT-
based scoring system has been described, which correlates well with existing 
histology and TEFI based analyses. Additionally OCT provides a tool for 
following dynamic intraretinal changes and will permit the reconciliation of 
mounting functional and cellular data arising from the EAU model (Table 12). 
 
Benefits Limitations 
Can detect intraretinal changes in real-time Expensive hardware limits availability 
Allows repeated scoring of the same eye over a 
time-course 
Large initial learning curve of user skill required to 
acquire good quality scans 
Can detect oedema in vivo, a characteristic 
otherwise lost by histological processing 
Severe disease (B10.RIII) with vitritis and 
posterior synaechiae can prevent adequate 
imaging. 
Enables correlation of OCT with matched 
immunohistochemistry that might inform the 
interpretation of human OCT images from patients 
with Uveitis. 
 
Requires less overall time compared to histology 
when processing, sectioning and staining are 
accounted for. 
 
Can result in less mice needed for experiments 
(3R’s) 
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Allows exactly matched eyes to proceed for 
alternative tissue analysis such as flow cytometry 
or multiplex ELISA, instead of surrogate severity 
scores from a parallel cohort. 
 
 
Table 12. A summary of benefits and l imitations of the novel OCT scoring system 
compared to conventional assessment of EAU.  
 
9.1.1 OCT	   Correlates	   with	   current	   EAU	   scoring	   methods	   and	   has	  
distinct	  advantages	  
 
In C57BL/6 mice, for the range of pathology historically used to score EAU 
severity – vitreous, disc, vessel and retinal structural changes – 
discrimination is possible using OCT. OCT can therefore be considered as a 
technique used for disease assessment, and substituted for post-mortem 
histology where appropriate will allow reduction and refinement of animal 
usage. Histology will inevitably still be performed for first describing novel 
findings and corroborative phenotyping, but could otherwise be widely 
replaced by OCT. This is because OCT remains conceptually analogous to 
and using our scoring system, is shown to be directly correlated to post-
mortem histology scores. The overall time per eye required for imaging and 
scoring is in general less once processing, sectioning and staining for 
histology are accounted for. For OCT scoring, it would take approximately 30 
minutes per eye, including scanning, processing and scoring. Histology 
would take at least 40 minutes per eye to embed, section and score, not 
including the time required for staining, which would be several hours, though 
could be performed in batches.  
 
A further advantage is that OCT can be used to observe directly features in 
vivo such as oedema and vascular leakage, which are seldom detectible on 
histology due to the dehydrating nature of tissue processing techniques. This 
platform has the additional ability to simultaneously perform fluorescein 
angiography, scanning at the exact location of any lesion. However, we 
noted that OCT was able to distinguish specific signals in tissue surrounding 
leaking vessels that could be used as surrogates to avoid unnecessary 
angiography. 
                                                                                                                   200 
 
OCT permits repeated in vivo examination of the same animal, allowing the 
progression of features, or intraretinal response to therapy to be closely 
monitored and examined. OCT also delivers a closer substitute for histology 
than TEFI. Whilst current in vivo monitoring with TEFI can detect disc and 
vessel alterations, it cannot detect intraretinal or vitreous changes.159 OCT 
avoids the disadvantages of intense light exposure, corneal contact and 
appears not to overestimate disc involvement to the same degree. 
Nevertheless, TEFI still has a role as a useful and quick screening step, 
identifying animals for subsequent detailed OCT scoring, or matching 
disease stage for other assessments. 
 
Wide inter- and intra-animal variation in disease severity in the C57BL/6 EAU 
model means many mice are often required to obtain reproducible data from 
functional or cellular analysis. The data implies that OCT will allow accurate 
intraretinal synchronisation of disease stage within experimental groups prior 
to any therapeutic intervention during established EAU. This should 
consequently narrow biological variation and allow the significant detection of 
interventions with smaller numbers of animals. By scoring disease without 
post-mortem histology, animals can also be repurposed to other analyses 
(flow cytometry, qPCR, cytokine ELISA) with additional knowledge of the 
exact disease stage of each eye.  
 
9.1.2 OCT	   can	   guide	   the	   discovery	   and	   characterisation	   of	   novel	  
retinal	  features	  
 
It has been demonstrated by employing OCT that vitreous and intraretinal 
changes can not only be evaluated in more detail, but can also identify and 
assess previously unrecognised features of the inflamed retina in a more 
targeted way. Using our platform, vessels can be imaged with combined FFA 
and OCT to localise leakage and analyse surrounding tissue in the 
associated areas. Deep retinal folds can be imaged and importantly, 
distinguished on OCT from other changes such as the abnormal vascular 
telangiectasia prior to neovascular outgrowths. This feature in EAU was 
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identified by FFA and OCT from day 36 onwards showing vascular re-
modelling to occur earlier in disease than indicated by similar vascular 
membranes recently observed only from day 60 post-induction.160  
 
The vascular lesions share some similarities with those described in 
degenerative models with low-grade chronic inflammatory components, such 
as rhodopsin kinase knockout mice210 or those carrying the rd8 mutation.30 
The mice used in our study carry neither defect and thus the lesion may 
represent a more widespread feature of tissue re-modelling in response to 
degenerative or inflammatory processes in the retina. Our data illustrates 
such changes, with vessels extending through the outer nuclear layer and 
under the RPE, before reconnecting with superficial retinal vasculature. The 
vessels are unlikely to represent choroidal neovascularisation as neither FFA 
findings nor the irregular, yet ordered splay of the abnormal vessels are 
characteristic of this. The pathogenesis is likely linked through the 
development of glial activation, which both degeneration and EAU would 
trigger. Further analysis including 3D-scanning electron microscopy to prove 
the integrity of Bruch’s membrane would be required to confirm this 
assertion. 
 
9.1.3 OCT	  scoring	  and	  future	  directions	  
Construction of the OCT scoring system proved complex and retaining 
adequate capture of detail had to be balanced against simplicity of use. Our 
system was designed purposely to remove subjectivity where possible and 
unlike histological and TEFI scoring systems does not use imprecise 
stratification such as ‘mild, moderate or subtotal’. The structural sub-score, 
calibrated for broad overview and time efficiency does not distinguish 
between subtypes of retinal changes. As such it remains necessary to 
carefully study specific structural features as required for the precise purpose 
of each experiment. 
 
As EAU in rats and B10.RIII mice is more severe17,171, the current data is 
based on C57BL/6 mice since the model permits detailed imaging of the 
retina at critical stages. The largest constraint is the limitation of the degree 
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of optical resolution. Further refinements in both the hardware and optics for 
rodent imaging will inevitability increase the quality of data obtained, which 
will allow progressively improved scoring accuracy and characterisation. 
Detailed analysis of choroidal changes may be possible using long 
wavelength, enhanced depth imaging OCT, whilst employing emerging 
adaptive optics technology may eventually allow the observation of dynamic 
processes on a single cell level in vivo.169 More work to further precisely 
delineate with OCT temporal changes and responses to therapeutic 
intervention are the likely next steps to be taken and could also include the 
development of algorithms and segmentation improvement to increase 
accuracy.  
 
In back-to-back publications, submitted to the same journal a week after our 
work, another group has presented an OCT-based analysis and scoring 
system for use in the B10.RIII mouse.174 Their use of both different hardware 
and strain is excellent validation of the approach of using OCT in EAU. As 
noticed during our own assessment of B10.RIII disease imaging quality in the 
system used by Chen et al was impeded by vitritis and posterior synaechiae. 
Whilst features could be identified, the final scoring system was based 
primarily only upon retinal thickness. Though this is a rapid and simple 
method, it may miss subtle changes in morphology and takes no account of 
which layer pathology may occur in. 
 
9.1.4 Interpreting	   OCT	   changes	   in	   human	   intraocular	   inflammatory	  
disease	  by	  correlation	  of	  histopathology	  and	  OCT	  in	  murine	  EAU	  
 
Several of the features we have described in EAU mirror OCT changes seen 
in some human posterior segment inflammatory diseases.211,212 An additional 
significant benefit of using our approach lies in the ability to directly correlate 
scan features with matched tissue, which can be directly analysed to identify 
immune cell composition and altered function. Due to the paucity of human 
material for histology, an identical human study is not feasible. OCT is 
however, already being used in clinical practice to phenotype and monitor 
posterior uveitis.213 By further examining other preclinical animal models, 
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including humanised and spontaneous EAU in mice, more accurate 
correlations might be drawn.37 Conversely, screening new EAU models with 
OCT for retinal changes closest to those of human disease, will allow 
selection and refinement during development. In the clinic, it remains 
challenging to judge the remission of posterior segment inflammatory 
disease or to detect early recurrence and relapse. Quantification and 
analysis of OCT features other than macular oedema, as we have used here 
in EAU, could distinguish remission versus low-grade chronic inflammation 
as well as tissue re-modelling in order to guide clinical decision-making. 
 
9.2 Flow cytometry provides a more comprehensive and 
quantitative assessment of the EIU model 
 
Whilst EIU is not an accurate model of human anterior uveitis, it is a useful 
tool for the interrogation of innate-triggered inflammation in the eye and 
mechanisms of cellular infiltration.32 Since its first proposal as an ocular 
model in 1980, use has not fallen over the last thirty years (Figure 72). This 
is likely to be a result of the simplicity and speed of the model that suits early 
in vivo drug screening, as well as initial interrogation of innate responses in 
many newly developed transgenic mice. Changing research interests and 
priorities are likely to only increase the use of EIU. Recent studies into age-
related macular degeneration (AMD), a highly active area of research, have 
highlighted the importance of the inflammasome.214 This is a key signalling 
mechanism engaged by EIU. As robust animal models of AMD are lacking, 
initial acute testing of several therapeutics directed against the 
inflammasome is already being performed in EIU. Microglial contributions to 
AMD are also becoming apparent and the model has also been used to 
examine this.215 
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Figure 72. Despite the l imitations of the EIU model i ts use has not fal len since 
introduction in 1980.  Publ icat ions for each year l is ted on MEDLINE contain ing search terms: 
[endotoxin]  AND [ induced] AND [uveit is ] .  Metr ics obtained from Medl ine trend: automated 
year ly stat ist ics of  PubMed results for any query, 2004. Web resource at 
ht tp: / /dan.cor lan.net/medl ine-trend.html.  
 
EIU has historically been assessed by histology with paraffin sections stained 
with H&E. Subjective counts of haematoxylin-staining cells in the AC and 
vitreous are then performed across a limited cross-section of the eye. This 
count is used as a measure of disease severity and therapeutic attenuation 
derived from this. It seems almost counterintuitive that flow cytometry is 
regularly used to assess EAU, where structural changes are important and 
mandate the additional use of histology, while in EIU only histology has been 
regularly employed, where it is widely acknowledged that structural damage 
seldom occurs and only the amount of infiltrate is important.31 In this setting 
flow cytometry seems an ideal assessment method for EIU, providing rapid, 
accurate and objective quantification of cell number.  
 
In results chapter 2, the evidence for the use of flow cytometry to score EIU 
was presented, alongside our technique, which allows efficient processing of 
multiple samples. Other aspects of the EIU model were explored. The ratio of 
anterior and posterior/vitreous infiltrate was shown to be approximately 
equivalent, with cells seen entering through the iris and optic disc 
respectively. The time-course of infiltration, divided into neutrophils and 
monocytes was determined and the two patterns of initial neutrophil (6-12hr) 
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then monocyte (18hr) ingress were identified.32 A similar observation has 
previous been made following systemic induction of EIU in the rat and 
analysis with immunohistochemistry.216 In that study, the first peak of iNOS+ 
cell infiltrate occurred at 12hrs, compared to 6hrs we identified with 
intravitreal delivery. This probably reflects the quicker initiation of 
chemotactic signals following local LPS delivery. We induced EIU by 
intravitreal injection of LPS, but the flow cytometry technique could be 
applied to either footpad or intraperitoneal induced systemic EIU models. 
These are likely to result in lower intraocular cell counts however. 
 
Flow cytometry Histology 
Fully quantitative and objective. Semi-quantitative and requires a subjective 
assessor. 
Ocular tissue is homogenised so sample evenly 
reflects the entire eye. 
Discontinuous sections provide only a limited 
cross-sectional sample of the eye. 
Up to 18 different markers can be assessed 
simultaneously dependent upon flow cytometer. 
Only 1-2 markers can be stained for on each 
paraffin section. 
Live-Dead discrimination feasible with vital dyes. Not possible as tissue fixed. 
Remaining RPE/iris/ciliary body tissue can be 
used for other analyses, as can cellular 
supernatants e.g. ELISA, qPCR. 
The whole eye must be used for histology. 
Rapid – as there are no long incubation steps, 
results can be obtained on the same day. 
Processing and embedding typically require 
several days. 
Allows large-scale processing – setup allows 96 
samples to be scored in one run. 
Manual sectioning and scoring is time-consuming 
and labour intensive. Limits throughput. 
Higher cost (flow cytometer & antibodies). Limited 
availability of dissecting microscopes and flow 
cytometry facility. 
Histology facilities widespread and cost-effective. 
Unexpected structural changes will not be 
detected. 
Unexpected structural changes will be detected. 
 
Table 13. Advantages and disadvantages of EIU assessment by f low cytometry 
compared to tradit ional histological analysis. Advantages are highl ighted with green text 
and disadvantages in red text.  
 
As summarised in Table 13, there are many additional benefits over 
histology by using flow cytometry. For new experiments, it is still 
recommended to check a sample of eyes by histology for unexpected 
structural changes. However, subsequent assessment performed by flow 
cytometry would allow rapid and large-scale processing of samples, 
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particularly suited to for example, high-throughput drug screening. 
Furthermore, simultaneous detection of subset specific changes and analysis 
of matched tissue samples and supernatants will maximise the opportunity to 
identify novel effects. The additional cost and access to a flow cytometer are 
potential barriers to widespread application, though it is available in most 
immunology labs, with commercial availability and price constantly improving. 
 
A final validation of the technique would be to directly correlate histology and 
flow cytometric counts. This is not possible directly using identical eyes, as 
the same tissue is required for both analyses. Comparison of the mean and 
spread of two simple EIU cohorts could be used. Alternatively observing the 
same pattern of dose-response to an interventional therapy could provide 
further support. Both would be time-consuming and it was felt that the 
techniques were likely to coincide, as we have detected the same responses 
to recombinant human IL-10 in EIU as were published by another group 
using histology.177 Further validation could be undertaken in the future. One 
advance that was described recently, is the use of OCT to image vitreous 
cells and retinal oedema in EIU.217 This could uniquely be used for repeated 
quantification of cellular infiltration in vivo, though no scoring structure has 
yet been proposed in the literature. No discrimination between the subtype of 
infiltrating cell would be possible currently, though with enhanced resolution 
and adaptive optics this may be feasible in the future. Additionally, the 
sedimentation effect of gravity may lead to artificially low cell counts, as the 
single-slice OCT might not sample all the cells in the AC. It is likely that both 
techniques could be combined ultimately for the most comprehensive 
analysis of EIU. 
 
9.3 Refinement of AAV production and the effect of 
Endotoxin contamination 
 
Minimal attention has been placed upon the refinement of AAV production for 
immunologically sensitive applications within the eye. Examination of 
published methods suggests that most research-grade preparations are not 
even checked routinely for endotoxin contamination, which would be 
                                                                                                                   207 
expected to be widespread.87 This project is the first to specifically address 
the effects of endotoxin in relation to intraocular use of AAV. Endotoxin 
contamination of AAV8-CMV-GFP injected into the subretinal space resulted 
in an increase in the number of CD11b+Ly6G+ cells in the eye. These cells 
are likely to be neutrophils and whilst not high in number are capable of 
releasing damaging free radicals. Direct activation of TLR4 as the receptor 
for endotoxin, has been implicated in photoreceptor oxidative stress, so in 
combination these two processes may have effects upon long-term 
photoreceptor cell survival.218 Use of the subretinal route curtailed some 
effects of LPS, with reduced numbers of infiltrating cells seen within the eye 
compared to intravitreal injection. It is unclear if this is purely due to 
compartmentalisation, preventing systemic or responsive cell type exposure 
to LPS, or some other active phenomenon of suppression unique to the 
subretinal space. 
 
It may be that many of the effects of endotoxin are not obvious in mice, which 
are generally less sensitive than many other animals.219  Dog eyes injected 
by one of the group using an AAV preparation found subsequently to be 
heavily contaminated with endotoxin, developed florid clinically apparent 
inflammation. Reinjection of the same vector testing negative at 2.5EU/ml 
endotoxin in a different dog did not result in any clinically detectable 
changes.220 In terms of endotoxin specifically confounding the effects of AAV, 
it was identified that in the short-term, there was no increase in expression as 
one study indirectly suggested.181  
 
It was hypothesised that endotoxin may be responsible for the discrepancy 
between the transduction pattern of ShH10 we observed in adult mice and 
the widespread transduction reported in publications. The ShH10 vector was 
used in adult mice and shown to transduce ciliary epithelium, corneal 
endothelium but only columns of Muller cells, rather than widespread 
transduction.57 Our vector was purified differently using an AVB column and 
certified as below 2.5EU/ml endotoxin. The discrepancy in results was 
thought to arise from the lack of contaminants or endotoxin, degrading the 
inner limiting membrane to allow improved ShH10 penetration of the retina. 
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Spiking vector with purified LPS however did not reproduce the original 
results. It remains possible however, that purified LPS alone may not be 
sufficient and it is contaminating cellular debris or mixed bacterial population 
derived endotoxins that are required. 
 
The degree of contamination with debris from HEK-293T cells used to 
produce AAV varies significantly dependent upon purification strategy. It 
would be expected to contain highly inflammatory intracellular components 
that whilst not apparently problematic for monogenic rescue applications, 
could affect therapeutic immunomodulation by AAV-mediated gene therapy. 
Using an AVB column to purify vectors markedly reduced the degree of 
cellular protein contaminants compared to the previous Sephacryl-Poros 
method. These impurities could be examined in the future by processing 
untransfected HEK-293T cells according to various AAV purification 
protocols and investigating the effects of the resultant samples upon the eye. 
 
A new protocol for enriching the number of active, full AAV capsids was 
trialled and found to be successful for AAV5, but not robust enough for 
AAV8, though subsequent work appears to suggest this is possible. Capsid 
enrichment as a final step was not employed, as the main strategy used 
AAV8 and ShH10. Theoretically the reduction in antigen load, in the form of 
unnecessary empty AAV capsids, could prevent the loss of subretinal 
deviation that has been reported to be antigen dose dependent.76 Another 
concern is that intraocular inflammation might negate the subretinal immune 
deviation to AAV, and EAU appears to cause loss of immune deviation in the 
vitreous cavity.221 Inducing EAU after the injection of subretinal AAV8 
however did not appear to lead to systemic adaptive immune responses 
when judged by ELISPOT and neutralising antibody assays.  
 
9.4 Suppressing autoimmunity using interleukin-10 is 
complex  
 
IL-10 was chosen as the initial target transgene as it has been widely used 
and is regarded as the archetypal anti-inflammatory cytokine. Specifically, 
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several publications from our group and others showed that gene transfer 
using IL-10 was able to suppress both EAU and EIU.34,93,110 In these initial 
publications, AAV2 and lentivirus were used to express IL-10 at relatively low 
levels compared to that achieved with AAV9 and AAV8 in this project. 
Additionally in this project, new methods of assessment such as OCT and 
CD45-immunolabelled EAU scores, or flow cytometry for EIU were employed 
to provide potentially more accurate and efficient measures. PBS controls 
were also included for the first time as a higher translational hurdle and a 
more consistent comparator, than potentially variable GFP expressing viral 
preparations.  
 
Using a variety of modern AAV vectors and routes murine IL-10 could not be 
shown to suppress EAU or EIU over a wide range of dose. Species 
differences were addressed by using viral and human IL-10, but again these 
did not obviously suppress disease. To obtain a strong positive control, 
recombinant human IL-10 was used in EIU with success. Using ShH10-CMV-
human IL-10, levels known to suppress EIU were matched and confirmed by 
ELISA. No reduction in cell count was seen, implying that either the delivery 
mechanism of AAV, or the dynamics of IL-10 production in the intraocular 
environment could be responsible for the difference. Future experiments to 
address this issue could involve injecting GFP and hIL-10 expressing vectors 
prior to the induction of EIU with simultaneous administration of 200ng 
recombinant human IL-10. This dose is known to suppress EIU and so if 
suppression is no longer seen in the GFP control, then the presence of AAV 
is responsible. If only seen in the hIL-10 expressing vector, it would be more 
likely due to induction of a refractory state to the effects of IL-10. 
 
Strong evidence for the therapeutic effect of IL-10 in the effector phase of 
EAU is lacking and our data using AAV-derived and recombinant IL-10 
further support this assertion. In other models of autoimmune disease, close 
examination of the literature reveals that several therapeutic IL-10 studies 
have demonstrated a lack of effect or even worsening of inflammation.222 
This is probably an under-representation due to publication bias towards 
positive results and may go some way towards explaining the striking failure 
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of clinical trials using recombinant IL-10.223 It is perhaps not surprising that 
IL-10 is complexly regulated as a result of many millennia of evolution, to 
counter the known hijack of IL-10 by viruses and parasites. 
 
Significant suppression is clearly affected by dose, route of administration, 
timing of intervention in the disease course and the target tissue. 222 It looks 
likely that IL-10 is capable of blocking initial systemic T-cell activation through 
reduced MHCII and co-stimulation on APCs. This appears to be the 
mechanism through which systemic IL-10 has an effect in prophylactic 
treatment of animal models and is the case in EAE when disease is induced 
by subcutaneous immunisation.224 Adoptive transfer models of EAE, where 
T-cells are already activated, fail to reduce and show a trend to worsen when 
recombinant hIL-10 is given at any stage.225 Much of our basic understanding 
of IL-10 arises from genetically deficient mice so at disease initiation there is 
already an effect upon antigen presentation. Further use of conditional 
knockout lines will clarify the exact action of IL-10 in the effector phase, with 
one study showing attenuated EAE following T-cell specific deletion of the IL-
10 receptor.226 Target tissue may prove critical as in rheumatoid arthritis 
models; IL-10 appears to cause almost universal suppression, unlike the eye 
or CNS.223 
 
In work using EAU, transgenic lines expressing IL-10 under either T-cell 
(CD2 and IL-2) or macrophage (CD68) promoters, initiation was attenuated 
through reduced antigen presentation to naïve T-cells.227 However, IL-10-/- 
mice show a strong trend towards reduced disease severity. Recombinant IL-
10 could also inhibit EAU initiation, but no data upon intervention was shown, 
suggesting the absence of effect.126  
 
Our experiments using IL-10 appeared to be highly variable. ShH10-vIL-10 
and ShH10-hIL-10, achieved suppression to a significant (and substantial) 
level in an experiment each, but the second-time did not show the effect to 
be repeatable. This is unlikely to be due to normal inter-experiment variation, 
and could be explained more by a narrow therapeutic window or small effect 
size. The improved methods of analysis and extra PBS controls, in concert 
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with this narrow window, may explain the previous work showing 
suppression. It is possible a change in systemic immune responses due to 
undetected parasitic infection or microbiome changes, could explain 
differences between cohorts of mice being alternately responsive and 
apparently refractory to IL-10. 
 
Interestingly, following high-level expression of human IL-10 from subretinal 
injection of ShH10, a significant increase in intraocular CD8+ cells was seen. 
This was not present in the control group. These may be cytotoxic T-cells 
functioning in an anti-viral response, though this was not observed with 
subretinal AAV8-IL-10. IL-10 however has been shown to stimulate the 
proliferation and activation of effector CD8+ T-cells and the high levels may 
have contributed to the local increase in cell number.228  
 
Future work could trial the use of hIL-10 under an inflammation-inducible 
promoter such as NFκB. There is some evidence that regulated expression 
might lead to different effects. Enhanced pancreatic islet destruction in the 
NOD mouse was seen when transgenic IL-10 was constitutively expressed, 
but a mild protective effect was seen when IL-10 was placed under the 
control of the IL-2 promoter in T-cells.229  
 
EAU as a more complex disease model may not be as likely to suppress with 
one agent alone, albeit one as pleiotropic as IL-10. It is clearly important in 
uveitis pathogenesis, evidenced by the association with genetic 
polymorphisms in the IL-10 promoter.117 The potentially narrow therapeutic 
window and multiplicity of variables involved in successful deployment of this 
target will however make translation difficult. Considering the current data, it 
is probably prudent to pursue other transgenes as gene therapy for uveitis. 
 
9.5 Local inhibition of TNF by p75-Ig may have a mild effect 
upon EAU 
 
Targeting TNF is a common approach to many autoimmune diseases 
including uveitis. Monomeric soluble TNF-receptors p55 and p75 were 
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already available within the lab and so they chosen for delivery by gene 
transfer but shown to have either no effect, or to even worsen the infiltration 
of CD11b+Ly6C+ cells in EAU. These findings led to a reappraisal of 
evidence and in vitro testing, which highlighted the inferior efficacy of 
monomeric soluble p75 compared to its Ig-fusion dimer. Extrapolating from 
published work, it is possible that soluble TNF receptors may actually 
stabilise and buffer the formation of active TNF trimers, except at very high 
doses.130 Returning to in vitro investigation, the p75-Ig construct was shown 
to functionally inhibit the effects of TNF. Despite this, no clear evidence of the 
suppression of EAU could be seen. 
 
TNF inhibitors are now widely used in clinical practice for uveitis and have 
been shown to be effective when administered systemically.15 In many 
patients however, they are not sufficient and disease remains uncontrolled. 
Formulations include Adalimumab, a humanised monoclonal IgG1 antibody 
and Etanercept, a dimeric Ig-fusion protein of the human p75 TNF receptor. 
Whilst both successfully treat rheumatoid arthritis, evidence is emerging that 
Etanercept is less effective than Adalimumab in uveitis and granulomatous 
inflammation.230 This is thought to result from the different way TNF is 
neutralised, with less stable binding of Etanercept to TNF trimers. 231 In this 
project, mouse p75-Ig fusion dimer was used, which would be closer to 
Etanercept in its action than Adalimumab. Any underlying idiosyncratic effect 
specific to TNF inhibition in uveitis, might have affected the ability of p75-Ig to 
suppress EAU. In retrospect, a construct based upon Adalimumab, human 
p55-Ig or newer generation antibodies specific to transmembrane or soluble 
forms of TNF such as XPro1595 might have been preferable.129 These are 
commercially sensitive however and their coding sequences are undisclosed, 
so they were unavailable for use. 
 
Whilst systemic blockade of soluble TNF alone clearly appears to attenuate 
EAU and cellular infiltration into the eye, local inhibition requires both soluble 
and transmembrane TNF neutralisation.129 Even then the magnitude of 
suppression appears to be small. Most reports suggest that infiltration is only 
mildly affected, whilst common to most is the delayed onset and reduction in 
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structural damage mediated through macrophage activation.133,201 Some 
groups have reported successful therapy of EAU with prophylactic local non-
viral expression of human p55-Ig from the ciliary muscle in the rat.60 Others 
used intravitreal Etanercept in the afferent phase of EAU, which results in a 
marginal reduction in severity.232 No suppression was seen however when 
given in the efferent phase, after the establishment of EAU. This potentially 
bodes poorly for anti-TNF therapy as a local treatment, as all human 
intervention would occur in established disease only. It could equally prove a 
limitation of the animal model itself however, as TNF inhibition might be still 
effectively used during remission to prevent cycles of relapse instead, as 
seen in human uveitis. This cannot be modelled and thus detected in EAU. 
 
Some reports have shown systemic TNF inhibition to worsen infiltration in 
systemically induced EIU.199 Certainly it is possible for TNF inhibitors to 
cause potential toxicity and worsen infiltration, as seen in the small number 
of eyes injected with recombinant human p55-Ig in this project. Elevated TNF 
transcripts in the RPE, iris and ciliary body were identified during intravitreally 
induced EIU suggesting its pathogenic importance. Other groups however 
have shown suppression with both systemic administration of Etanercept176 
and local inhibition of TNF by p55-Ig expressed from the ciliary muscle in 
EIU.107 These discrepancies highlight more difficulties and variables involved 
in targeting TNF, even when attempting to suppress a relatively simple model 
of ocular inflammation. 
 
In aggregate the studies may partly explain why suppression of EAU was not 
achieved. Local inhibition of TNF in EAU may not be efficacious, as the site 
of peripheral activation in the immunised skin and draining lymph nodes will 
be untreated and T-cells continue to be activated. It may be that the dose of 
p75-Ig was too low, as near complete neutralisation of TNF might be required 
for any effect even if suppression in the efferent phase can occur. A key 
action of TNF is to degrade the blood-retinal barrier partly by acting on 
endothelial cells, so if cells are already activated and infiltrated, then the 
effects of inhibition are limited to preventing macrophage activation. This 
reduction may not be sufficient or widespread enough to counter the damage 
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from simultaneous, widespread infiltration of peripherally activated cell types. 
It may be effective as mentioned however, to maintain remission between 
active episodes, if used in a more faithful animal model of human uveitis that 
has repeated cycles of activation. 
 
9.6 The NFκB-motif promoter drives inflammation-responsive 
transcription in proportion to the severity of EAU 
 
Initial investigation used the IRF1-promoter as a dual response enhancer, as 
it had been characterised as responsive to both NFκB and IFNγ signaling.162 
Whilst NFκB activation triggered by recombinant TNF caused a response in 
proportion to the number of copies, no response at all could be obtained 
using a range of doses of IFNγ from two different suppliers. The relative 
change compared with baseline expression was higher using a pure five-
repeat NFκB-motif fused to the minimal SV40 promoter and so this construct 
was taken forward. 
 
Delivered in AAV8 and driving the expression of GFP, it was first confirmed 
that in vitro activation of the promoter occurred in response to TNF, a pro-
inflammatory cytokine known to be critical in EAU. In vivo examination 
revealed minimal activation following subretinal injection itself, with eyes 
remaining free of GFP signal for over 33 days. At peak EAU, expression of 
GFP is seen in the RPE consistent with the well-known presence of NFκB 
signalling in this cell type.233 AAV8 transduces photoreceptors efficiently, but 
only rarely were seen to express GFP in each eye. Evidence in the literature 
is scant and does not unequivocally support the presence of canonical NFκB 
signaling in photoreceptors. It is likely that these occasional transduced cells 
could represent low-level contamination with AAV8-CMV-GFP from the 
production process. It is also possible that lower levels of transcription from 
the NFκB-motif promoter, combined with less genome copies of AAV 
transducing photoreceptors compared to RPE, could lead to below detection 
levels of GFP. 
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The NFκB-motif promoter, apparently restricted to RPE only, appears to 
generate lower levels of GFP compared to the CMV promoter. Whilst the 
NFκB-motif promoter is undoubtedly weaker, this could be compounded as 
RPE cells are less numerous than photoreceptors. The positive findings 
however, are that the NFκB-motif promoter is not active in the absence of 
inflammation and when it is triggered, the degree of transcription appears to 
be directly proportional to the severity of disease. Uniquely, this was 
demonstrated with flow cytometry upon matched tissues from the same eye, 
analysing the RPE for GFP signal and other ocular tissues for infiltrating 
CD45+ leukocytes known to be responsible for disease pathogenesis in 
EAU. It has been reported that AAV may use non-canonical NFκB signalling 
in its life cycle, as levels increase following infection and inhibition prevents 
AAV-mediated gene expression in vitro.181 Our construct would be expected 
to respond to non-canonical signalling, though this is usually at a lower level 
than fast IκB-complex mediated signals.234 It is possible that the NFκB 
requirement is only during initial infection and so any signal would be missed 
by the two-week baseline. 
 
This is the first intrinsic inflammation-regulated promoter to be used with 
gene therapy in the eye. Similar promoters have been used in other organ 
systems, but the same degree of assessment is not possible and ex vivo 
histology is required.96,235 The eye is suited to in vivo monitoring and 
baseline, peak and post-peak responses could be repeatedly gauged for the 
same eye. One group looking at an animal model of rheumatoid arthritis used 
repeated invasive sampling of articular fluid and ELISA for the transgene 
product.94 This could detect responses to stimulation, but the procedure may 
in itself have contributed to the inflammation. 
 
The CMV promoter has been reported to be silenced following delivery by 
AAV in different tissues and in response to inflammation.236 
Whilst not designed specifically to address this question, a marked reduction 
in GFP signal was not observed in RPE during the presence of EAU after 
subretinal delivery of AAV8-CMV-eGFP. 
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The NFκB-motif promoter was not employed in any therapeutic experiments 
to suppress EAU. This was due to the absence of a robust therapeutic target, 
with both IL-10 and soluble TNF-receptors failing to suppress disease under 
the constitutive CMV promoter. It was intended that once a treatment had 
been established, it could be tested to see if the therapeutic effect was 
maintained or enhanced under a responsive promoter. In terms of future 
work, it may be that for some targets such as IL-10, only regulated 
production will result in successful suppression.222 It is likely however that 
using a different therapeutic transgene, effective under both constitutive and 
regulated expression would be more robust and likely to translate to clinical 
therapy. 
 
The NFκB-motif promoter driving the expression of eGFP was used as a 
reporter to assess the activation status of the RPE during the post-peak 
stages of EAU. Whilst possible that the promoter fails to deactivate, it is more 
likely that as has been increasingly suspected, there is no true resolution of 
inflammation and so continued NFκB signaling in the RPE.24 It is not known if 
NFκB activation at this point results in pro-inflammatory cytokine synthesis, 
as NFκB could be equally involved in proliferative, survival or angiogenic 
stimuli.105 Future work will use small molecule NFκB inhibitors and activators 
to delineate the capacity to terminate transcription from the promoter. The 
approach of in vivo monitoring using this promoter could be deployed in other 
models such as laser-induced CNV and models of dry AMD or retinal 
degenerations, to assess the localization and magnitude of RPE activation.  
 
9.7 Reconciling the failure to suppress intraocular 
inflammation and implications to future gene therapy for 
uveitis  
 
During this project, modern AAV serotypes such as AAV9, AAV8 and ShH10 
were used to overexpress IL-10 variants and block TNF with soluble TNF-
receptors in uveitis models. The assumption was that faster onset and higher 
levels of therapeutic transgene compared to AAV2 would only improve 
efficacy. No other studies to date have used these vectors for modulation of 
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intraocular inflammation. Novel readouts such as OCT for EAU and flow 
cytometry for EIU were used alongside traditional measures to improve the 
reliability and detection of therapeutic suppression. Unfortunately the 
suppression seen in previous published literature with lentivirus and AAV2 
could not be achieved using these modern serotypes.34,93,110  
 
There are many possible reasons why previous results could not be 
replicated or matched using modern AAV serotypes. It is possible that the 
attenuation in disease previously seen was small in magnitude and with more 
objective readouts is not repeatable. The use of IL-10 as examined in current 
work, is affected by many variables and has a narrow therapeutic window, so 
prior positive results might have occurred by chance. There could also be 
confounding features specific to modern AAV serotypes themselves.  
 
9.7.1 Vectors	  
Modern serotypes efficiently infect cell types that AAV2 could not. Perhaps 
uniquely perturbing and activating cells such as Muller glia resulted in a 
greater pro-inflammatory stimulus than the degree of suppression by 
encoded transgenes. High levels of viral expression and corresponding 
levels of cellular transcriptional stress may themselves potentially have an 
adverse effect upon the inflammatory environment, though techniques to 
determine this are likely to be imprecise. Support for this hypothesis comes 
from the observation that in many cases GFP-expressing vectors showed 
worsened disease than PBS injected controls. Given potential worsening with 
GFP vector alone, the absence of PBS or uninjected controls as in several 
previous studies could result in the misinterpretation of suppression from an 
interventional vector that is transcriptionally less efficient. 
 
It could be envisaged that the use of new serotypes such as ShH10 would be 
beneficial by avoiding retinal detachment. This is known to be inflammatory 
and for several weeks results in photoreceptor dysfunction as measured by 
ERG.179,180 The reduced trauma may have been countered though by the 
increased likelihood of adaptive systemic responses to intravitreally delivered 
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AAV.77 Any response to ocular transduction by AAV is likely to be additionally 
dependent upon coincident innate stimuli such as endotoxin.92 
 
9.7.2 Dose	  
It is hard to draw direct comparisons of dose as no other studies showed 
matched in vivo levels of transgene product. One showed protein levels of 
AAV2 delivered IL-4 by ELISA during treatment, but without data from any 
control group, so it is hard to ascertain what the background level was and 
therefore the degree of elevation.113 In one study reporting successful 
attenuation of EAU with AAV2, ELISA upon eyes without disease did not 
show a statistically significant elevation in murine IL-10 levels.110 If this truly 
caused suppression, then the implication is that a near undetectable level of 
elevation is required. As significantly increased levels were confirmed in 
present experiments using modern serotypes, this could explain the lack of 
disease attenuation. 
 
To address one aspect of dosage the positive control of human recombinant 
IL-10 was used in the EIU model. Exact levels were matched between 
recombinant protein and ShH10-delivered IL-10 after 6hrs. No inhibition was 
seen with virally mediated IL-10 delivery at doses that did show inhibition 
using recombinant protein. Either a direct effect of the presence of AAV or 
the dynamics of IL-10 administration are likely to be responsible. For 
example, if microglia are a key target of IL-10 induced suppression by 
preventing chemokine release, then prior activation through a response to 
AAV might render them insensitive to deactivation.  
 
A future experiment could be to inject AAV8 or ShH10 carrying GFP and IL-
10 one week before EIU induction and simultaneous administration of a dose 
of recombinant human IL-10 known to suppress disease. If suppression is no 
longer achieved, the effects of either prior AAV transduction or tolerance to 
persistently elevated levels of IL-10 might be distinguished. It will also be 
worthwhile to re-visit non-viral methods of gene transfer to examine if these 
effects are confined to delivery by vectors such as AAV.    
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9.7.3 Therapeutic	  transgenes	  
In view of the present findings, it appears that neither IL-10 nor TNF 
inhibitors are ideal therapeutic transgenes for several aforementioned 
reasons and success may have been achieved by delivering other targets. 
The data obtained suggests that murine IL-10 is ineffective in EIU, in contrast 
to human IL-10. This difference makes is hard to reconcile many published 
studies and may go some way to explaining the mixed results seen using 
different species of IL-10 interchangeably in approaches across multiple 
organ systems.223,225,226 Whilst systemic TNF inhibition clearly affects the 
recruitment of infiltrating cells, it is less firmly established whether local 
inhibition will suppress disease. If it does the degree of suppression is likely 
to be small.187 It may be that other methods of neutralising TNF in the eye 
are required, such as with encoded recombinant antibody Fab domains or the 
p55-Ig fusion protein, as it will have a greater effect upon soluble TNF. 
 
Future work should consider other targets that ideally are beneficially 
pleiotropic, effective at low levels, but with a wide therapeutic window. IL-27 
appears to be one such target and has been effectively used to treat EAU 
expressed from AAV2, but it is unusual that no further progress towards 
clinical trial has been forthcoming.114 Combining targets is an appealing 
strategy and was intended once effective transgenes had been identified. 
Given that none reliably performed it was not felt appropriate to empirically 
attempt combination of different vectors. 
 
9.7.4 Local	  versus	  systemic	  therapy	  
The gene therapy approach in uveitis relies upon the assumption that local 
modulation of the immune environment can treat disease, deactivating, killing 
or preventing initial entry of infiltrating cells. Systemic TNF inhibition and IL-
10 have been shown to inhibit disease when given prior to the initiation of 
C57BL/6 EAU, though this is likely due to prevention of induction and down-
regulation of peripheral antigen presentation. In the effector phase of 
disease, local therapy with IL-10 has not convincingly been shown to prevent 
tissue damage in EAU.  
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Local ocular TNF inhibition with Etanercept has a very mild protective effect 
upon C57BL/6 EAU in the afferent phase. This is possibly due to pre-
conditioning and preventing subsequent blood-retinal barrier degradation as 
no effect is seen when delivered in the efferent phase when cells have 
already entered the eye.232 Gene delivery when tested in this project 
however was given prophylactically so expression was occurring in the 
afferent phase of EAU, and the possibility to suppress disease should have 
existed. 
 
A strong local mechanism action for any successful future target transgene 
may be required, particularly as T-cells that are already activated can be 
resistant to IL-10 and other forms of suppression.222 A more effective 
treatment might involve triggering an anergic state or cell death in infiltrating 
activated cells. Fas ligand might serve this function and was considered, 
though not trialled as there is evidence of the Fas receptor expression on 
normal ocular tissues.237 Another alternative target could be CD200, a 
member of the immunoglobulin superfamily expressed ubiquitously by 
neurons including those in the retina. The CD200 receptor (CD200R), in 
contrast, is restricted to cells of the myeloid lineage and likely contributes to 
the immune-privilege of the eye. Ligation of CD200R acts to deliver a 
constitutive inhibitory signal on retinal microglial cells, preventing the 
induction of NOS and IL-6 in response to IFNγ. An agonist antibody to 
CD200R has been used successfully to delay and attenuate murine EAU in 
the effector phase. Conceivably, a strategy to overexpress CD200 across the 
retina could decrease the activation of resident and infiltrating myeloid cells 
to reduce disease, even once established. 
 
Even local modulation by IL-10 or TNF inhibition might work if the target 
organ (i.e. the eye) were the site of primary or even secondary antigen 
presentation. In terms of human and mouse biology, this is still a contentious 
issue. Regardless the choice of experimental model could be critical if this 
were the case, as inducible models in the C57BL/6 and B10.RIII strains will 
undergo antigen presentation artificially in the inguinal lymph nodes when 
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typically subcutaneous injected. With an established reservoir of antigen 
presentation in the periphery, even an reasonably effective local therapy 
might soon be overwhelmed by the constant flow of cells from such a 
peripheral site of activation. 
 
9.7.5 Animal	  models	  
Using a spontaneous model of EAU could enable local gene therapy to be 
effective if the primary site of antigen presentation is in the eye, such as 
IRBP promoter-HEL transgenic mice.22 In this instance IL-10 and TNF 
blockade might prevent initiation of disease. Whether this will ultimately 
translate to humans with pre-existing pathology though is debatable but 
slowly being clarified through the use of spontaneous mouse models 
transgenic for RBP-3 as found in human uveitis.23 
 
Pertussis toxin is used in most inducible models of EAU, but publications 
suggest it may have long-lasting underappreciated effects upon T-cell 
polarisation and activation that could render them resistant to subsequent 
modulation and suppression.238 One group reporting successful modulation 
of EAU with AAV2 used the B10.RIII strain, which they were able to induce 
without pertussis toxin. This is a difference that could explain why 
suppression in the C57BL/6 model has not been possible.  
 
9.7.6 Immune	  privilege	  and	  implications	  for	  ocular	  gene	  therapy	  
The identified trends for worsening inflammatory disease scores even in GFP 
control vector treated eyes, raises the possibility that trauma from the route 
of delivery or the vector itself, could abrogate the constitutive immune 
privilege of the eye and immune deviation mechanisms. Precedence arises 
from work looking at ACAID, which is lost in the contralateral eye following 
even the relatively mild stimulus of a retinal laser burn.239 Further 
experiments to look at worsening of contralateral disease and loss of immune 
privilege following AAV-mediated gene delivery, could have implications for 
the expanding number of trials for ocular diseases affected by inflammation, 
such as diabetic retinopathy and choroidal neovascularization. 
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9.8 Conclusion 
 
This project has highlighted the complexity of using viral-mediated gene 
transfer to suppress intraocular inflammation. Perhaps it is unsurprising that 
the eye is potentially hostile to the presence of viral vectors, as many viruses 
such as CMV, Herpes simplex and Varicella zoster are all evolutionarily well-
established ocular pathogens. In a similar manner, microbes are engaged in 
a continuing battle to overcome the immune system often subverting targets 
such as the IL-10 pathway. Again the eye may have evolved tight regulatory 
mechanisms that make intervention challenging. Few other local approaches 
for chronic uveitis are upon the horizon and emerging systemic therapies still 
require long-term administration and have numerous side effects. Gene 
therapy for uveitis is still a promising goal but as this project has 
demonstrated, several hurdles remain and further work will be needed to 
resolve the many variables and factors impeding progress towards clinical 
trial.  
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• Figure 43. The experimental repeat and addition of a PBS control demonstrates no 
significant suppression of EIU by Lenti.mIL-10, despite detection of elevated mIL-10 
protein levels in the eye. 
• Figure 44. ShH10 delivered viral IL-10 does not reliably suppress EIU. 
• Figure 45. Unlike recombinant murine IL-10, human IL-10 suppresses EIU in a dose-
dependent manner. 
• Figure 46. ShH10-mediated transfer of mouse, human or viral IL-10 does not suppress 
EIU at 18-hours following injection one-week prior. 
• Figure 47. A comparative timecourse of recombinant protein demonstrates comparable 
levels at 18-hours post injection to ShH10-derived human IL-10 in the eye. 
• Figure 48. ShH10-derived human IL-10 suppresses EIU at the 6-hour timepoint, with 
corresponding reduction in key neutrophil chemokines. 
• Figure 49. Repeat experiment of ShH10-human IL-10 with additional controls fails to 
reproduce the suppression of EIU at the 6hr timepoint. 
• Figure 50. Levels of human IL-10 comparable to suppressive recombinant protein doses 
can be obtained using subretinal ShH10, but no therapeutic effect is seen upon EIU. 
Furthermore, a local infiltration of CD8+ cytotoxic T-cells is detected. 
• Figure 51. Extending the time to three weeks following intravitreal injection of ShH10-
human IL-10 achieves higher transgene levels, but still does not suppress EIU. 
• Figure 52. Repeat of AAV2 mediated delivery of mIL-10 with the addition of flow 
cytometric analysis fails to reproduce the reported suppression. 
• Figure 53. Administration of intravitreal recombinant human IL-10 at peak EAU fails to 
suppress EAU. 
• Figure 54. TNF-licenced nitric oxide synthetase induction in myeloid cells during EAU 
leads to detectable nitrotyrosine residues and structural damage. 
• Figure 55. AAV8 expression of soluble p55 monomeric receptor does not affect infiltration 
or CD4 polarisation in EAU compared to GFP control. 
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• Figure 56. Expression of p75 fails to suppress EAU and increases the number of 
CD11b+Ly6C+ cells in the eye. 
• Figure 57. eGFP compared with hrGFP expression does not significantly alter the 
severity of EAU and the presence of an IRES-GFP segment does not markedly reduce 
the level of the preceding transgene. 
• Figure 58. Prophylactic ShH10 mediated expression of monomeric p55 receptor does not 
affect infiltration in EAU compared to GFP control, despite detectably elevated levels in 
the tissue. 
• Figure 59. ShH10 expression of monomeric p55 receptor does not affect EIU at double 
the control level. 
• Figure 60. Administration of recombinant human p55-Ig at the induction of EIU leads to 
retinal haemorrhage and worsened infiltration. 
• Figure 61. WEHI-164 cytotoxicity assays confirm the neutralising effect of p75-Ig in vitro 
and the negligible action of monomeric p75. 
• Figure 62. Prophylactic p75-Ig expression from subretinal delivery of AAV8 fails to 
suppress histological EAU scores. 
• Figure 63. Prophylactic intraocular p75-Ig expression fails to suppress disease in the 
B10.RIII model of EAU. 
• Figure 64. Interventional p75-Ig expression by ShH10 trends towards a mild reduction of 
structural changes in EAU. 
• Figure 65. Schematics of Luciferase plasmids to test inflammation-responsive promoters. 
• Figure 66. IFNγ-receptor 1 was identified on Muller cells but the IRF1 promoter construct 
fails to respond to IFNγ. 
• Figure 67. The NFκB-motif promoter rapidly responds in a dose-dependent manner, with 
low background activity and a detectable decrease in activity after withdrawal of 
stimulation. 
• Figure 68. HEK-293T cells infected with AAV8-NFκB-eGFP in vitro respond to stimulation 
by TNF. 
• Figure 69. Unlike the CMV promoter, which is constitutively active, the NFκB-promoter 
only leads to expression following the induction of EAU. 
• Figure 70. Flow cytometry of GFP signal and CD45+ cell infiltration confirms activation 
the NFκB-motif promoter in proportion to the degree of inflammation caused by EAU. 
• Figure 71. The NFκB-GFP construct confirms the presence of persistent inflammatory 
activity in the eye at timepoints classically labelled as resolved disease. 
• Figure 72. Despite the limitations of the EIU model its use has not fallen since 
introduction in 1980. 
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